学术周报 · IF≥10 或专科旗舰刊
肾内科领域文献阅读汇编
2026年第45周 (2026-11-06) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选: IF≥10 或专科旗舰刊 · 完整摘要不截断
数据来源: PubMed E-utilities · 影响因子筛选: IF≥10 或专科旗舰刊 · 完整摘要不截断
★本周 Top 10 高影响力文献
Ŧ期刊分布统计
| 期刊 | 篇数 | IF |
|---|---|---|
| Kidney international | 20 | IF 21.8 |
| American journal of kidney diseases : the official journal of the National Kidney Foundation | 20 | IF 0.0 |
| Journal of the American Society of Nephrology : JASN | 10 | IF 0.0 |
| Diabetologia | 5 | IF 10.4 |
| Redox biology | 4 | IF 16.2 |
| Ageing research reviews | 4 | IF 15.5 |
| Environmental science & technology | 2 | IF 12.2 |
| MedComm | 2 | IF 14.1 |
| Pharmacological research | 2 | IF 12.2 |
| Circulation research | 1 | IF 18.0 |
1慢性肾脏病 CKD (23篇)
临床研究 (16篇)
Sodium-glucose cotransporter-2 inhibitors (SGLT-2is) have evolved from glucose-lowering agents to foundational therapies for the management of type 2 diabetes mellitus, heart failure, and chronic kidney disease, with substantial benefits for cardiovascular, kidney, and survival outcomes. As their indications continue to expand, a comprehensive understanding of their safety and tolerability has become increasingly important for optimizing patient care. Building on our recent state-of-the-art review of glucagon-like peptide-1 receptor agonists, this review provides a contemporary synthesis of the evidence on the safety and tolerability of SGLT-2is. We critically appraise data from randomized controlled trials, cardiovascular and kidney outcome trials, pharmacovigilance databases, large observational studies, and systematic reviews and meta-analyses. The available evidence demonstrates that SGLT-2is have a favorable overall safety profile, with genital mycotic infections representing the most consistently observed adverse event. Volume depletion and euglycemic diabetic ketoacidosis remain clinically important but are uncommon and are largely preventable through appropriate patient selection, patient education, and temporary treatment interruption during high-risk clinical situations. Fournier's gangrene should be regarded as a very rare but serious complication requiring prompt recognition and treatment. In contrast, randomized trials and meta-analyses generally indicate a reduced risk of acute kidney injury, while evidence concerning fracture, lower-limb amputation, hepatotoxicity, pancreatitis, and cancer is less definitive. Although consistent class-wide increases in these latter outcomes have not been established, uncommon or agent-specific risks cannot be excluded, particularly where event numbers are small or follow-up is limited. Overall, treatment discontinuation because of adverse events is low across major cardiovascular, heart failure, and kidney outcome trials, supporting the excellent tolerability of this therapeutic class. Comparative evidence suggests only modest differences among individual SGLT-2is, although definitive conclusions remain limited by the absence of direct, large, randomized head-to-head trials. We also summarize practical strategies for adverse-event mitigation, monitoring, temporary treatment interruption, and individualized patient selection. As the clinical applications of SGLT-2is continue to broaden, ongoing pharmacovigilance, inclusive clinical trials, and comparative safety studies will be essential to further refine their benefit-risk profile and optimize their safe use across diverse patient populations.
中文摘要:钠-葡萄糖协同转运蛋白2抑制剂(SGLT-2is)已从降糖药物发展为2型糖尿病、心力衰竭和慢性肾脏病管理的基础治疗,对心血管、肾脏和生存结局有显著获益。随着适应证持续扩展,全面理解其安全性和耐受性对优化患者照护日益重要。在近期关于胰高血糖素样肽-1受体激动剂的最新综述基础上,本综述对SGLT-2is安全性和耐受性证据作出当代综合。我们批判性评估随机对照试验、心血管和肾脏结局试验、药物警戒数据库、大型观察性研究以及系统综述和荟萃分析的数据。现有证据显示,SGLT-2is总体安全性良好,生殖器真菌感染是最持续观察到的不良事件。容量不足和正常血糖性糖尿病酮症酸中毒仍具临床重要性,但不常见,且通过合适患者选择、患者教育及高风险临床情境下暂时中断治疗大多可预防。福尼尔坏疽应视为非常罕见但严重的并发症,需要及时识别和处理。相比之下,随机试验和荟萃分析通常提示急性肾损伤风险降低,而关于骨折、下肢截肢、肝毒性、胰腺炎和癌症的证据较不明确。尽管尚未确立这些后者结局在全类别中一致增加,但不能排除不常见或药物特异性风险,尤其在事件数较少或随访有限时。总体而言,主要心血管、心力衰竭和肾脏结局试验中因不良事件停药率较低,支持该治疗类别具有良好耐受性。比较证据提示各SGLT-2is之间差异不大,但缺乏直接、大型、随机头对头试验限制了确定性结论。我们还总结不良事件缓解、监测、暂时中断治疗和个体化患者选择的实用策略。随着SGLT-2is临床应用不断拓宽,持续药物警戒、具有包容性的临床试验和比较安全性研究对进一步完善其获益-风险特征并在多样患者人群中优化安全使用至关重要。
Chronic kidney disease (CKD) is a global public health challenge, yet therapeutic evaluation and regulatory acceptance are constrained by reliance on late clinical endpoints such as kidney failure. Albuminuria, assessed as urine albumin-to-creatinine ratio (UACR) reflects glomerular and systemic vascular injury and responds rapidly to treatment. Epidemiologic evidence demonstrates a continuous, graded association between both baseline and changes in UACR and subsequent risk for kidney failure, cardiovascular events, and mortality. Trial level analyses demonstrate that treatment effects on change in UACR is also associated with long-term treatment benefit on CKD progression across drug classes and disease populations. Meta-analysis indicates that a treatment benefit of ≥30% decline in UACR is associated with approximately a 20% treatment benefit on CKD progression, supporting its use as a clinically meaningful surrogate endpoint. Residual albuminuria during treatment identifies patients at persistently high risk and provides a rationale for therapy intensification. Recent studies demonstrate that combination therapies can achieve substantial additional reductions in UACR, in selected settings exceeding 50%. This review synthesizes biological, epidemiologic, and clinical trial evidence supporting albuminuria-guided risk stratification and a treat-to-target approach using serial UACR monitoring to personalize CKD care, while improving clinician understanding of albuminuria changes as markers of therapeutic response.
中文摘要:慢性肾脏病(CKD)构成全球公共卫生挑战,但治疗评估与监管接受仍受制于对肾衰竭等晚期临床终点的依赖。以尿白蛋白/肌酐比值(UACR)评估的白蛋白尿反映肾小球与全身血管损伤,并对治疗作出快速反应。流行病学证据显示,基线UACR及其变化均与随后肾衰竭、心血管事件和死亡风险呈连续、分级相关。试验层面分析表明,不同药物类别和疾病人群中,治疗对UACR变化的影响也与CKD进展的长期治疗获益相关。荟萃分析提示,UACR下降≥30%的治疗获益与CKD进展约20%的治疗获益相关,支持其作为具有临床意义的替代终点。治疗期间残留白蛋白尿可识别持续高危患者,并为强化治疗提供依据。近期研究显示,联合治疗可使UACR进一步大幅降低,在特定情形下超过50%。综述整合生物学、流行病学和临床试验证据,支持以白蛋白尿指导风险分层,并采用连续UACR监测的达标治疗策略以实现CKD个体化照护,同时增进临床医生对白蛋白尿变化作为治疗反应标志物的理解。
Hypertension prevention, diagnosis, and management are central to modifying the progression of chronic kidney disease (CKD). Although the nephrology community has long recognized CKD as an independent risk factor for cardiovascular disease, CKD has not historically been incorporated in cardiovascular risk prediction models. The new 2025 American Heart Association and American College of Cardiology (AHA/ACC) Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults addresses this gap by formally adopting the PREVENT calculator, which combines cardiovascular, kidney, and metabolic health parameters to guide risk assessment and clinical decision making. The AHA/ACC guideline reinforces the broad blood pressure target of <130/80 mm Hg as well as makes recommendations for complex and resistant hypertension. Given the impact of these recommendations on persons living with kidney disease, the Kidney Disease Outcomes Quality Initiative (KDOQI) convened an expert work group to review and comment on the guideline. This KDOQI commentary focuses on recommendations from the AHA/ACC guideline that are pertinent to individuals at risk of CKD or with non-dialysis-dependent CKD (stages 1-5), hence excluding commentary on hypertension management in patients receiving maintenance dialysis. In areas where the AHA/ACC guideline does not offer formal recommendations (eg, medication interactions, electrolyte imbalances, and kidney injury), the work group provides expert commentary about implications for people with CKD. Overall, the work group supports the majority of the AHA/ACC recommendations and identifies areas where evidence remains limited or management in CKD warrants additional consideration.
中文摘要:高血压的预防、诊断和管理对改变慢性肾脏病(CKD)进展具有核心作用。肾脏病学界早已将CKD视为心血管疾病的独立危险因素,但CKD此前未被纳入心血管风险预测模型。2025年美国心脏协会/美国心脏病学会(AHA/ACC)成人高血压预防、检测、评估和管理新指南正式采用PREVENT计算器,将心血管、肾脏和代谢健康参数结合起来指导风险评估和临床决策,从而弥补这一缺口。AHA/ACC指南重申<130/80 mm Hg的广泛血压目标,并对复杂性和难治性高血压提出建议。鉴于这些建议对肾脏病患者的影响,肾脏病结局质量倡议(KDOQI)召集专家工作组对该指南进行审查和评论。本KDOQI评论聚焦AHA/ACC指南中与CKD风险个体或非透析依赖CKD(1-5期)患者相关的建议,因此不评论接受维持性透析患者的高血压管理。在AHA/ACC指南未给出正式建议的领域(如药物相互作用、电解质紊乱和肾损伤),工作组就其对CKD患者的意义提供专家评论。总体而言,工作组支持AHA/ACC的多数建议,并指出证据仍有限或CKD管理需进一步考虑的领域。
Schultheiss et al. show that replacing Chronic Kidney Disease Epidemiology Collaboration with European Kidney Function Consortium cystatin C-based equations reclassifies women, but not men, into milder chronic kidney disease stages, while outcome prediction is unchanged. We argue that prediction of kidney failure cannot validate a glomerular filtration rate equation: dialysis initiation is a clinical decision, not a filtration measurement. The analysis is cross-sectional, leaving longitudinal performance untested. Equations are population tools; at the bedside, non-glomerular filtration rate determinants of both creatinine and cystatin C can mislead.
中文摘要:Schultheiss 等的研究显示,以欧洲肾功能联盟基于胱抑素C的方程替代慢性肾脏病流行病学协作组方程,会将女性而非男性重新分类到更轻的慢性肾脏病分期,而结局预测没有变化。我们认为,对肾衰竭的预测不能验证一个肾小球滤过率方程:开始透析是临床决策,不是滤过测量。该分析为横断面设计,未检验纵向性能。方程是人群工具;在床旁,肌酐和胱抑素C的非肾小球滤过率决定因素都可能造成误导。
To examine 3-year longitudinal trajectories of continuous glucose monitoring (CGM) metrics across subgroups at risk for suboptimal glycemic control among adults with type 1 diabetes. In this multicenter study, 1,028 individuals contributed 3,441 longitudinal CGM profiles. Participants were stratified on the basis of age, chronic kidney disease (CKD), β-cell function, BMI, and triglyceride-glucose (TyG) tertile. Linear mixed-effects models were used to estimate subgroup differences in longitudinal changes. At baseline, there was more time spent with glucose above target range (>180 mg/dL), for the subgroups of older age, CKD, severe β-cell failure, higher BMI, and highest TyG tertile (all P < 0.05), while severe β-cell failure was additionally associated with more time spent with glucose below target range (time below range [TBR]) (<70 mg/dL), along with greater glycemic variability (all P < 0.001). In relation to younger individuals, for older adults, improvement in time spent with glucose in target range (time in range [TIR]) (70-180 mg/dL) was comparable (β = 0.110; P = 0.102) and lower TBR was maintained (3.5% vs. 1.7%, respectively; P < 0.001). Among the CKD group, significant improvement in TIR was seen (β = 0.228; P = 0.002) without exacerbation of hypoglycemia. Severe β-cell failure attenuated TIR improvement (β = -0.119; P = 0.025) and TBR reduction (β = 0.046; P < 0.001). Lower absolute TIR was seen for those with higher BMI and those in the highest TyG tertile. Greater TIR improvement was observed for those in the highest TyG tertile (β = 0.083; P = 0.001). CGM metrics varied widely within these subgroups. Older age and CKD were associated with longitudinal glycemic improvement without worsening of hypoglycemia, whereas severe β-cell failure limited glycemic gains; substantial within-group heterogeneity supports individualized glycemic targets informed by CGM trajectories in type 1 diabetes.
中文摘要:考察成人1型糖尿病中血糖控制欠佳风险亚组的连续血糖监测指标3年纵向轨迹。这项多中心研究中,1,028人提供了3,441份纵向CGM资料。参与者按年龄、慢性肾脏病、β细胞功能、BMI和甘油三酯-葡萄糖三分位分层。采用线性混合效应模型估计纵向变化的亚组差异。基线时,年龄较大、合并CKD、严重β细胞功能衰竭、较高BMI和最高TyG三分位亚组葡萄糖高于目标范围的时间更多(均P<0.05),严重β细胞功能衰竭还与葡萄糖低于目标范围的时间更多及血糖变异性更大相关(均P<0.001)。与年轻个体相比,老年人的目标范围内时间改善程度相当(β=0.110;P=0.102),低血糖时间维持较低(分别为3.5%与1.7%;P<0.001)。CKD组目标范围内时间显著改善(β=0.228;P=0.002),低血糖未加重。严重β细胞功能衰竭减弱目标范围内时间改善(β=-0.119;P=0.025)和低血糖时间降低(β=0.046;P<0.001)。BMI较高者和最高TyG三分位者的绝对目标范围内时间较低。最高TyG三分位者目标范围内时间改善更大(β=0.083;P=0.001)。这些亚组内CGM指标差异很大。年龄较大和CKD与纵向血糖改善相关且低血糖未恶化,严重β细胞功能衰竭限制血糖获益;组内明显异质性支持依据CGM轨迹为1型糖尿病制定个体化血糖目标。
Bipolar disorder, major depressive disorder, and schizophrenia are associated with substantial excess mortality, principally from cardiovascular disease. Identifying strategies to reduce this burden is a critical psychiatric priority. To evaluate associations between initiation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) vs sodium-glucose cotransporter-2 (SGLT2) inhibitors and all-cause mortality and major adverse cardiovascular events (MACEs) among adults with and without serious mental illness (SMI). This was a retrospective target trial emulation within the TriNetX Analytics Network, a multinational federated electronic health record network. Adults initiating GLP-1 RAs or SGLT2 inhibitors were included using a new-user, active-comparator design with propensity score matching and separate psychiatric and nonpsychiatric cohorts. The study included all available data in the TriNetX network through the most recent database refresh. Data were queried and analyzed in March 2026, with prespecified follow-up intervals of 1, 4, and 10 years. Additional subgroup analyses were conducted following peer review in May 2026. First-recorded GLP-1 RA vs SGLT2 inhibitor prescription. The primary outcome was 4-year all-cause mortality; the key secondary outcome, 1-year mortality. Additional outcomes included 3- and 5-point MACEs and individual cardiovascular end points. Sensitivity analyses included diabetes stratification, exclusion of baseline heart failure and chronic kidney disease, and censoring at crossover. Exploratory analyses examined SMI subgroups, agent-specific effects, and combination therapy. For the primary 4-year analysis, 1 528 230 adults were propensity score matched (764 115 pairs; 195 184 pairs with serious mental illness [SMI] and 568 931 pairs without SMI). The mean [SD] age in the GLP-1RA and SGLT2 inhibitor groups was 60.5 [12.0] and 60.2 [13.3] years, respectively, in the SMI cohort and 60.9 [12.2] and 60.6 [13.0] years, respectively, in the non-SMI cohort; 112 911 [57.8%], 113 488 [58.1%], 251 679 [44.2%], and 260 480 [45.8%] were female, respectively. Among participants with SMI, mortality was lower with GLP-1RA initiation than with SGLT2 inhibitor initiation (9585 of 195 184 [4.91%] vs 12 584 of 195 184 [6.45%]; hazard ratio [HR], 0.76; 95% CI, 0.74-0.78; absolute risk difference [ARD], -1.54 percentage points; 95% CI, -1.68 to -1.39; P < .001). Among participants with SMI and type 2 diabetes, semaglutide initiation, compared with SGLT2 inhibitor initiation, was associated with lower risks of 3-point MACE (HR, 0.77; 95% CI, 0.76-0.79), 5-point MACE, myocardial infarction, stroke, heart failure, and coronary artery bypass grafting. In a separately matched 1-year SMI cohort, mortality was lower with GLP-1RA initiation than with SGLT2 inhibitor initiation (2898 of 198 065; 1.46% vs 5624 of 198 065; 2.84%; RR, 0.52; 95% CI, 0.49-0.54; ARD, -1.38 percentage points; 95% CI, -1.47 to -1.29; P < .001). In 10-year exploratory analyses among participants with type 2 diabetes, semaglutide initiation, compared with SGLT2 inhibitor initiation, was associated with lower mortality in the major depressive disorder (RR, 0.55; 95% CI, 0.53-0.56), bipolar disorder (RR, 0.57; 95% CI, 0.51-0.63), and schizophrenia (RR, 0.67; 95% CI, 0.59-0.75) groups (all P < .001). The primary mortality association persisted across prespecified sensitivity analyses. In this study, GLP-1 RA initiation was associated with lower mortality and cardiovascular events compared to SGLT2 inhibitor initiation, with greater absolute reductions in SMI. Benefits were evident within 1 year, consistent across SMI subgroups, and driven by semaglutide and tirzepatide. Prospective randomized trials are warranted.
中文摘要:双相障碍、重度抑郁障碍和精神分裂症与显著超额死亡相关,主要死因为心血管疾病。识别降低这一负担的策略是精神科的重要优先事项。研究评估在有或无严重精神疾病(SMI)的成人中,启动胰高血糖素样肽-1受体激动剂(GLP-1 RA)与钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂相比,与全因死亡和主要不良心血管事件(MACE)的关联。该研究为TriNetX Analytics Network内的回顾性目标试验模拟,该网络为跨国联邦电子健康记录网络。采用新使用者、活性对照设计,并进行倾向评分匹配,分别建立精神疾病和非精神疾病队列,纳入启动GLP-1 RA或SGLT2抑制剂的成人。研究使用TriNetX网络中截至最近数据库更新的全部可用数据。数据于2026年3月查询和分析,预设随访间隔为1年、4年和10年。同行评审后于2026年5月进行额外亚组分析。暴露为首个记录的GLP-1 RA与SGLT2抑制剂处方。主要结局为4年全因死亡;关键次要结局为1年死亡。其他结局包括3项和5项MACE及单个心血管终点。敏感性分析包括糖尿病分层、排除基线心力衰竭和慢性肾脏病、交叉时删失。探索性分析考察SMI亚组、药物特异性效应和联合治疗。主要4年分析中,1 528 230名成人经倾向评分匹配(764 115对;195 184对伴SMI,568 931对不伴SMI)。GLP-1RA组和SGLT2抑制剂组平均[SD]年龄在SMI队列分别为60.5[12.0]岁和60.2[13.3]岁,在非SMI队列分别为60.9[12.2]岁和60.6[13.0]岁;女性分别为112 911[57.8%]、113 488[58.1%]、251 679[44.2%]和260 480[45.8%]。在SMI参与者中,启动GLP-1RA者死亡低于启动SGLT2抑制剂者(195 184例中9585例[4.91%] vs 195 184例中12 584例[6.45%];风险比[HR] 0.76;95%CI 0.74-0.78;绝对风险差[ARD] -1.54个百分点;95%CI -1.68至-1.39;P<.001)。在伴2型糖尿病的SMI参与者中,与启动SGLT2抑制剂相比,启动司美格鲁肽与较低的3项MACE(HR 0.77;95%CI 0.76-0.79)、5项MACE、心肌梗死、卒中、心力衰竭和冠状动脉旁路移植术风险相关。在单独匹配的1年SMI队列中,启动GLP-1RA者死亡低于启动SGLT2抑制剂者(198 065例中2898例,1.46% vs 198 065例中5624例,2.84%;RR 0.52;95%CI 0.49-0.54;ARD -1.38个百分点;95%CI -1.47至-1.29;P<.001)。在伴2型糖尿病参与者的10年探索性分析中,与启动SGLT2抑制剂相比,启动司美格鲁肽与重度抑郁障碍组(RR 0.55;95%CI 0.53-0.56)、双相障碍组(RR 0.57;95%CI 0.51-0.63)和精神分裂症组(RR 0.67;95%CI 0.59-0.75)较低死亡相关(均P<.001)。主要死亡关联在预设敏感性分析中持续存在。本研究中,与启动SGLT2抑制剂相比,启动GLP-1RA与较低死亡和心血管事件相关,在SMI中绝对降幅更大。获益在1年内显现,在各SMI亚组中一致,并由司美格鲁肽和替尔泊肽驱动。有必要开展前瞻性随机试验。
Air pollution is the leading environmental cause of disease burden worldwide and is increasingly recognized as a potent driver of accelerated biological aging. Rather than acting through organ-specific toxicity alone, air pollutants appear to affect the fundamental hallmarks of aging itself, including oxidative stress, chronic inflammation, epigenetic dysregulation, telomere attrition, mitochondrial dysfunction, and cellular senescence. The pollutants of greatest concern are fine and ultrafine particulate matter (PM2.5, PM0.1), traffic-related air pollution, and household combustion emissions. This review synthesizes epidemiological and mechanistic evidence linking ambient and household air pollution to biological aging across the full spectrum of biomarker classes, including molecular measures (epigenetic clocks, telomere length, transcriptomic signatures), system-level indices (composite clinical biomarkers, proteomic aging clocks, inflammatory markers), and whole-organism measures (frailty). The strength of evidence varies meaningfully across biomarker classes. System-level composite measures, particularly the Klemera-Doubal method biological age, PhenoAge, and frailty scores, show the most robust and consistent associations with air pollution. Causal mediation analyses across independent cohorts support the role of biological aging as a mechanistic pathway linking air pollution exposure to clinical disease outcomes, including cardiovascular disease, neuropsychiatric disorders, and chronic kidney disease. Epigenetic clock findings remain inconclusive at the meta-analytic level despite strong biological plausibility, likely reflecting differences in exposure assessment methods, study design, and cell composition of the target tissue. Life-course vulnerability windows are also examined, with prenatal and early-life exposures shown to shape biological aging trajectories that persist into later life. Key research gaps include underrepresentation of household air pollution and low-income settings, and the shortage of longitudinal multimarker or multi-omics study designs. Air quality improvements and clean cooking fuel transitions have been shown to partially reverse air pollution-associated aging acceleration, reinforcing the public health relevance of these findings. Reducing air pollution thus remains the most equitable strategy for slowing biological aging at the population level, and incorporating aging-focused endpoints into environmental health research and regulatory policy is both a scientific and public health priority.
中文摘要:空气污染是全球疾病负担的首位环境原因,并被日益视为加速生物衰老的重要驱动因素。空气污染物似乎并非仅通过器官特异性毒性起作用,而是影响衰老的基本标志,包括氧化应激、慢性炎症、表观遗传失调、端粒磨损、线粒体功能障碍和细胞衰老。最受关注的污染物是细颗粒物和超细颗粒物(PM2.5、PM0.1)、交通相关空气污染以及家庭燃烧排放。该综述整合流行病学与机制证据,将室外和家庭空气污染与覆盖完整生物标志物类别的生物衰老联系起来,这些类别包括分子指标(表观遗传时钟、端粒长度、转录组特征)、系统层面指数(复合临床生物标志物、蛋白质组衰老时钟、炎症标志物)和整体机体指标(衰弱)。不同生物标志物类别的证据强度存在明显差异。系统层面的复合指标,尤其是Klemera-Doubal法生物学年龄、PhenoAge和衰弱评分,与空气污染的关联最为稳健且一致。跨独立队列的因果中介分析支持生物衰老作为连接空气污染暴露与临床疾病结局的机制通路,这些结局包括心血管疾病、神经精神障碍和慢性肾脏病。尽管生物学合理性较强,表观遗传时钟发现在荟萃分析层面仍无定论,可能反映暴露评估方法、研究设计和目标组织细胞组成的差异。生命历程脆弱窗口也受到考察,产前和生命早期暴露可塑造持续至晚年的生物衰老轨迹。关键研究空白包括家庭空气污染和低收入环境代表性不足,以及纵向多标志物或多组学研究设计缺乏。空气质量改善和清洁烹饪燃料转型已被证明可部分逆转空气污染相关的衰老加速,强化了这些发现的公共卫生意义。减少空气污染仍是人群层面减缓生物衰老最公平的策略,将衰老相关终点纳入环境健康研究和监管政策既是科学优先事项也是公共卫生优先事项。
Chronic kidney disease (CKD) is a major cause of death in Mexico, and blood pressure (BP) may be an important contributor. This study investigated the associations of BP with CKD, albuminuria, and death from kidney failure. Prospective cohort study. 133,470 adults aged ≥35 to <85 years without CKD or other chronic disease (except diabetes), recruited from 2 districts of Mexico City between 1998 and 2004, and who had survived ≥5 years after recruitment. A random subset of 9,198 underwent additional evaluation from 2015 to 2019. Systolic BP (SBP), diastolic BP (DBP) and hypertension (defined as participant report, taking BP-lowering medication, and/or BP ≥ 140/90 mm Hg). Kidney failure mortality during follow-up, and CKD (self-report and/or estimated glomerular filtration rate < 60 mL/min/1.73 m2) and albuminuria at the time of repeat clinical evaluation. Multivariable Cox regression for the association of BP with kidney failure mortality and multivariable logistic regression for the association of baseline BP with CKD and albuminuria at the time of re-evaluation. Among all participants, SBP showed a continuous log-linear association with kidney failure mortality; each 20 mm Hg lower SBP was associated with a 24% lower risk at ages 40-84 years (kidney failure death HR, 0.76 [95% CI, 0.69-0.84]). The association was stronger among those without diabetes (HR, 0.54 [95% CI, 0.45-0.69]) than with diabetes (HR, 0.90 [95% CI, 0.80-1.01]), but the absolute excess risk associated with higher BP was similar in these subgroups. Hypertension accounted for 9% of kidney failure deaths. Among those re-evaluated, 6% had developed CKD, and 25% had albuminuria. A 20 mm Hg lower baseline SBP was associated with 24% lower odds of both CKD (OR, 0.76 [95% CI, 0.68-0.85]) and albuminuria (OR, 0.76 [95% CI, 0.68-0.84]) at the time of re-evaluation. The results were similar for DBP. Baseline urine samples were unavailable, and kidney function trends over time could not be assessed. This large prospective study in Mexican adults highlights elevated BP as a major modifiable risk factor for kidney failure mortality, CKD, and albuminuria. Kidney disease is a major cause of death in Mexico, and high blood pressure may play an important role. The Mexico City Prospective Study followed approximately 150,000 Mexican adults aged 35 years or older for approximately 20 years, tracking causes of death over time. These analyses found that lower blood pressure was linked to a lower risk of dying from kidney failure. For every 20 mm Hg lower systolic blood pressure, the risk of dying from kidney failure was lower by approximately one quarter. High blood pressure accounted for 9% of all deaths from kidney failure. Lower blood pressure also was associated with better kidney function-as measured by blood tests, participant questionnaires, and urine protein levels-some years later. These analyses suggest that reducing high blood pressure is likely to prevent kidney disease and deaths related to kidney disease in Mexico.
中文摘要:慢性肾脏病是墨西哥的重要死亡原因,血压可能是重要影响因素。该研究分析血压与慢性肾脏病、白蛋白尿及肾脏衰竭死亡之间的关联。研究为前瞻性队列,纳入1998至2004年在墨西哥城两个区招募的133470名35岁及以上、85岁以下且无慢性肾脏病或其他慢性病(糖尿病除外)的成年人,并要求招募后存活至少5年;其中9198人的随机子集在2015至2019年接受额外评估。暴露包括收缩压、舒张压和高血压(参与者报告、服用降压药和/或血压≥140/90 mmHg)。结局为随访期间肾脏衰竭死亡,以及重复临床评估时的慢性肾脏病(自我报告和/或估算肾小球滤过率<60 mL/min/1.73 m2)和白蛋白尿。采用多变量Cox回归分析血压与肾脏衰竭死亡的关联,采用多变量logistic回归分析基线血压与再评估时慢性肾脏病和白蛋白尿的关联。在所有参与者中,收缩压与肾脏衰竭死亡呈连续对数线性关联;在40至84岁人群中,收缩压每低20 mmHg,风险低24%(肾脏衰竭死亡HR 0.76,95%CI 0.69-0.84)。无糖尿病者关联更强(HR 0.54,95%CI 0.45-0.69),糖尿病患者为HR 0.90(95%CI 0.80-1.01),但较高血压相关的绝对超额风险在两个亚组相似。高血压占肾脏衰竭死亡的9%。再评估人群中,6%发生慢性肾脏病,25%有白蛋白尿。基线收缩压低20 mmHg与再评估时慢性肾脏病风险低24%相关(OR 0.76,95%CI 0.68-0.85),也与白蛋白尿风险低24%相关(OR 0.76,95%CI 0.68-0.84)。舒张压结果相似。基线尿样不可获得,无法评估肾功能随时间的变化趋势。这项在墨西哥成年人中开展的大型前瞻性研究提示,血压升高是肾脏衰竭死亡、慢性肾脏病和白蛋白尿的重要可改变危险因素。肾脏疾病是墨西哥的重要死亡原因,高血压可能起重要作用。墨西哥城前瞻性研究随访约15万名35岁及以上墨西哥成年人约20年,持续追踪死亡原因。这些分析发现,较低血压与较低肾脏衰竭死亡风险相关;收缩压每低20 mmHg,肾脏衰竭死亡风险约低四分之一。高血压占所有肾脏衰竭死亡的9%。较低血压还与数年后较好的肾功能相关,肾功能通过血液检测、参与者问卷和尿蛋白水平衡量。这些分析提示,降低高血压可能有助于预防墨西哥的肾脏疾病及其相关死亡。
Chronic kidney disease (CKD) is more prevalent in women than men, but men progress faster to kidney failure (KF). Equations may estimate glomerular filtration rate (eGFR) differently by sex. This study assessed sex-specific reclassification using the creatinine- and cystatin C-based European Kidney Function Consortium (EKFC) versus the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) eGFR equations and evaluated KF prediction. We compared classification in Kidney Disease: Improving Global Outcomes (KDIGO) GFR stages at baseline by sex based on GFR estimated with EKFC vs CKD-EPI equations in the German CKD study (GCKD) (5085 persons). Findings were validated in the National Unified Renal Translational Research Enterprise (NURTuRE)-CKD cohort (2589 persons) and the population-based RENIS-3 (Renal Iohexol Clearance Survey) study (1383 persons), the latter with gold-standard measured GFR (mGFR). Among GCKD participants, men (60%) had a higher urine albumin-to-creatinine ratio (UACR), whereas women had higher eGFR. Over 8.5 years, 181 women (3.6%) and 459 men (9.0%) developed KF. Using EKFC formulas based on cystatin C only or combined with creatinine, women were consistently and more frequently reclassified into milder eGFR stages and 4- to 5.7-fold more frequently classified as not having CKD than men. Sex-specific reclassification patterns were replicated in NURTuRE-CKD (2589 persons). In RENIS-3, comparison with mGFR showed sex-specific misclassification for both equations, with better alignment in the lower eGFR ranges for EKFC. Predictive performance for progression to KF was similar between the EKFC and CKD-EPI equations and became equivalent after adjusting for age, sex, and UACR. Women were more frequently reclassified into a less severe stage of CKD using the EKFC eGFR than the CKD-EPI equation, yet the prognostic performance for KF did not differ significantly between the two equations for both women and men. This suggests that the reclassification has limited clinical influence on KF risk prediction.
中文摘要:慢性肾脏病在女性中更常见,但男性进展至肾衰竭更快。不同估算公式可能按性别给出不同的肾小球滤过率估计值。本研究评估基于肌酐和胱抑素C的欧洲肾脏功能联盟EKFC公式与慢性肾脏病流行病学协作组CKD-EPI公式相比的性别特异性重分类,并评价肾衰竭预测。研究在德国慢性肾脏病研究GCKD的5085人中,按性别比较基线时基于EKFC与CKD-EPI估算的肾小球滤过率对应的KDIGO GFR分期。结果在NURTuRE-CKD队列2589人和基于人群的RENIS-3研究1383人中验证,后者采用金标准测量的肾小球滤过率。GCKD参与者中,男性占60%,其尿白蛋白与肌酐比值更高,女性估算肾小球滤过率更高。随访8.5年间,181名女性(3.6%)和459名男性(9.0%)发生肾衰竭。使用仅基于胱抑素C或联合肌酐的EKFC公式时,女性持续且更频繁地被重分类至更轻的估算肾小球滤过率分期,被判定为无慢性肾脏病的频率比男性高4至5.7倍。性别特异性重分类模式在NURTuRE-CKD中得到重复。RENIS-3中与测量肾小球滤过率比较显示,两种公式均存在性别特异性错误分类,EKFC在较低估算肾小球滤过率范围内一致性更好。EKFC与CKD-EPI对进展至肾衰竭的预测性能相似,调整年龄、性别和尿白蛋白与肌酐比值后二者相当。使用EKFC而非CKD-EPI时,女性更频繁地被重分类至较轻的慢性肾脏病分期,但两种公式对女性和男性的肾衰竭预后性能无显著差异。这提示该重分类对肾衰竭风险预测的临床影响有限。
Peritubular capillary (PTC) rarefaction occurs in chronic kidney disease (CKD), but the independent association of PTC histological features with CKD progression is uncertain. This study assessed this relationship. Historical cohort study. Patients who underwent radical nephrectomy for a kidney tumor. PTC histological features including density, mean area, major axis length, and circularity were defined in the cortex (excluding regions of interstitial fibrosis and tubular atrophy [IFTA]) and medulla using previously developed deep learning models. Progressive CKD was defined as the composite of dialysis, kidney transplantation, a sustained decline in estimated glomerular filtration rate (eGFR) of ≥30%, or a sustained eGFR <10 mL/min/1.73 m2 that was ≥5 mL/min/1.73 m2 lower than the postnephrectomy value. Cox proportional hazards analysis where follow-up was censored at death, cancer recurrence, or the last serum creatinine value adjusted for chronic histological changes (IFTA, glomerulosclerosis, arteriosclerosis, and arteriolar hyalinosis) and the CKD risk factors of age, sex, body mass index, hypertension, diabetes, eGFR, and proteinuria. Progressive CKD was experienced by 94 patients (6.1%) of 1,553 followed for a median of 4.3 years. A mean of 28,055 PTCs and 332 glomeruli were detected in each wedge section. In cortical and medullary tissue, a lower density of PTCs and PTCs that were more circular and less elongated were associated with progressive CKD in analyses adjusted for kidney function and CKD risk factors. After additional adjustment for chronic histological changes, only cortical PTCs that were more circular and less elongated were associated with progressive CKD. Study limited to patients who underwent a radical nephrectomy for a tumor. Reduction and simplification of the microvasculature in nonscarred regions of cortex and medulla are associated with progressive CKD. Peritubular capillaries support oxygen transport, nutrient exchange, and waste elimination by the renal tubules in the kidney. Using artificial intelligence and image processing tools, we characterized the size, shape, and density of these capillaries in sections of human kidneys removed from patients with a kidney tumor. The study found that in the nonscarred regions of kidney tissue, lower density and rounder capillaries in the space between tubules were associated with a subsequent loss of kidney function.
中文摘要:慢性肾脏病(CKD)中存在管周毛细血管(PTC)稀疏,但PTC组织学特征与CKD进展的独立关联尚不确定。本研究评估了这一关系。历史性队列研究。对象为因肾脏肿瘤接受根治性肾切除术的患者。采用既往开发的深度学习模型,在皮质(排除肾间质纤维化和肾小管萎缩[IFTA]区域)和髓质中定义PTC的组织学特征,包括密度、平均面积、长轴长度和圆度。进展性CKD定义为透析、肾移植、估算肾小球滤过率(eGFR)持续下降≥30%,或eGFR持续<10 mL/min/1.73 m2且较肾切除后值低≥5 mL/min/1.73 m2的复合终点。采用Cox比例风险分析,随访在死亡、肿瘤复发或末次血清肌酐值时删失,并校正慢性组织学改变(IFTA、肾小球硬化、动脉硬化和小动脉玻璃样变)以及年龄、性别、体质指数、高血压、糖尿病、eGFR和蛋白尿等CKD危险因素。1,553例患者中位随访4.3年,94例(6.1%)发生进展性CKD。每个楔形切片平均检测到28,055条PTC和332个肾小球。在校正肾功能和CKD危险因素的分析中,皮质和髓质组织中较低的PTC密度以及PTC更圆、更不细长与进展性CKD相关。进一步校正慢性组织学改变后,仅皮质中更圆、更不细长的PTC与进展性CKD相关。研究仅限于因肿瘤接受根治性肾切除术的患者。皮质和髓质无瘢痕区域的微血管减少和简化与进展性CKD相关。管周毛细血管支持肾脏中肾小管的氧运输、营养物质交换和废物清除。利用人工智能和图像处理工具,我们在因肾脏肿瘤切除的人肾切片中描述了这些毛细血管的大小、形状和密度。研究发现,在肾脏组织无瘢痕区域,小管间空间中较低的毛细血管密度和更圆的毛细血管与随后的肾功能丧失相关。
Lived Experiences of Home-Based Conservative Kidney Management in Older Adults: A Qualitative Study.
Despite growing interest in conservative kidney management (CKM) for older adults with advanced chronic kidney disease (CKD), little is known about the lived experiences of those involved in CKM care. This study explored the perceptions and experiences of patients, informal caregivers, nephrologists, and health care professionals participating in a coordinated home-based CKM pathway in France. Multicenter qualitative study using grounded theory. Participants were recruited from a regional, coordinated home-based CKM pathway involving 20 nephrology centers and a multidisciplinary care network across urban and semirural areas in northern France. Semistructured interviews explored experiential themes and the perceived value of CKM in 4 stakeholder groups. Analysis used grounded theory with open, axial, and selective coding. Fifty-three participants were interviewed: 12 patients, 12 informal caregivers, 15 nephrologists, and 14 home-care professionals. Three interrelated themes emerged. First, CKM was perceived as a meaningful and legitimate alternative to dialysis, centered on remaining at home, preserving autonomy, and prioritizing quality of life. The decision not to dialyze was usually described as patient-driven and grounded in a rejection of dependence and hospitalization. Second, communication, decision making, and coordination emerged as central but uneven pillars of the pathway. Introducing conservative care and discussing end-of-life preferences remained difficult, and the coordinating nurse consistently appeared as the key structural link between patients, caregivers, nephrologists, and community professionals. Third, informal caregivers occupied a central yet vulnerable position, combining emotional support, practical coordination, and symptom monitoring; although increasingly involved in organizing care, they frequently experienced substantial burden, anticipatory distress, and mutual protective silences within families. Single-region study; limited generalizability; possible selection bias. CKM involves complex relational, emotional, and practical dynamics. Incorporating the perspectives of various stakeholders may help optimize coordinated, home-based care pathways tailored to older adults with advanced CKD. Some people with advanced kidney disease are too frail or simply do not wish to receive dialysis. For them, an alternative exists: conservative kidney management, which focuses on comfort, quality of life, and avoiding hospitalization. In France, a coordinated team of nurses, doctors, and allied health professionals delivers this care in the home. This study explored how patients, their family caregivers, and the health care professionals experience this care. Using in-depth interviews, we found that effective care relies on the services of a specialized coordinating nurse, that family caregivers carry heavy and often invisible responsibilities, and that honest conversations about the end of life are challenging. These insights can inform better home-based care for older adults facing kidney failure worldwide.
中文摘要:尽管对晚期慢性肾脏病(CKD)老年人采取保守肾脏管理(CKM)的兴趣日益增加,但参与CKM照护者的真实体验仍知之甚少。本研究探讨在法国参与协调式居家CKM路径的患者、非正式照护者、肾科医生和卫生保健专业人员的看法与体验。研究为多中心定性研究,采用扎根理论。参与者来自法国北部城市和半农村地区一个区域性协调式居家CKM路径,该路径涉及20个肾科中心和一个多学科照护网络。半结构式访谈探讨四类利益相关群体的体验主题及对CKM价值的感知。分析采用扎根理论,进行开放编码、轴心编码和选择性编码。共访谈53名参与者:12名患者、12名非正式照护者、15名肾科医生和14名居家照护专业人员。形成三个相互关联的主题。第一,CKM被视为透析之外有意义且合理的替代选择,核心是留在家里、保持自主和优先考虑生活质量。不进行透析的决定通常被描述为由患者驱动,并基于对依赖和住院的拒绝。第二,沟通、决策和协调成为该路径的核心支柱,但发展并不均衡。引入保守治疗和讨论临终偏好仍然困难,协调护士始终是连接患者、照护者、肾科医生和社区专业人员的关键结构性纽带。第三,非正式照护者处于核心但脆弱的位置,同时承担情感支持、实际协调和症状监测;他们越来越多地参与照护安排,却常经历显著负担、预期性痛苦以及家庭内相互保护的沉默。研究限于单一区域;外推性有限;可能存在选择偏倚。CKM涉及复杂的关系、情感和实践动态。纳入不同利益相关者的视角,可能有助于优化针对晚期CKD老年人的协调式居家照护路径。部分晚期肾病患者过于虚弱或不愿接受透析。对他们而言存在替代选择:保守肾脏管理,关注舒适、生活质量和避免住院。在法国,由护士、医生和相关卫生专业人员组成的协调团队在居家提供这种照护。本研究探讨患者、家庭照护者和卫生保健专业人员如何体验这种照护。通过深度访谈,我们发现有效照护依赖专职协调护士的服务,家庭照护者承担沉重且常被忽视的责任,关于临终的坦诚对话具有挑战性。这些认识可为全球面临肾衰竭的老年人提供更好的居家照护。
Observational evidence suggests that metabolic acidosis in chronic kidney disease (CKD) is a driver of CKD progression, but there remains significant debate regarding the quantity and quality of published evidence to support treatment. The Kidney Disease: Improving Global Outcomes (KDIGO) guidance on metabolic acidosis in CKD highlighted this controversy by publishing practice points, not recommendations, based primarily on placebo-controlled randomized controlled trials. These practice points suggest considering treatment to prevent metabolic acidosis with a proposed cutoff for serum bicarbonate < 18 mmol/L. However, this approach means a substantial number of individuals with CKD may now remain untreated for their metabolic acidosis, which may impact CKD progression with associated adverse health outcomes. Additionally, the guidance does not include all the available evidence. From our critical appraisal we suggest that the evidence cited could have been interpreted differently. We recommend that the practice points published are revised based on critical appraisal of the cited evidence to inform the clinical management of individuals with metabolic acidosis in CKD. We also suggest a research agenda for future studies to help resolve this issue.
中文摘要:观察性证据提示,慢性肾脏病(CKD)患者的代谢性酸中毒可推动CKD进展;不过,已发表的证据在数量和质量上是否足以支持治疗,仍有明显争议。KDIGO关于CKD代谢性酸中毒的指导文件主要依据安慰剂对照随机对照试验,发布的是实践要点,并未给出推荐意见,这也凸显了该争议。这些实践要点提出,可考虑通过治疗预防代谢性酸中毒,建议的血清碳酸氢盐切点为低于18 mmol/L。但这一做法意味着相当数量CKD患者的代谢性酸中毒可能得不到治疗,进而可能影响CKD进展,并带来相关不良健康结局。该指导文件也未纳入全部现有证据。经我们批判性评价,我们认为所引证据可有不同解读。我们建议根据对所引证据的批判性评价修订已发布的实践要点,以指导CKD代谢性酸中毒患者的临床管理。我们还提出了未来研究议程,以帮助解决这一问题。
The plasma proteomic signatures of sleep disturbance remain poorly characterized. Using data from 43,709 predominantly European-ancestry, middle-aged and older UK Biobank participants, we depict a large-scale atlas of plasma proteomic signatures of seven self-reported sleep traits (sleep duration, chronotype, insomnia symptoms, daytime napping, daytime sleepiness, snoring, and ease of getting up in the morning) and a derived sleep health score. We identify 935 proteins associated with at least one sleep trait, converging on lipid metabolism, immune function and inflammation, cell adhesion, and neurochemical signaling. Leveraging genomic structural equation modeling to define three latent sleep factors, namely circadian preference, daytime sleep burden, and nighttime sleep adequacy, bidirectional Mendelian randomization (MR) identifies one protein (LTA) with robust cis-instrument and strong colocalization support (PP.H4 = 0.98) for a putative causal effect on nighttime sleep adequacy. Sixteen additional genetically supported candidate proteins rely primarily on trans-pQTL instruments or weaker colocalization. These genetically supported candidates are prospectively associated with incident cardiovascular disease, stroke, type 2 diabetes, dementia, chronic kidney disease, depression, and mortality over a median 13.6-year follow-up, with the strongest per-SD hazard ratio (HR) associations observed for chronic kidney disease (e.g., BTN2A1: HR = 2.33) and type 2 diabetes (e.g., RBP5: HR = 1.58). Collectively, these findings highlight the potential of large-scale proteomics in elucidating sleep pathogenesis, and generate testable hypotheses for validation in independent cohorts and experimental models.
中文摘要:睡眠障碍的血浆蛋白组学特征仍缺乏系统描述。研究利用英国生物银行43709名以欧洲血统为主的中老年参与者数据,构建了七种自我报告睡眠特征(睡眠时长、晨晚型、失眠症状、日间小睡、日间嗜睡、打鼾、晨起难易程度)及一个衍生睡眠健康评分的血浆蛋白组学特征大规模图谱。共识别出935种与至少一种睡眠特征相关的蛋白,这些蛋白集中于脂质代谢、免疫功能与炎症、细胞黏附及神经化学信号传导。利用基因组结构方程模型定义三个潜在睡眠因子,即昼夜偏好、日间睡眠负担和夜间睡眠充足度,双向孟德尔随机化识别出一种蛋白(LTA),其顺式工具变量稳健且共定位支持强(PP.H4=0.98),提示其对夜间睡眠充足度可能存在因果效应。另外16种获遗传学支持的候选蛋白主要依赖反式pQTL工具变量或较弱的共定位证据。这些获遗传学支持的候选蛋白与随访中位13.6年内新发心血管疾病、卒中、2型糖尿病、痴呆、慢性肾脏病、抑郁和死亡前瞻性相关,其中每增加1个标准差风险比最强见于慢性肾脏病(如BTN2A1:HR=2.33)和2型糖尿病(如RBP5:HR=1.58)。这些发现凸显大规模蛋白组学在阐明睡眠发病机制方面的潜力,并为在独立队列和实验模型中验证提供了可检验的假设。
Frailty is common in chronic kidney disease (CKD) and is independently associated with disability and mortality. However, evidence on the optimal treatment of frail adults with CKD remains limited. Consequently, regulators have encouraged routine assessment of frailty and the reporting of outcomes stratified by frailty in clinical studies. In this narrative review, we found that several recent clinical trials of disease-modifying therapies for CKD evaluated treatment effects across frailty strata and reported consistent benefits, with potentially greater benefits in the highest frailty subgroup. However, frailty was not formally assessed in any of these trials, and the proxy measures used may not have fully captured the multidimensional aspects of frailty needed to inform treatment decisions.
中文摘要:衰弱在慢性肾脏病(CKD)中常见,并与失能和死亡独立相关。针对CKD衰弱成人最佳治疗的证据仍有限。监管机构因此鼓励临床研究常规评估衰弱,并按衰弱分层报告结局。在这篇叙述性综述中,我们发现若干近期CKD疾病修饰治疗临床试验在不同衰弱分层中评估了治疗效应,报告获益一致,最高衰弱亚组可能获益更大。不过,这些试验均未正式评估衰弱,所用替代指标可能未能充分反映为治疗决策所需的衰弱多维特征。
Physical frailty has been linked to cardiovascular-kidney-metabolic (CKM) multimorbidity, but the role of cognitive frailty and its dynamic changes in CKM progression remains unclear. We investigated the associations of baseline cognitive frailty and changes in cognitive frailty status with incident CKM multimorbidity. This cohort study included participants aged ≥ 45 years from the CHARLS (2011-2018). Cognitive frailty was classified as Robust, reversible cognitive frailty (RCF), or potentially reversible cognitive frailty (PRCF). A five-level score quantified the magnitude of cognitive change (Δscore). CKM multimorbidity was defined as ≥ 2 of cardiovascular disease, chronic kidney disease, and metabolic disease. Cox models and trend tests estimated hazard ratios (HRs) and 95% CIs. Among 9816 participants, 3836 were included in baseline CKM analysis and 1891 in transition analysis. Both RCF (HR=2.74, 95%CI:2.25-3.34) and PRCF (HR=2.51, 95%CI:1.96-3.21) were associated with increased CKM risk (both P < 0.001). Cognitive status provided additional risk stratification beyond physical frailty. RCF-to-Robust improvement reduced CKM risk by 56% (HR=0.44, 95%CI:0.23-0.85, P = 0.015), while deterioration markedly increased risk (HR≈5.3, P < 0.001). The Δscore trend test showed a significant dose-response relationship (P < 0.001). Substantial improvement (Δscore=-3) significantly reduced risk, whereas minor improvements showed protective trends without statistical significance. Cognitive frailty is independently associated with CKM multimorbidity progression. Within each direction of cognitive change, the magnitude of change provided additional prognostic information beyond direction alone. These findings support the brain-CKM interconnection framework and suggest cognitive screening should be considered in CKM prevention strategies. Cognitive frailty-a condition where physical decline and memory problems occur together-is common in older adults. In this study, we analysed data from nearly 10,000 middle-aged and older adults in China to understand whether cognitive frailty increases the risk of developing cardiovascular-kidney-metabolic (CKM) multimorbidity, a cluster of conditions including heart disease, kidney disease, and diabetes. We found that people with cognitive frailty had significantly higher risks of developing CKM multimorbidity. More importantly, we found that the magnitude of change in cognitive function added prognostic information on top of its direction-greater worsening tracked with higher CKM risk. These findings suggest that monitoring changes in cognitive function over time could help identify individuals at high risk of CKM multimorbidity, and that interventions aimed at improving cognitive health may need to achieve meaningful improvement to reduce this risk.
中文摘要:身体衰弱与心血管-肾脏-代谢(CKM)多病共存有关,但认知衰弱及其动态变化在CKM进展中的作用仍不清楚。我们考察基线认知衰弱及认知衰弱状态变化与新发CKM多病共存的关联。本队列研究纳入CHARLS(2011-2018)中年龄≥45岁的参与者。认知衰弱分为稳健、可逆性认知衰弱(RCF)或潜在可逆性认知衰弱(PRCF)。五级评分量化认知变化幅度(Δscore)。CKM多病共存定义为心血管疾病、慢性肾脏病和代谢性疾病中≥2种。Cox模型和趋势检验估计风险比(HR)和95%CI。9816名参与者中,3836名纳入基线CKM分析,1891名纳入转变分析。RCF(HR=2.74,95%CI:2.25-3.34)和PRCF(HR=2.51,95%CI:1.96-3.21)均与CKM风险升高相关(均P<0.001)。认知状态在身体衰弱之外提供额外风险分层。RCF转为稳健使CKM风险降低56%(HR=0.44,95%CI:0.23-0.85,P=0.015),而恶化显著增加风险(HR≈5.3,P<0.001)。Δscore趋势检验显示显著剂量反应关系(P<0.001)。大幅改善(Δscore=-3)显著降低风险,小幅改善显示保护趋势但无统计学意义。认知衰弱与CKM多病共存进展独立相关。在认知变化的每个方向上,变化幅度在方向之外提供额外预后信息。这些发现支持脑-CKM互联框架,并提示CKM预防策略应考虑认知筛查。认知衰弱指身体衰退与记忆问题同时出现,在老年人中常见。本研究分析中国近1万名中老年人数据,了解认知衰弱是否增加心血管-肾脏-代谢(CKM)多病共存风险,该多病共存包括心脏病、肾病和糖尿病。我们发现认知衰弱者发生CKM多病共存风险显著更高。更重要的是,认知功能变化幅度在变化方向之外增加预后信息,恶化越大CKM风险越高。这些发现提示随时间监测认知功能变化有助于识别CKM多病共存高风险个体,改善认知健康的干预可能需要达到有意义的改善才能降低该风险。
Non-invasive wearable sensing of sweat uric acid (UA) and urea provides a promising strategy for early chronic kidney disease screening. Nevertheless, most electrochemical sensors for UA and urea detection suffer from insufficient anti-interference and require exogenous redox probes, restricting reagent-free on-body measurement. Herein, we develop a wearable microfluidic electrochemical platform based on Prussian blue-embedded molecularly imprinted polymer (PB-MIP) composite materials for reagent-free, enzyme-free dual-biomarker quantification. Urea-specific and UA-specific PB-MIP composites are prepared via a facile one-step ultraviolet polymerization strategy. PB uniformly embedded within the imprinted framework acts as an intrinsic solid-state redox mediator, integrating specific molecular recognition and built-in electrochemical signal transduction into a single functional material. The two PB-MIP composites are drop-coated on dual working electrodes of a screen-printed carbon electrode, coupled with a capillary-driven microfluidic chip to construct a wearable electrochemical platform. Benefiting from the microfluidic design, the system enables pump-free spontaneous collection of trace sweat samples and achieves simultaneous quantification of sweat UA and urea. The platform exhibits wide linear ranges (0.1-600 μM for uric acid, 0.1-300 mM for urea), low limits of detection, excellent anti-interference capacity, recyclability, and favorable storage stability. On-body dietary intervention tests capture clear postprandial biomarker fluctuations, and detection results show good agreement with HPLC-MS reference values. This work offers a straightforward material-engineering strategy to develop probe-free MIP sensing interfaces and integrated wearable microfluidic devices, showing promising prospects for noninvasive preliminary screening of kidney function.
中文摘要:对汗液尿酸(UA)和尿素进行无创可穿戴传感,为慢性肾脏病早期筛查提供了有前景的策略。现有用于UA和尿素检测的电化学传感器大多抗干扰能力不足,且需要外源氧化还原探针,限制了免试剂的人体在体测量。为此,我们开发了一种基于普鲁士蓝嵌入分子印迹聚合物(PB-MIP)复合材料的可穿戴微流控电化学平台,用于免试剂、免酶的双标志物定量检测。通过简便的一步紫外聚合策略制备尿素特异性与UA特异性PB-MIP复合材料。均匀嵌入印迹骨架中的PB作为内置固态氧化还原介体,将特异性分子识别与内置电化学信号转导整合于单一功能材料中。将两种PB-MIP复合材料滴涂在丝网印刷碳电极的双工作电极上,并与毛细驱动微流控芯片结合,构建可穿戴电化学平台。借助微流控设计,系统可无泵自发采集微量汗液样本,并实现汗液UA与尿素的同步定量。平台具有较宽的线性范围(尿酸0.1–600 μM,尿素0.1–300 mM)、低检出限、良好抗干扰能力、可重复使用性和较好的储存稳定性。人体在体饮食干预试验捕捉到清晰的餐后标志物波动,检测结果与HPLC-MS参考值一致。该工作提供了一种直接的材料工程策略,用于构建免探针MIP传感界面和集成式可穿戴微流控器件,在肾功能无创初步筛查方面具有应用前景。
基础研究 (7篇)
Vascular calcification is a hallmark of chronic kidney disease (CKD)-mineral and bone disorder and a major determinant of cardiovascular mortality. Secondary calciprotein particles (CPP2) are key mediators of vascular calcification; however, the mechanisms regulating their maturation and pathogenic properties remain incompletely understood. CPT (Calprotectin, S100A8/A9), a myeloid-derived inflammatory mediator, is elevated in CKD and predicts cardiovascular events and mortality, particularly under high-phosphate conditions, but the underlying mechanisms remain unclear. We investigated the role of CPT in vascular calcification using CKD-mineral and bone disorder mice with myeloid-specific CPT deletion. Aortic calcification was assessed by ex vivo imaging, histology, and calcium quantification. Serum calciprotein particle (CPP) fractions were determined by flow cytometry. Mechanistic studies were performed in vascular smooth muscle cells exposed to CPP2 in the presence or absence of macrophage-derived CPT. Calcification propensity was evaluated using the T50 assay, and CPP2 elemental composition was analyzed by high-angle annular dark-field scanning transmission electron microscopy-energy-dispersive X-ray spectroscopy. Myeloid-specific CPT deletion significantly attenuated aortic calcification and osteogenic gene expression in CKD-mineral and bone disorder mice without altering renal function or systemic mineral parameters. These changes were accompanied by an increased circulating immature CPP fraction. Macrophage-derived CPT markedly enhanced CPP2-induced vascular smooth muscle cell calcification by accelerating CPP maturation, reflected by a shortened T50, and by altering CPP2 composition to be enriched in calcium and phosphate. Although no direct interaction between CPT and CPPs was detected, CPT modified the physicochemical milieu, including ionized calcium and pH. Consistently, CPP2 from CPT-deficient serum exhibited substantially reduced calcification potency, indicating that CPT shapes CPP pathogenicity by modulating particle quality rather than quantity. Importantly, CPT-mediated CPP maturation occurred in a cell-free milieu, indicating a TLR4-independent mechanism distinct from its known receptor-mediated actions. CPT is a previously unrecognized regulator of pathogenic CPP maturation and composition, thereby promoting vascular calcification in CKD-mineral and bone disorder. Targeting CPT may represent a novel therapeutic strategy to attenuate vascular calcification in CKD.
中文摘要:血管钙化是慢性肾脏病(CKD)矿物质和骨异常的特征,也是心血管死亡的主要决定因素。次级钙蛋白颗粒(CPP2)是血管钙化的关键介质;然而,调控其成熟及致病特性的机制仍未完全阐明。CPT(钙卫蛋白,S100A8/A9)是一种髓系来源的炎症介质,在CKD中升高,并可预测心血管事件和死亡,尤其在高磷条件下,但其潜在机制尚不清楚。我们利用髓系特异性CPT敲除的CKD-矿物质和骨异常小鼠研究CPT在血管钙化中的作用。通过离体成像、组织学和钙定量评估主动脉钙化。采用流式细胞术测定血清钙蛋白颗粒(CPP)组分。机制研究在暴露于CPP2且存在或不存在巨噬细胞来源CPT的条件下在血管平滑肌细胞中进行。使用T50试验评估钙化倾向,并通过高角环形暗场扫描透射电子显微镜-能量色散X射线光谱分析CPP2元素组成。髓系特异性CPT敲除显著减轻CKD-矿物质和骨异常小鼠的主动脉钙化和成骨基因表达,而未改变肾功能或全身矿物质参数。这些变化伴随循环未成熟CPP组分增加。巨噬细胞来源CPT通过加速CPP成熟(表现为T50缩短)和改变CPP2组成使其富含钙和磷酸盐,显著增强CPP2诱导的血管平滑肌细胞钙化。尽管未检测到CPT与CPP之间的直接相互作用,CPT改变了理化环境,包括离子钙和pH。一致地,来自CPT缺陷血清的CPP2钙化效力显著降低,表明CPT通过调节颗粒质量而非数量来塑造CPP致病性。重要的是,CPT介导的CPP成熟发生在无细胞环境中,表明这是一种不依赖TLR4的机制,不同于其已知的受体介导作用。CPT是致病性CPP成熟和组成的此前未被认识的调节因子,从而促进CKD-矿物质和骨异常中的血管钙化。靶向CPT可能代表减轻CKD血管钙化的新治疗策略。
Secondary hyperparathyroidism is a major contributor to skeletal fragility in chronic kidney disease, yet fracture risk remains high despite parathyroid hormone-lowering therapy. In a rat model of chronic kidney disease, Allen et al. showed that combining the prebiotic fiber inulin with a calcimimetic further suppresses elevated bone turnover while improving cortical bone architecture and mechanical properties. These findings highlight the potential of gut-targeted interventions to complement established parathyroid hormone-lowering strategies for improving skeletal health.
中文摘要:继发性甲状旁腺功能亢进是慢性肾脏病骨骼脆性的重要原因,尽管采用降低甲状旁腺激素的治疗,骨折风险仍然较高。在慢性肾脏病大鼠模型中,Allen等发现,将益生元纤维菊粉与拟钙剂联合使用,可进一步抑制升高的骨转换,同时改善皮质骨结构和力学性能。这些发现提示,肠道靶向干预有望补充现有的降低甲状旁腺激素策略,以改善骨骼健康。
Renal fibrosis is a common endpoint of chronic kidney disease (CKD), yet effective targeted anti-fibrotic therapies remain limited. Ovatodiolide (OVA) has anti-fibrotic activity but poor drug-like properties, whereas ACT004, a synthetic OVA derivative, has improved water solubility and metabolic stability. However, whether ACT004 acts through the same mechanism as OVA or through a distinct target remains unclear. In this study, we evaluated the anti-fibrotic effects of ACT004 in unilateral ureteral obstruction (UUO) and unilateral ischemia-reperfusion injury (UIRI) mouse models and investigated its underlying mechanism using RNA sequencing, HuProt human protein microarray, microscale thermophoresis, pull-down assays, cellular thermal shift assay, molecular docking, siRNA, mutant plasmids, co-immunoprecipitation, and pharmacological inhibition. ACT004 markedly attenuated renal fibrosis in UUO and UIRI mice and suppressed inflammatory signaling and Smad2/3 activation in vivo and in TGF-β1-stimulated renal tubular epithelial cells. Four-and-a-half LIM domain protein 1 (FHL1) was identified as a direct ACT004-binding target. ACT004 bound FHL1 at Lys102 and Thr128, and mutation of these residues weakened ACT004-FHL1 binding. FHL1 knockdown reduced TGF-β1-induced profibrotic activation, whereas ACT004 failed to further suppress fibrotic marker expression after FHL1 silencing. Mechanistically, ACT004 disrupted the FHL1-Smad2/3 interaction, inhibited Smad2/3 phosphorylation, and promoted ubiquitination-mediated degradation of FHL1. FHL1 overexpression aggravated UUO-induced renal fibrosis, whereas ACT004 alleviated FHL1-associated fibrotic injury in vivo. These findings identify FHL1 as a previously unrecognized pro-fibrotic scaffold in the kidney and position ACT004 as a next-generation anti-fibrotic candidate with a dual mechanism of action.
中文摘要:肾纤维化是慢性肾脏病(CKD)的共同终末结局,有效的靶向抗纤维化治疗仍然有限。Ovatodiolide(OVA)具有抗纤维化活性,但成药性差;ACT004是人工合成的OVA衍生物,水溶性和代谢稳定性更好。不过,ACT004是否与OVA通过相同机制起作用,还是作用于另一个不同的靶点,尚无定论。本研究在单侧输尿管梗阻(UUO)和单侧缺血再灌注损伤(UIRI)小鼠模型中评价ACT004的抗纤维化效果,并借助RNA测序、HuProt人类蛋白质微阵列、微量热泳动、pull-down实验、细胞热位移实验、分子对接、siRNA、突变质粒、免疫共沉淀和药理学抑制等手段探究其机制。ACT004明显减轻UUO和UIRI小鼠的肾纤维化,在体内以及TGF-β1刺激的肾小管上皮细胞中抑制炎症信号与Smad2/3活化。Four-and-a-half LIM domain protein 1(FHL1)被确定为ACT004的直接结合靶点。ACT004在Lys102和Thr128位点与FHL1结合,这两个残基突变后ACT004与FHL1的结合减弱。敲低FHL1可削弱TGF-β1诱导的促纤维化活化,而沉默FHL1后ACT004无法进一步抑制纤维化标志物的表达。机制上,ACT004破坏FHL1与Smad2/3的相互作用,抑制Smad2/3磷酸化,并促进泛素化介导的FHL1降解。过表达FHL1加重UUO诱导的肾纤维化,ACT004则在体内减轻FHL1相关的纤维化损伤。这些结果把FHL1确认为肾脏中此前未被认识的促纤维化支架蛋白,也使ACT004成为具有双重作用机制的新一代抗纤维化候选药物。
Chronic kidney disease (CKD) is increasingly recognized as a model of accelerated biological aging, characterized by premature cardiovascular disease and frailty. Although frailty has become a cornerstone of gero-nephrology, current frailty models primarily emphasize physical performance and functional decline, providing limited insight into the vascular mechanisms underlying biological vulnerability. Conversely, vascular aging is traditionally framed within cardiovascular medicine, with little integration into contemporary frailty research, limiting our understanding of how vascular dysfunction contributes to biological aging in CKD. In this review, we propose vascular frailty as a unifying framework that bridges geroscience, nephrology, and vascular medicine. We summarize the mechanisms through which CKD accelerates vascular aging and discuss vascular reserve and vascular resilience as key biological concepts linking vascular aging to systemic frailty. This underlies our claim that vascular frailty could be a multidimensional phenotype integrating structural vascular remodeling, functional vascular impairment, and conventional frailty assessment. Emerging approaches for operationalizing vascular frailty through vascular imaging, physiological assessment, and biomarker profiling are also highlighted. Rather than representing another frailty subtype, vascular frailty provides a conceptual framework linking vascular aging, loss of vascular reserve, and systemic vulnerability in CKD. Emerging evidence supports the feasibility of integrating structural and functional vascular measures with conventional frailty assessment, although its incremental prognostic and clinical value remain to be established. Further longitudinal and interventional studies are needed to determine whether vascular frailty can contribute to risk stratification, individualized management, and strategies aimed at preserving vascular resilience in CKD and other aging-related conditions.
中文摘要:慢性肾脏病(CKD)日益被视为生物学衰老加速的模型,其特点是早发心血管疾病与衰弱。衰弱已成为老年肾脏病学的基石,但现有衰弱模型主要关注躯体功能表现与功能衰退,对生物学易损性背后的血管机制揭示有限。血管衰老传统上被置于心血管医学框架内,与当代衰弱研究整合不足,限制了人们对血管功能障碍如何促成CKD生物学衰老的理解。我们提出血管衰弱作为连接衰老科学、肾脏病学与血管医学的统一框架,概述CKD加速血管衰老的机制,并将血管储备与血管韧性作为连接血管衰老与全身性衰弱的关键生物学概念加以讨论。由此我们认为,血管衰弱可能是一种多维表型,整合血管结构重构、血管功能受损与常规衰弱评估。通过血管影像、生理评估与生物标志物谱系将血管衰弱可操作化的新兴方法亦被提及。血管衰弱并非又一衰弱亚型,而是提供连接CKD中血管衰老、血管储备丧失与全身易损性的概念框架。已有新证据支持将血管结构与功能指标同常规衰弱评估相结合的可行性,但其额外的预后与临床价值仍待确立。尚需纵向与干预性研究来确定血管衰弱能否用于风险分层、个体化管理,以及旨在维持CKD和其他衰老相关疾病中血管韧性的策略。
A fundamental challenge in treating chronic kidney disease (CKD) is the lack of therapies to reverse established fibrosis. While systemic hypoxia sensors like erythrocyte sphingosine kinase 1 (eSPHK1) can initiate fibrotic signaling, the mechanisms driving self-perpetuating and progressive fibrosis remain unknown. eSphk1 specific deficient mice underwent four-week angiotensin-II infusion, unilateral ureteral obstruction or ischemia reperfusion injury. Untargeted metabolomics profiled purified kidney macrophages, and [13C615N4]-arginine fluxomic tracked arginine-creatine metabolism in hypoxia treated macrophages. Multi-color immunofluorescent images of kidney tissues were scanned and scored. Preclinical studies by hypoxia inducible factor-1α (HIF-1α) inhibitor or knockdown macrophage creatine kinase B (Ckb) were performed. Clinical relevance was evaluated by measuring CKB mRNA level in peripheral blood mononuclear cells obtained from 131 patients with CKD and determining its correlation with disease severity. We identify a HIF-1α-CKB feedforward loop within profibrotic macrophages that functions as an autonomous engine of kidney fibrosis. This circuit, which can be triggered by established pathways such as eSphk1 dysfunction, is characterized by its capacity for self-renewal. Specifically, HIF-1α drives Ckb expression, reprogramming arginine metabolism toward creatine-phosphate shunt (CPS) to generate an ATP surge that synergizes with an S1PR3-PKC signaling cascade to phosphorylate and stabilize HIF-1α, effectively bypassing the need for continued hypoxic input. This metabolic rewiring drives macrophage profibrotic polarization and leads to kidney fibrosis. Preclinically, pharmacologic HIF-1α inhibition or knockdown of macrophage Ckb collapses this autonomous loop and halts fibrosis. Translationally, CKB mRNA in peripheral blood mononuclear cells rises in parallel with estimated glomerular filtration rate decline and histologic fibrosis score in patients with CKD. Our work identifies a novel HIF-1α-CKB feedforward circuit in macrophages that sustains HIF-1α induction, channeling arginine metabolism toward CPS and thus promoting kidney fibrosis. These findings highlight that fibrosis is conceptualized from a passive end-stage outcome to an actively maintained process driven by the macrophage metabolic-polarization circuit, suggesting that breaking this malicious loop, in addition to initiating triggers, is critical to halt kidney fibrosis.
中文摘要:治疗慢性肾脏病(CKD)的一项根本挑战是缺乏逆转已建立纤维化的疗法。虽然红细胞鞘氨醇激酶1(eSPHK1)等全身性缺氧传感器可启动纤维化信号,但驱动自我维持和进展性纤维化的机制仍不清楚。eSphk1特异性缺陷小鼠接受四周血管紧张素II输注、单侧输尿管梗阻或缺血再灌注损伤。对纯化的肾脏巨噬细胞进行非靶向代谢组学分析,并使用[13C615N4]-精氨酸流量组学追踪缺氧处理巨噬细胞中的精氨酸-肌酸代谢。对肾脏组织多色免疫荧光图像进行扫描和评分。开展使用缺氧诱导因子-1α(HIF-1α)抑制剂或敲低巨噬细胞肌酸激酶B(Ckb)的临床前研究。通过检测131例CKD患者外周血单个核细胞中CKB mRNA水平并确定其与疾病严重程度的相关性来评估临床相关性。我们发现促纤维化巨噬细胞内存在HIF-1α-CKB前馈环路,其作为肾脏纤维化的自主引擎发挥作用。该环路可由eSphk1功能障碍等既有通路触发,其特征是具备自我更新能力。具体而言,HIF-1α驱动Ckb表达,使精氨酸代谢重编程转向磷酸肌酸穿梭(CPS),产生ATP激增,并与S1PR3-PKC信号级联协同,使HIF-1α磷酸化并稳定,从而有效绕过对持续缺氧输入的需求。这种代谢重编程驱动巨噬细胞促纤维化极化并导致肾脏纤维化。在临床前研究中,药物抑制HIF-1α或敲低巨噬细胞Ckb可瓦解该自主环路并阻止纤维化。在转化层面,CKD患者外周血单个核细胞中CKB mRNA升高与估算肾小球滤过率下降及组织学纤维化评分平行。我们的工作发现巨噬细胞中一种新的HIF-1α-CKB前馈环路,其维持HIF-1α诱导,将精氨酸代谢导向CPS,从而促进肾脏纤维化。这些发现提示,纤维化应从被动的终末期结局重新理解为由巨噬细胞代谢-极化环路驱动的主动维持过程,表明除针对启动触发因素外,打破这一恶性环路对于阻止肾脏纤维化至关重要。
Chronic kidney disease (CKD) has devastating effects on the skeletal system, resulting in an increased fracture risk. CKD results in the buildup of metabolites in the blood (often referred to as uremic toxins), and several uremic toxins have been linked to adverse skeletal outcomes. We have shown that dietary fiber inulin reduced uremic toxins and had a positive effect on bone. Here, we determine whether combining inulin with parathyroid hormone (PTH)-lowering therapies could improve skeletal properties beyond either therapy alone. An animal model of CKD-mineral bone disorder (CKD-MBD) (Cy/+ rats) was treated with or without inulin in the presence or absence of the PTH-suppressing agents (KP-2326, an analogue of the calcimimetic etelcalcetide, or 2% calcium). Key outcome measures included bone architecture, bone remodeling, mechanical properties and serum biomarkers. Dietary inulin groups had lower circulating levels of the uremic toxin p-cresol sulfate and higher circulating butyrate levels, indicating diet-induced differences in gut-derived metabolites. Combining inulin with KP-2326 resulted in lower cortical bone porosity than that in untreated animals and lower trabecular bone turnover (relative to untreated animals) than did either treatment alone. Combining inulin with KP-2326 led to improved mechanical properties. Combining inulin with calcium treatment suppressed bone turnover below healthy control levels. The improvement in bone remodeling and mechanical properties speaks favorably for combining dietary fiber intervention with calcimimetics for reducing the skeletal deterioration in CKD with hyperparathyroidism.
中文摘要:慢性肾脏病(CKD)对骨骼系统造成严重损害,增加骨折风险。CKD导致代谢物在血液中蓄积(常称为尿毒症毒素),多种尿毒症毒素与不良骨骼结局相关。我们已发现膳食纤维菊粉可降低尿毒症毒素并对骨产生积极作用。为确定将菊粉与降低甲状旁腺激素(PTH)的治疗联合应用能否在任一单药治疗基础上进一步改善骨骼特性,采用CKD-矿物质骨异常(CKD-MBD)动物模型(Cy/+大鼠),给予或不给予菊粉,并联合或不联合PTH抑制药物(KP-2326,一种拟钙剂依特卡肽的类似物,或2%钙)。主要结局指标包括骨结构、骨重建、力学性能和血清生物标志物。膳食菊粉组循环尿毒症毒素对甲酚硫酸盐水平较低,循环丁酸盐水平较高,提示饮食引起肠道来源代谢物差异。菊粉联合KP-2326使皮质骨孔隙率低于未治疗动物,小梁骨转换相对未治疗动物的降低幅度大于任一单药治疗。菊粉联合KP-2326改善了力学性能。菊粉联合钙治疗使骨转换低于健康对照水平。骨重建和力学性能的改善支持将膳食纤维干预与拟钙剂联合用于减轻伴甲状旁腺功能亢进的CKD患者的骨骼恶化。
Chronic kidney disease (CKD) is a major global health issue, affecting over 10% of the population and causing significant mortality. While kidney biopsy remains the gold standard for CKD diagnosis and treatment, the lack of comprehensive benchmarks for kidney pathology segmentation hinders progress in the field. To address this, we organized the Kidney Pathology Image Segmentation (KPIs) Challenge, introducing a dataset that incorporates preclinical rodent models of CKD with over 10,000 annotated glomeruli from 50 Periodic Acid Schiff (PAS)-stained whole slide images. As a preclinical benchmark, this challenge is designed to evaluate and compare computational methods under controlled experimental conditions. The challenge includes two tasks, patch-level segmentation and whole slide image segmentation and detection, evaluated using the Dice Similarity Coefficient (DSC) and F1-score. By encouraging innovative segmentation methods that adapt to diverse CKD models and tissue conditions, the KPIs Challenge aims to advance kidney pathology analysis, establish new benchmarks, and enable precise, large-scale quantification to support preclinical disease research and future translation to human kidney pathology.
中文摘要:慢性肾脏病(CKD)是重大全球健康问题,影响超过10%的人口并造成显著死亡。肾活检仍是CKD诊断与治疗的金标准,但肾脏病理分割缺乏全面基准,阻碍了该领域进展。为此,我们组织了肾脏病理图像分割(KPIs)挑战赛,推出一个纳入CKD临床前啮齿动物模型的数据集,包含50张过碘酸雪夫(PAS)染色全切片图像中逾10,000个标注肾小球。作为临床前基准,该挑战赛旨在在受控实验条件下评估和比较计算方法。挑战赛包括两个任务,即图像块级分割和全切片图像分割与检测,采用Dice相似系数(DSC)和F1分数评估。KPIs挑战赛鼓励适应不同CKD模型和组织条件的创新分割方法,以推进肾脏病理分析、建立新基准,并实现精确的大规模量化,支持临床前疾病研究及未来向人类肾脏病理的转化。
2肾小球疾病 (13篇)
临床研究 (10篇)
Treatment of type I cryoglobulinemic glomerulonephritis depends on identifying the monoclonal clone responsible for cryoglobulin secretion. We report the case of a woman in whom the culprit clone proved exceptionally difficult to detect, making treatment guidance highly uncertain. Using the RACE RepSeq technique combined with innovative bone marrow cell sorting, and later through direct visualization within the kidney, we identified a likely plasma cell clone responsible for the cryoglobulin. Despite targeted interventions, the disease remained refractory to conventional therapies, teclistamab, a bispecific T-cell-engaging antibody redirecting T cells against plasma cells, achieved efficacy. Finally, residual disease monitoring was possible through a novel targeted mass spectrometry approach (MALDI-TOF MS), sensitive enough to visualize the cryoglobulin M-protein. This case highlights the challenges of detecting elusive monoclonal clones in many monoclonal gammopathies of renal significance, illustrates the potential of advanced diagnostic tools, and underscores the promise of T-cell-redirecting therapies in refractory cryoglobulinemic glomerulonephritis.
中文摘要:I型冷球蛋白血症性肾小球肾炎的治疗取决于识别负责冷球蛋白分泌的单克隆克隆。我们报告一名女性病例,其致病克隆极难检测,使治疗指导高度不确定。采用RACE RepSeq技术并结合创新的骨髓细胞分选,随后在肾脏内直接观察,我们识别出可能导致冷球蛋白产生的浆细胞克隆。尽管进行了靶向干预,疾病对常规治疗仍难治,teclistamab是一种双特异性T细胞衔接抗体,可将T细胞重定向至浆细胞,最终取得疗效。残余疾病监测通过一种新的靶向质谱方法(MALDI-TOF MS)实现,其灵敏度足以显示冷球蛋白M蛋白。该病例凸显了在多种具有肾脏意义的单克隆丙种球蛋白病中检测隐匿单克隆克隆的挑战,展示了先进诊断工具的潜力,并强调了T细胞重定向治疗在难治性冷球蛋白血症性肾小球肾炎中的前景。
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) often affect the kidneys, driving morbidity and mortality in AAV. Clinical trials have investigated kidney outcomes using a variety of definitions. The standardization of kidney disease response criteria in AAV remains an unmet need, with an urgency to define kidney endpoints for daily clinical practice and new drug development to optimize patient management. A European Vasculitis Society (EUVAS) Focus Group was formed to review the literature and discuss the wide range of definitions used. The group involved nephrologists, pathologists and rheumatologists who met four times over a time frame of two years with the objective of formulating a consensus proposal for standardized kidney endpoint definitions for AAV. The group investigated the terminology and outcome relations of active kidney disease, treatment response and refractory kidney disease, remission and relapse, kidney function recovery and kidney failure requiring kidney replacement therapy. The group reviewed and discussed measurable parameters used for the assessments, such as kidney biopsy, hematuria and proteinuria, serum creatinine and estimated glomerular filtration rate and novel biomarkers. Here, we report on the current variability in terminology, present an expert proposal for kidney endpoints with a research agenda and outline the future strategy for a Delphi consensus.
中文摘要:抗中性粒细胞胞浆抗体(ANCA)相关血管炎(AAV)常累及肾脏,是AAV发病和死亡的重要驱动因素。临床试验采用多种定义考察肾脏结局。AAV肾脏疾病应答标准的标准化仍是未满足需求,日常临床实践和新药研发亟需明确肾脏终点以优化患者管理。欧洲血管炎学会(EUVAS)成立焦点组,回顾文献并讨论所用广泛定义。该组包括肾脏科、病理科和风湿科医师,在两年内召开四次会议,目标是形成AAV标准化肾脏终点定义的共识提案。焦点组考察了活动性肾脏病、治疗应答和难治性肾脏病、缓解和复发、肾功能恢复以及需要肾脏替代治疗的肾衰竭等术语及其结局关系。焦点组回顾并讨论了评估所用可测量参数,如肾活检、血尿和蛋白尿、血清肌酐和估算肾小球滤过率以及新型生物标志物。报告当前术语的差异,提出肾脏终点的专家提案及研究议程,并概述未来开展Delphi共识的策略。
Most cases of proliferative glomerulonephritis with monotypic immunoglobulin deposits (PGNMID) are associated with IgG3. The characteristics of IgG1 deposits within PGNMID have not been well defined and are the focus of this study. Retrospective case series. Forty-six PGNMID cases with granular monotypic IgG1 deposits (PGNMID-IgG1) identified in nephropathology archives. 57% of cases were male and 78% had hematuria. The median age was 57 years, the median proteinuria level was 4.8 g/day, and the median eGFR level was 52 mL/min/1.73 m2. Hypocomplementemia was uncommon (12%). Kidney biopsy revealed MPGN (54%) or mesangial proliferative GN (33%), with membranous features in nearly half (43%). A nephropathic clone or monoclonal Ig (mIg) was detected in 19 of 42 patients with PGNMID-IgG1 who underwent evaluation, including 10 with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). Among patients >50 years, the detection rate was 72% (18/25) vs. 6% (1/17) among younger patients. SPEP/SIF detected the nephropathic mIg in 13 of 40, and bone marrow biopsy done in 25 detected clonal B-cells in eight and clonal plasma cells in two patients. Follow-up (median 27 months) was available for 37 patients. Ten (83%) of 12 patients with an identifiable clone or mIg responded to clone-targeted (anti-plasma or B- cell) therapy, whereas 4 of 8 patients without an identifiable clone or mIg responded to anti-plasma cell therapy. At 60 months, the overall cumulative incidence of kidney failure requiring dialysis or death was 31.1% (7.9% to 48.5%). Four patients underwent kidney transplantation and three with transplant biopsies exhibited recurrent disease. Retrospective, single-center study, non-standardized hematologic workup and management. Nearly 75% of PGNMID-IgG1 cases >50 years of age have a clonal population detected and nearly a quarter have CLL/SLL. Response to anti-B-cell therapy may be greater in those with an identifiable clone or mIg. These data may inform treatment strategies for people with PGNMID-IgG1.
中文摘要:大多数伴单型免疫球蛋白沉积的增生性肾小球肾炎(PGNMID)病例与IgG3相关。PGNMID中IgG1沉积的特征尚未明确,本研究聚焦于此。回顾性病例系列。从肾病理档案中识别46例伴颗粒状单型IgG1沉积的PGNMID病例(PGNMID-IgG1)。57%为男性,78%有血尿。中位年龄57岁,中位蛋白尿4.8 g/d,中位eGFR 52 mL/min/1.73 m2。低补体血症不常见(12%)。肾活检显示MPGN(54%)或系膜增生性GN(33%),近半数(43%)具有膜性特征。在接受评估的42例PGNMID-IgG1患者中,19例检测到肾病性克隆或单克隆Ig(mIg),其中10例患有慢性淋巴细胞白血病或小淋巴细胞淋巴瘤(CLL/SLL)。在>50岁患者中,检出率为72%(18/25),而较年轻患者为6%(1/17)。SPEP/SIF在40例中检出肾病性mIg 13例,25例接受骨髓活检者中检出克隆性B细胞8例和克隆性浆细胞2例。37例患者有随访资料(中位27个月)。12例可识别克隆或mIg的患者中10例(83%)对克隆靶向(抗浆细胞或B细胞)治疗有反应,而8例无可识别克隆或mIg的患者中4例对抗浆细胞治疗有反应。60个月时,需要透析的肾衰竭或死亡的总体累积发生率为31.1%(7.9%至48.5%)。4例患者接受肾移植,3例移植肾活检显示疾病复发。回顾性、单中心研究,血液学检查和管理未标准化。>50岁的PGNMID-IgG1病例中近75%检测到克隆性群体,近四分之一患有CLL/SLL。可识别克隆或mIg者对抗B细胞治疗的反应可能更高。这些数据可能为PGNMID-IgG1患者的治疗策略提供信息。
Glucocorticoid (GC) withdrawal remains a major challenge for lupus nephritis (LN). In this 20-year retrospective cohort, we evaluated whether B-lymphocyte stimulator (BLyS) inhibitors facilitated GC discontinuation. Among 702 LN patients, 553 were treated with standard-of-care alone, and 149 received add-on BLyS inhibitors (belimumab or telitacicept). Patients receiving BLyS inhibitors achieved a higher rate of GC withdrawal than those receiving standard-of-care alone (10.7% vs. 5.61%, p = 0.026). Kaplan-Meier analysis confirmed a higher cumulative incidence of GC withdrawal in the BLyS inhibitor group (p = 0.001). After adjusting for age, sex, Systemic Lupus Erythematosus Disease Activity Index, acute kidney injury, nephrotic syndrome, and renal histopathology, time-dependent Cox regression revealed that BLyS inhibitor therapy was independently associated with a higher GC withdrawal rate (hazard ratio [HR] = 7.97, 95% confidence interval [CI]: 4.11-15.5, p < 0.001). Exploratory subgroup analyses indicated that among GC‑discontinued patients, Class IV LN predominated in the BLyS inhibitor group, whereas Class V LN was more prevalent in controls. During follow-up, no renal flares occurred in BLyS inhibitor-treated patients who discontinued GCs, though there was no significant between-group difference. In conclusion, add-on BLyS inhibitor therapy may serve as a potential steroid withdrawal-permissive approach for LN, pending further prospective validation of its clinical applicability.
中文摘要:糖皮质激素停用仍是狼疮肾炎治疗中的主要难题。这项为期20年的回顾性队列研究评估B淋巴细胞刺激因子(BLyS)抑制剂是否有助于停用糖皮质激素。702例狼疮肾炎患者中,553例单用标准治疗,149例在标准治疗基础上加用BLyS抑制剂(贝利尤单抗或泰它西普)。接受BLyS抑制剂者的糖皮质激素停用率高于单用标准治疗者(10.7%对5.61%,p=0.026)。Kaplan-Meier分析显示BLyS抑制剂组的糖皮质激素停用累积发生率更高(p=0.001)。校正年龄、性别、系统性红斑狼疮疾病活动指数、急性肾损伤、肾病综合征和肾脏组织病理后,时间依赖Cox回归显示BLyS抑制剂治疗与更高的糖皮质激素停用率独立相关(风险比[HR]=7.97,95%置信区间[CI]:4.11-15.5,p<0.001)。探索性亚组分析提示,在已停用糖皮质激素的患者中,BLyS抑制剂组以IV型狼疮肾炎为主,对照组以V型更常见。随访期间,停用糖皮质激素的BLyS抑制剂治疗患者未出现肾脏复发,但组间差异无统计学意义。加用BLyS抑制剂治疗可能成为狼疮肾炎中有利于停用激素的策略,其临床适用性尚待前瞻性研究验证。
The complement cascade is part of the innate immune system, and it provides an important line of defense against infections. Inappropriate or excessive activation of this system, however, is also a driver of kidney inflammation in many diseases. Complement inhibitory drugs have now been approved by the US Food and Drug Administration for the treatment of 5 renal diseases: atypical hemolytic uremic syndrome, C3 glomerulopathy, immune-complex membranoproliferative glomerulonephritis, antineutrophil cytoplasmic antibody-associated vasculitis, and IgA nephropathy. Ongoing clinical trials are testing new anticomplement drugs and additional renal indications for complement inhibitors. Most immunosuppressive drugs do not directly block complement activation, and the use of complement inhibitors for renal indications is likely to expand in the coming years. Complement activation in renal diseases also generates plasma, urine, and tissue biomarkers, and laboratory evaluation of the complement system is an important part of the clinical work-up of patients with these inflammatory and autoimmune conditions. It is essential, therefore, that nephrologists are familiar with the available anticomplement drugs and with complement diagnostics.
中文摘要:补体级联是先天免疫系统的一部分,为抵御感染提供重要防线。但该系统的异常或过度激活也是许多疾病中肾脏炎症的驱动因素。美国FDA已批准补体抑制药物用于治疗5种肾脏疾病:非典型溶血性尿毒症综合征、C3肾小球病、免疫复合物型膜增生性肾小球肾炎、抗中性粒细胞胞质抗体相关性血管炎和IgA肾病。正在进行的临床试验在测试新型抗补体药物以及补体抑制剂的其他肾脏适应证。多数免疫抑制药物并不直接阻断补体激活,补体抑制剂用于肾脏适应证的范围未来可能扩大。肾脏疾病中的补体激活还会产生血浆、尿液和组织生物标志物,补体系统的实验室评估是这些炎症性和自身免疫性疾病患者临床检查的重要部分。因此,肾脏科医生必须熟悉可用的抗补体药物和补体诊断方法。
C3 glomerulopathy (C3G)-primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) is an ultrarare disease spectrum associated with a significant health burden and for which there is a huge unmet need for safe and effective treatment. The underlying pathophysiology is dysregulation and overactivation of the alternative complement pathway. Two new therapeutic agents, iptacoplan and pegcetacoplan, that target proximal steps in the cascade, have demonstrated to be effective and have been approved for use in patients with C3G alone and with C3G/IC-MPGN, respectively. A key challenge to the nephrology community is how to incorporate these disease-modifying drugs into clinical practice in a timely and equitable manner. This report summarizes the deliberations and recommendations that emerged from the Addressing Access Issues in Diagnosis and Treatment of C3G Nephropathy and IC-MPGN (SEISMIC) summit in July 2025. The meeting assembled a broad panel of experts and patients and addressed the following 3 aims: (i) define issues in proper and timely diagnosis of this complex disease spectrum, (ii) assess management strategies in light of the availability of this new class of therapeutic agents, and (iii) identify barriers to access to care and treatment with these new therapeutic agents and design strategies to surmount them.
中文摘要:C3肾小球病(C3G)与原发性免疫复合物膜增生性肾小球肾炎(IC-MPGN)构成一个超罕见疾病谱,带来显著健康负担,对安全有效治疗存在巨大未满足需求。其潜在病理生理机制为替代补体途径失调与过度激活。两种靶向补体级联近端步骤的新治疗药物iptacoplan和pegcetacoplan已显示有效,并分别获批用于C3G患者以及C3G/IC-MPGN患者。肾病学界面临的关键挑战是如何及时、公平地将这些疾病修饰药物纳入临床实践。本报告总结2025年7月召开的诊断和治疗C3G肾病与IC-MPGN可及性问题(SEISMIC)峰会的讨论与建议。会议汇集了广泛的专家与患者群体,围绕3项目标展开:(i)界定这一复杂疾病谱在正确、及时诊断方面的问题;(ii)在新一类治疗药物可及的背景下评估管理策略;(iii)识别获取诊疗和这些新治疗药物的障碍,并设计克服障碍的策略。
C3 glomerulopathy (C3G) and primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) are both prototypical complement disorders in which complement overactivation is the primary driver of disease. Complement is not the primary cause of disease in IgA nephropathy (IgAN); however, increasing evidence implicates complement as a secondary factor in kidney damage in this more complex, multifactorial disorder. The success of recent clinical trials using alternative pathway complement inhibitors in C3G, IC-MPGN, and IgAN pose questions as to how they should be used in the real world. We report the findings of the 2025 International Society of Nephrology Forum on Complement Therapeutics in C3G and IgAN, where a global panel of experts considered the current state of knowledge, identified areas of uncertainty, and proposed optimal solutions. Areas of uncertainty and areas for future research included how complement biomarkers, complement autoantibodies, genetics, and the kidney biopsy guide therapy. The current rationale for the use of complement inhibitors and their place within the current therapeutic landscape are discussed.
中文摘要:C3肾小球病(C3G)和原发性免疫复合物膜增生性肾小球肾炎(IC-MPGN)均为典型的补体疾病,补体过度激活是疾病的主要驱动因素。在IgA肾病(IgAN)中,补体并非主要病因;但越来越多证据表明,在这一更复杂、多因素疾病中,补体是肾损伤的次要因素。近期采用替代途径补体抑制剂治疗C3G、IC-MPGN和IgAN的临床试验取得成功,由此产生如何在真实世界中应用这些药物的问题。我们报告2025年国际肾脏病学会C3G和IgAN补体治疗论坛的讨论结果,全球专家小组评估了当前知识状况,明确了不确定领域并提出优化方案。不确定领域和未来研究方向包括补体生物标志物、补体自身抗体、遗传学和肾活检如何指导治疗。文中讨论了当前使用补体抑制剂的依据及其在现有治疗格局中的位置。
Autoantibodies targeting complement factor B (anti-FB) are among the most recently described alternative pathway anomalies. Although they have been strongly associated with post-infectious glomerulonephritis in children, the clinical phenotypes associated with such antibodies, along with their effects on the alternative pathway in adults, remain elusive and require further characterization, which was the goal of this study. Retrospective case series. Patients for whom anti-FB immunoglobulin G (IgG) was systematically detected by the French reference center for complement abnormalities between October 2017 and June 2020 and who underwent concurrent kidney biopsy confirming kidney disease were included as cases. Seventy-one patients tested positive for anti-FB antibodies using ELISA and single-bead antigen assays in the setting of newly diagnosed biopsy-proven kidney disease. Detection of both anti-FB and anti-C3b autoantibodies occurred for 36 of 71 patients (51%). In vitro, total purified IgG from these patients enhanced alternative pathway activity, with anti-FB titers being correlated with C3bB proconvertase formation (R2 = 0.40, P < 0.001) and anti-C3b titers being correlated with C3bBb convertase stabilization (R2 = 0.46, P < 0.001), suggesting distinct and potentially synergistic functional effects. Clinically, the most frequent diagnosis associated with anti-FB detection was infection-related glomerulonephritis (IR-GN) (46 of 71, 65%), with higher anti-FB titers in patients with IR-GN compared with other diagnoses (median, 791 [IQR, 287-2,000] vs 326 [IQR, 173-790] AU/mL; Hodges-Lehmann difference, 354 AU/mL [95% CI, 58-1020]; P = 0.01). No difference was detected in anti-C3b titers between IR-GN and other diagnoses. Anti-FB antibodies became undetectable in 21 of 36 retested patients (58%); among the 10 patients with persistent detection beyond 3 months, 8 (80%) had uncontrolled infection. After a median follow-up period of 12.5 (IQR, 5-24) months, 18 of 67 patients (27%) experienced a major adverse kidney event (kidney failure or a sustained ≥50 decline in estimated glomerular filtration rate below the baseline value). Retrospective design, the series was enriched in alternative pathway anomalies due to reference center recruitment. Detection of anti-FB antibodies is strongly associated with infection-related glomerulonephritis in adult patients, highlighting an important mechanism of alternative pathway deregulation in such diseases. Antibodies targeting factor B, a key protein of the complement cascade, have been shown to activate the complement system and promote kidney inflammation. However, the clinical characteristics and outcomes of patients with such autoantibodies remain largely understudied, particularly in adults. This study systematically screened over 700 adults referred for complement investigation and identified 71 patients with anti-factor B antibodies and concurrent biopsy-proven kidney disease. These antibodies were predominantly associated with infection-related glomerulonephritis, activated the alternative complement pathway, and tended to disappear once the underlying infection was controlled. These findings highlight the importance of screening for anti-factor B antibodies in patients with complement-mediated kidney disease, as their detection may prompt the search for an underlying infection and guide therapeutic decisions.
中文摘要:靶向补体因子B的自身抗体(抗FB)是近年描述的替代途径异常之一。此类抗体在儿童中与感染后肾小球肾炎密切相关,但在成人中的临床表型及对替代途径的影响仍不明确,需要进一步刻画,这也是本研究的目标。回顾性病例系列。纳入2017年10月至2020年6月由法国补体异常参考中心系统检测抗FB免疫球蛋白G(IgG),并同期接受肾活检证实肾脏病的患者。71例新诊断且经肾活检证实肾脏病的患者通过ELISA和单珠抗原检测抗FB抗体阳性。71例中36例(51%)同时检出抗FB和抗C3b自身抗体。体外实验中,这些患者纯化的总IgG增强替代途径活性,抗FB滴度与C3bB前转化酶形成相关(R2=0.40,P<0.001),抗C3b滴度与C3bBb转化酶稳定相关(R2=0.46,P<0.001),提示二者功能效应不同且可能协同。临床上,抗FB检出最常见的诊断是感染相关肾小球肾炎(IR-GN)(46/71,65%),IR-GN患者的抗FB滴度高于其他诊断(中位数791[IQR 287-2000]比326[IQR 173-790]AU/mL;Hodges-Lehmann差值354 AU/mL[95%CI 58-1020];P=0.01)。抗C3b滴度在IR-GN与其他诊断间未见差异。36例复测患者中21例(58%)抗FB抗体转为不可检出;10例抗体持续检出超过3个月的患者中8例(80%)存在未控制的感染。中位随访12.5(IQR 5-24)个月后,67例中18例(27%)发生主要不良肾脏事件(肾衰竭或估算肾小球滤过率较基线持续下降≥50)。回顾性设计,且因参考中心招募,该系列替代途径异常患者比例偏高。成人中抗FB抗体检出与感染相关肾小球肾炎强相关,凸显此类疾病中替代途径失调的重要机制。靶向补体级联关键蛋白因子B的抗体已被证明可激活补体系统并促进肾脏炎症,但此类自身抗体患者的临床特征和结局仍研究不足,尤其在成人中。本研究系统筛查了700余例因补体检查转诊的成人,识别出71例抗因子B抗体阳性且同期肾活检证实肾脏病的患者。这些抗体主要与感染相关肾小球肾炎相关,可激活替代补体途径,并倾向于在基础感染控制后消失。这些发现提示,在补体介导的肾脏病患者中筛查抗因子B抗体具有重要性,检出后可能促使寻找潜在感染并指导治疗决策。
Syphilis-associated kidney disease is rare and most commonly occurs in active syphilis. This systematic review summarizes the clinicopathologic spectrum, treatment, and outcomes of syphilis-associated kidney disease. Systematic review of published case reports and case series. Cases with serologically confirmed syphilis and kidney disease attributed to syphilis, reported between January 1990 and December 2025. PubMed and Web of Science were searched for case reports and case series with extractable individual-level data. Reports of congenital syphilis, conference abstracts, articles without full-text access, and cases lacking individual patient data were excluded. Case-level data were extracted for demographics, the clinical presentation of syphilis, HIV status, serology findings, kidney manifestations including biopsy findings, treatment, kidney outcomes, and follow-up. Data were synthesized descriptively. Continuous variables were summarized as median and interquartile range, categorical variables as counts and percentages. Between-group and paired comparisons implemented using nonparametric or categorical tests, as appropriate. 99 cases from 78 publications were identified and included. Median age was 34 years, and 75% of patients were male. The median non-treponemal titer category was 1:256. Nephrotic syndrome occurred in 81% of patients and acute kidney injury in 32%. Membranous nephropathy was the most common biopsy diagnosis (79%), and a full-house immunofluorescence pattern was reported in 26% of biopsied cases. All patients received anti-syphilitic therapy, and 11% also received immunosuppressive therapy. Among patients with available outcome data, complete remission occurred in 75% and partial remission in 23%, with a median follow-up of 4 weeks. Kidney parameters generally improved after anti-syphilitic treatment. Evidence was derived mainly from case reports and case series, with potential publication, reporting, language, and database-selection bias. Detailed histopathology and treatment duration were inconsistently reported. Syphilis-associated kidney disease most commonly presents as membranous nephropathy with nephrotic syndrome and usually improves after anti-syphilitic therapy. Registered at PROSPERO with identification number CRD420261322314.
中文摘要:梅毒相关肾病罕见,多发生于活动性梅毒。本系统综述总结其临床病理谱、治疗和结局。对已发表病例报告和病例系列进行系统综述。纳入1990年1月至2025年12月报告、血清学确诊梅毒且肾病归因于梅毒的病例。检索PubMed和Web of Science,寻找可提取个体水平数据的病例报告和病例系列。排除先天性梅毒、会议摘要、无法获取全文及缺乏个体患者数据的病例。提取病例层面数据,包括人口学、梅毒临床表现、HIV状态、血清学结果、肾脏表现(含活检结果)、治疗、肾脏结局和随访。数据作描述性综合。连续变量以中位数和四分位间距汇总,分类变量以计数和百分比汇总。组间及配对比较按情况采用非参数或分类检验。共识别并纳入78篇文献中的99例病例。中位年龄34岁,75%为男性。非梅毒螺旋体抗体滴度中位类别为1:256。81%出现肾病综合征,32%出现急性肾损伤。膜性肾病是最常见活检诊断(79%),26%活检病例报告满堂亮免疫荧光模式。所有患者均接受抗梅毒治疗,11%同时接受免疫抑制治疗。在有结局数据的患者中,完全缓解75%,部分缓解23%,中位随访4周。抗梅毒治疗后肾脏指标总体改善。证据主要来自病例报告和病例系列,存在发表、报告、语言和数据库选择偏倚。组织病理细节和治疗疗程报告不一致。梅毒相关肾病最常表现为膜性肾病伴肾病综合征,抗梅毒治疗后通常改善。已在PROSPERO注册,识别号CRD420261322314。
Rapidly progressive glomerulonephritis is an uncommon but fulminant cause of acute kidney injury that requires urgent diagnosis and immunosuppression to prevent permanent kidney failure. We present a rare case of ANCA-negative pauci-immune crescentic glomerulonephritis occurring within weeks of transitioning from infliximab to the biosimilar infliximab-abda in a patient who had maintained years of complete stability on originator therapy, used for psoriasis. Although tumor necrosis factor-α inhibitors have been associated with paradoxical autoimmune phenomena, reported renal complications typically involve immune-complex glomerulonephritis, lupus-like nephritis, or ANCA-associated vasculitis, often accompanied by new autoantibody formation. The absence of serologic abnormalities, combined with the abrupt onset following biosimilar substitution, suggests a unique tolerance-breaking mechanism potentially driven by differences between biosimilars in higher-order protein structure or glycosylation. This case underscores the importance of recognizing that biosimilars, while highly similar to their reference products, may differ subtly in manufacturing-dependent attributes that influence immunogenicity in susceptible individuals. Clinicians should maintain vigilance for renal complications following biosimilar switches, particularly in patients with underlying autoimmune disease. Early biopsy confirmation and prompt initiation of immunosuppression remain essential to optimize renal recovery.
中文摘要:快速进展性肾小球肾炎是急性肾损伤少见但凶险的病因,需要紧急诊断并给予免疫抑制治疗,以避免永久性肾衰竭。本报告一例罕见的ANCA阴性寡免疫复合物新月体性肾小球肾炎,患者因银屑病长期使用英夫利西单抗原研药并保持多年完全稳定,在换用生物类似药英夫利西单抗-abda后数周内发病。肿瘤坏死因子-α抑制剂可伴随矛盾性自身免疫现象,但既往报告的肾脏并发症多涉及免疫复合物肾小球肾炎、类狼疮肾炎或ANCA相关性血管炎,常伴新发自身抗体形成。本例无血清学异常,且在换用生物类似药后突然起病,提示一种独特的耐受破坏机制,可能由生物类似药在高阶蛋白结构或糖基化方面的差异驱动。该病例提醒,生物类似药虽与参照药高度相似,但生产相关属性可能存在细微差异,从而影响易感个体的免疫原性。临床医生应在换用生物类似药后警惕肾脏并发症,尤其是存在基础自身免疫病的患者。早期活检确认并及时启动免疫抑制治疗仍是优化肾脏恢复的关键。
基础研究 (3篇)
Modified immune cells (MIC), i.e. mononuclear cells challenged with mitomycin C can induce immunotolerance. MIC treatment has been successful in several animal models of autoimmunity and in clinical trials after solid organ transplantation, but the mechanism for reduced inflammation is not fully understood. To investigate the efficacy of MIC therapy in lupus nephritis, splenocytes from syngeneic NZB/W F1 (BWF1) donor mice were incubated with mitomycin C, and then into BWF1 recipients at 25 weeks of age. Animals were followed for another five weeks to assess disease progression by histological, flow cytometric, and serological parameters. An in vitro phagocytosis assay was conducted to determine the clearance of MIC from 25 patients with lupus and from matched healthy individuals by autologous macrophages. In BWF1 mice, MIC therapy reduced the clinical burden of lupus nephritis disease progression with lower protein excretion and lower serum creatinine levels in the standard-dose compared to the control group. High-dose MIC therapy during active diseases showed no additional benefit. More than 86% of animals had dense lymphocytic aggregates close to the kidney pelvis. These tertiary lymphoid structures differed between MIC-treated animals and controls, with a loss of organization, loss of separation of B-cell and T-cell areas and disintegration of germinal centers after MIC treatment. In the peripheral blood, MIC-treated animals had higher numbers of CD19+CD5+CD1dhigh regulatory-like B lymphocytes. Although MIC treatment was beneficial, higher dosing offered no additional clinical benefit in mice. Macrophages from the patients with lupus efficiently cleared MIC in vitro, ruling out defective clearance as a limiting factor. Our clinically applicable cell therapy approach has the potential to control lupus nephritis by specifically dampening deleterious autoimmune responses.
中文摘要:改良免疫细胞(MIC)即经丝裂霉素C处理过的单核细胞,可诱导免疫耐受。MIC治疗已在多种自身免疫动物模型和实体器官移植后的临床试验中取得成功,但减轻炎症的机制尚未完全明确。为考察MIC治疗狼疮性肾炎的疗效,将同基因NZB/W F1(BWF1)供体小鼠的脾细胞与丝裂霉素C孵育,再于25周龄输入BWF1受体小鼠。随后继续观察5周,通过组织学、流式细胞术和血清学指标评估疾病进展。用自体巨噬细胞对25例狼疮患者及匹配健康个体的MIC进行体外吞噬实验,以测定清除情况。在BWF1小鼠中,与对照组相比,标准剂量MIC治疗降低了狼疮性肾炎疾病进展的临床负担,尿蛋白排泄减少,血清肌酐水平降低。疾病活动期给予高剂量MIC治疗未显示额外获益。超过86%的动物在肾盂附近出现密集淋巴细胞聚集。这些三级淋巴结构在MIC治疗组与对照组之间存在差异:MIC治疗后结构组织性丧失,B细胞区与T细胞区分离消失,生发中心解体。外周血中,MIC治疗动物CD19+CD5+CD1dhigh调节样B淋巴细胞数量增高。MIC治疗虽有益,但更高剂量在小鼠中未带来额外临床获益。狼疮患者巨噬细胞在体外能有效清除MIC,排除了清除缺陷作为限制因素。我们这种可临床应用的细胞治疗方法有望通过特异性抑制有害自身免疫反应来控制狼疮性肾炎。
Crescentic glomerulonephritis (cGN) is characterized by aggressive immune-mediated glomerular injury with prominent macrophage accumulation that correlates with disease severity. However, the distinct contributions of kidney-resident macrophages (KRMs) of different ontogenies remain poorly defined. To explore this, we used single-cell RNA sequencing (scRNA-seq), reporter-based bone marrow chimeras, timed clodronate liposome treatment, and chemokine blockade to define the spatiotemporal dynamics and functional roles of macrophage populations in nephrotoxic serum nephritis (NTSN), a model of cGN. ScRNA-seq of total kidney and CD45+ immune cells revealed that proliferating macrophages and infiltrating monocytes expanded sharply by day five and declined by day ten, indicating that local proliferation, in addition to monocyte recruitment, contributes substantially to early macrophage accumulation in NTSN. Two major KRM subpopulations were distinguished by high Ccr2 or Mrc1 expression, consistent with bone marrow and embryonically seeded, self-renewing KRM population, respectively. In Cx3cr1-GFP recipient mice reconstituted with Ccr2-RFP+ donor bone marrow, embryonic-derived GFP+ KRMs were enriched in the outer medulla and corticomedullary region, whereas donor-derived RFP+ monocytes/macrophages preferentially accumulated in the cortex, including within and around the inflamed glomeruli. A timed clodronate liposome regimen that preferentially reduced recipient-retained GFP+ KRMs decreased the cortical accumulation of RFP+ cells, albuminuria, and histologic kidney injury in NTSN mice. Cell-cell communication analysis identified macrophage-associated CCL12 expression, a murine ortholog of human CCL2, as a candidate mediator of cortical CCR2+ monocyte recruitment. CCL12 neutralization reduced cortical monocyte accumulation and ameliorated kidney damage in NTSN mice. These findings indicate that ontogenically distinct and spatially segregated macrophage populations cooperate during early cGN and support further investigation of the CCR2 axis as a therapeutic target for macrophage-mediated kidney injury in cGN.
中文摘要:新月体性肾小球肾炎(cGN)以免疫介导的侵袭性肾小球损伤为特征,伴有显著的巨噬细胞积聚,且与疾病严重程度相关。不同来源的肾脏驻留巨噬细胞(KRMs)各自的作用仍不清楚。为探索这一问题,我们采用单细胞RNA测序(scRNA-seq)、基于报告基因的骨髓嵌合体、定时氯膦酸盐脂质体处理和趋化因子阻断,在肾毒性血清肾炎(NTSN)这一cGN模型中界定巨噬细胞群体的时空动态和功能作用。对全肾组织和CD45+免疫细胞进行的scRNA-seq显示,增殖性巨噬细胞和浸润性单核细胞在第5天明显扩增,到第10天下降,提示除单核细胞招募外,局部增殖也对NTSN早期巨噬细胞积聚有实质贡献。两类主要KRM亚群分别以Ccr2或Mrc1高表达为特征,分别符合骨髓来源和胚胎期播种、可自我更新的KRM群体。在经Ccr2-RFP+供体骨髓重建的Cx3cr1-GFP受体小鼠中,胚胎来源的GFP+ KRMs富集于外髓和皮髓质区域,而供体来源的RFP+单核细胞/巨噬细胞优先积聚于皮质,包括炎症肾小球内及周围。一种优先减少受体保留的GFP+ KRMs的定时氯膦酸盐脂质体方案,降低了NTSN小鼠皮质RFP+细胞积聚、白蛋白尿和组织学肾损伤。细胞间通讯分析发现巨噬细胞相关CCL12表达(人CCL2的小鼠直系同源物)是皮质CCR2+单核细胞招募的候选介质。中和CCL12减少了NTSN小鼠皮质单核细胞积聚并改善肾损伤。这些发现表明,来源不同且空间分隔的巨噬细胞群体在早期cGN中协同作用,并支持进一步研究CCR2轴作为cGN中巨噬细胞介导肾损伤的治疗靶点。
Podocyte adhesion to the glomerular basement membrane is essential for kidney function, and adhesion failure leads to podocyte loss and glomerulosclerosis. However, how initial adhesion impairment progresses to irreversible podocyte dysfunction remains poorly understood. Here, we investigated early molecular changes following adhesion impairment to identify new therapeutic targets. We performed single-cell RNA sequencing on kidneys from doxycycline-inducible podocyte-specific Talin (Tln1)-cKO mice, an established model of impaired focal adhesion, before overt kidney dysfunction. To test the function of a key downregulated gene, we generated podocyte-specific Nsf knockout (Nsf-cKO) mice and analyzed them using biochemical, cell biological, and live-cell imaging approaches. We also examined publicly available human kidney single-nucleus RNA sequencing datasets. Nsf was among the most significantly downregulated genes in Tln1-cKO podocytes. NSF (N-ethylmaleimide-sensitive factor) is an AAA+ ATPase essential for vesicular trafficking through disassembly of SNARE complexes. Nuclear Yes-associated protein (YAP) was reduced in Tln1-cKO podocytes, and pharmacologic inhibition of TEA domain transcription factor (TEAD) or soft-substrate culture lowered NSF expression, indicating that YAP/TEAD signaling links mechanotransduction to Nsf expression. Podocyte-specific Nsf deletion caused massive proteinuria, podocyte loss, glomerulosclerosis, and death by 3 weeks. NsfcKO podocytes showed impaired spreading and defective integrin regulation: integrin α3 maturation was blocked, whereas integrin β1 underwent ER stress-induced proteasomal degradation. Trafficking of nephrin and podoplanin was also affected. Live-cell imaging showed markedly delayed ER-to-Golgi trafficking in Nsf-cKO podocytes (90-120 minutes versus 15 minutes in controls). In human datasets, NSF expression was reduced in podocytes from patients with diabetic and hypertensive chronic kidney disease. Adhesion impairment suppresses NSF through reduced YAP/TEAD activity, disrupting ER-to-Golgi trafficking and integrin maturation, and generating a feed-forward cascade of progressive adhesion failure. NSF-mediated trafficking is essential for podocyte homeostasis and a potential therapeutic target in proteinuric kidney diseases.
中文摘要:足细胞黏附于肾小球基底膜对肾功能至关重要,黏附失败会导致足细胞丢失和肾小球硬化。初始黏附损伤如何进展为不可逆的足细胞功能障碍仍不清楚。为识别黏附损伤后的早期分子改变并寻找新的治疗靶点,研究者在明显肾功能异常出现之前,对多西环素诱导的足细胞特异性Talin(Tln1)条件性敲除小鼠肾脏进行单细胞RNA测序,该小鼠是局灶黏附受损的成熟模型。为检验一个关键下调基因的功能,研究者构建了足细胞特异性Nsf敲除(Nsf-cKO)小鼠,并采用生化、细胞生物学和活细胞成像方法进行分析,同时检查了公开可用的人肾脏单核RNA测序数据集。Nsf是Tln1-cKO足细胞中下调最显著的基因之一。NSF(N-乙基马来酰亚胺敏感因子)是一种AAA+ ATP酶,通过解聚SNARE复合物在囊泡运输中发挥必需作用。Tln1-cKO足细胞中核内Yes相关蛋白(YAP)减少,药物抑制TEA结构域转录因子(TEAD)或软基底培养均降低NSF表达,提示YAP/TEAD信号将机械转导与Nsf表达联系起来。足细胞特异性Nsf缺失导致大量蛋白尿、足细胞丢失、肾小球硬化,并在3周内死亡。Nsf-cKO足细胞铺展受损并出现整合素调控缺陷:整合素α3成熟受阻,而整合素β1发生内质网应激诱导的蛋白酶体降解。nephrin和podoplanin的运输也受到影响。活细胞成像显示Nsf-cKO足细胞中内质网到高尔基体的运输明显延迟(90-120分钟,对照为15分钟)。在人类数据集中,糖尿病和高血压慢性肾脏病患者的足细胞中NSF表达降低。黏附损伤通过降低YAP/TEAD活性抑制NSF,破坏内质网到高尔基体运输和整合素成熟,并形成进行性黏附失败的级联放大。NSF介导的运输对足细胞稳态必不可少,是蛋白尿性肾脏疾病的潜在治疗靶点。
3急性肾损伤 AKI (13篇)
临床研究 (8篇)
Landscape fire-sourced PM2.5 (LFS PM2.5) is increasingly recognized as an important air pollutant, but its short-term contribution to renal hospitalizations remains unclear. Here, we assessed the associations between LFS PM2.5 and renal hospitalizations across 1020 locations in Australia, Brazil, Canada, Chile, New Zealand, and Thailand during 2000-2019 using a two-stage time-series design and estimated the attributable hospitalizations. LFS PM2.5 was associated with increased renal hospitalization risk, with the strongest associations observed for acute kidney injury. A 10 μg/m3 increase in cumulative LFS PM2.5 exposure over lag 0-5 was associated with a 1.1% increase in renal hospitalizations (RR = 1.011, 95% CI: 1.007-1.015). Associations were stronger in warmer areas and differed across levels of GDP per capita. Associations were consistently stronger for LFS PM2.5 than for non-LFS PM2.5. We estimated that LFS PM2.5 contributed to 1.38 renal hospitalizations per 100,000 population annually across the study regions. These findings highlight renal disease as an underrecognized health consequence of landscape fire smoke and support strengthened strategies to reduce wildfire smoke exposure under a changing climate.
中文摘要:景观火灾来源的PM2.5(LFS PM2.5)日益被视为重要空气污染物,但其对肾脏住院的短期影响仍不清楚。研究采用两阶段时间序列设计,评估2000—2019年澳大利亚、巴西、加拿大、智利、新西兰和泰国1020个地点LFS PM2.5与肾脏住院的关联,并估算归因住院数。LFS PM2.5与肾脏住院风险升高相关,急性肾损伤的关联最强。滞后0—5天累积LFS PM2.5暴露每增加10 μg/m3,肾脏住院增加1.1%(RR=1.011,95% CI:1.007—1.015)。气候较暖地区关联更强,且在不同人均GDP水平间存在差异。LFS PM2.5的关联始终强于非LFS PM2.5。研究估算,LFS PM2.5每年在研究地区造成每10万人1.38例肾脏住院。这些发现提示肾脏疾病是景观火灾烟雾中未被充分认识的健康后果,并支持在气候变化背景下加强减少野火烟雾暴露的策略。
GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text] Nephrology: [Formula: see text].
中文摘要:普通内科/家庭医学/全科医学:[公式见正文]。心脏病学:[公式见正文]。肾脏病学:[公式见正文]。
Fetal growth restriction has long been associated with reduced nephron number and chronic kidney disease, but its relationship with acute kidney injury has remained unclear. Fog-Høyer et al. demonstrated that fetal growth restriction increases acute kidney injury risk from infancy through early adulthood, particularly in children with congenital anomalies. We examine the study's strengths, limitations, biological basis, and clinical relevance, highlighting opportunities for targeted risk stratification, preventive care, and future research.
中文摘要:胎儿生长受限长期与肾单位数量减少和慢性肾脏病相关,但其与急性肾损伤的关系仍不明确。Fog-Høyer等发现,胎儿生长受限使急性肾损伤风险从婴儿期持续到成年早期,在合并先天性异常的儿童中尤为明显。我们审视该研究的优势、局限、生物学基础与临床意义,并指出开展针对性风险分层、预防性照护和未来研究的机会。
Contrast-associated acute kidney injury (CA-AKI) after endovascular thrombectomy (EVT) worsens outcomes in acute ischemic stroke, but threshold-based definitions do not capture prognostic information from subthreshold changes. We tested whether early creatinine change within 48 hours of EVT conveys graded prognostic information beyond dichotomous CA-AKI. We performed a secondary analysis of the CAN-REST registry (Contrast-Associated Nephropathy After Endovascular Stroke Treatment), a retrospective multicenter observational cohort study of 6638 EVT-treated adults with acute ischemic stroke enrolled at 73 centers in 16 countries between January 1 and December 31, 2023. Early creatinine change was quantified as the natural logarithm ratio of 48-hour creatinine to baseline creatinine (ln[48-hour/baseline creatinine]), with CA-AKI defined per Kidney Disease: Improving Global Outcomes criteria (≥0.3 mg/dL or ≥1.5× baseline rise within 48 hours). Multivariable logistic regression adjusted for prespecified baseline and periprocedural covariates examined associations with 90-day modified Rankin Scale shift and in-hospital mortality; linear versus restricted cubic spline specification was selected by likelihood ratio testing, and contrasts were estimated at ±10%, ±25%, and ±50%. Greater creatinine worsening within 48 hours of EVT was independently associated with an unfavorable 90-day modified Rankin Scale shift (adjusted common odds ratio per 1-unit log-ratio increase, 1.48 [95% CI, 1.07-2.04]; linear) and in-hospital mortality (nonlinear dose-response, of larger magnitude). A 10% increase in creatinine at 48 hours-well below Kidney Disease: Improving Global Outcomes threshold-was associated with worse functional outcome (adjusted common odds ratio, 1.04 [95% CI, 1.01-1.07]) and death (adjusted odds ratio, 1.22 [95% CI, 1.13-1.32]); a 10% decrease in creatinine at 48 hours was associated with lower odds of both outcomes (adjusted common odds ratio, 0.96 [95% CI, 0.93-0.99]; adjusted odds ratio, 0.74 [95% CI, 0.65-0.86]). The functional-outcome association concentrated at upper modified Rankin Scale cut-points (severe disability, death); effect modification by baseline renal function was not significant. Early creatinine change after EVT conveys graded, outcome-specific prognostic information extending below formal CA-AKI thresholds, with a dose-response detectable at changes as modest as ±10%, complementing binary CA-AKI as a framework for post-EVT renal risk assessment. URL: https://www.clinicaltrials.gov; Unique identifier: NCT06596603.
中文摘要:急性缺血性卒中患者接受血管内取栓(EVT)后发生的对比剂相关急性肾损伤(CA-AKI)会加重结局,但基于阈值的定义无法捕捉阈下变化所携带的预后信息。检验EVT后48小时内早期肌酐变化是否在二分类CA-AKI之外提供分级预后信息。CAN-REST登记(血管内卒中治疗后对比剂肾病)的二次分析,该登记为回顾性多中心观察性队列研究,纳入2023年1月1日至12月31日期间16个国家73个中心的6638例接受EVT治疗的急性缺血性卒中成人。早期肌酐变化以48小时肌酐与基线肌酐比值的自然对数(ln(48小时/基线肌酐))量化,CA-AKI按肾脏病改善全球结局(KDIGO)标准定义(48小时内升高≥0.3 mg/dL或≥1.5倍基线)。多变量logistic回归校正预设的基线和围手术期协变量,分析其与90天改良Rankin量表位移及院内死亡率的关联;线性与限制性立方样条设定通过似然比检验选择,并在±10%、±25%和±50%处估计对比。EVT后48小时内肌酐恶化程度越大,与不良的90天改良Rankin量表位移独立相关(对数比值每增加1单位,校正共同比值比1.48[95%CI 1.07-2.04];线性),也与院内死亡率相关(非线性剂量反应,幅度更大)。48小时肌酐升高10%——远低于KDIGO阈值——与更差的功能结局(校正共同比值比1.04[95%CI 1.01-1.07])和死亡(校正比值比1.22[95%CI 1.13-1.32])相关;48小时肌酐降低10%与两种结局的更低几率相关(校正共同比值比0.96[95%CI 0.93-0.99];校正比值比0.74[95%CI 0.65-0.86])。功能结局关联集中在改良Rankin量表较高切点(严重残疾、死亡);基线肾功能对效应修饰不显著。EVT后早期肌酐变化提供分级、结局特异的预后信息,其范围延伸至正式CA-AKI阈值以下,在低至±10%的变化即可检测到剂量反应,可补充二分类CA-AKI作为EVT后肾脏风险评估框架。网址:https://www.clinicaltrials.gov;唯一标识:NCT06596603。
Fetal growth restriction is associated with reduced nephron endowment, suggesting increased kidney vulnerability across the life course. However, its association with acute kidney injury (AKI) beyond the neonatal period is not well defined. Individuals born with major birth defects may be particularly vulnerable due to impaired organ development and early-life comorbidities. Here, we examined whether fetal growth restriction, measured as birth weight for gestational age, is associated with the risk of AKI from infancy to early adulthood in individuals with and without major birth defects. In this nationwide population-based cohort study, we included all individuals born alive in Denmark from August 1995 to February 2022. Data from national health registers and laboratory databases were linked using personal identifiers. Birth weight for gestational age was categorized as small (SGA, under 10th percentile), appropriate (AGA, 10th-90th percentile), and large (LGA, over 90th percentile). AKI was defined biochemically based on plasma creatinine according to current consensus. Outcomes included 25-year risk of AKI and adjusted hazard ratios (aHRs) from Cox regression models, stratified by the presence of major birth defects. The cohort comprised 585,624 individuals without birth defects and 21,900 with birth defects. Among those without defects, the 25-year risk of AKI was 3.7% for SGA, 3.2% for AGA, and 3.1% for LGA. SGA was associated with higher AKI rates (aHR 1.20; 95% confidence interval, 1.13-1.27) compared to AGA. Among individuals with defects, risks were 15.2% for SGA, 9.9% for AGA, and 10.1% for LGA, with corresponding aHR 1.45 (95% confidence interval, 1.29-1.64) for SGA compared to AGA. Being born small for gestational age was associated with an increased risk of AKI from infancy to early adulthood, particularly among individuals with major birth defects. Greater clinical awareness may guide monitoring and prevention to protect kidney health in growth-restricted individuals.
中文摘要:胎儿生长受限与肾单位数量减少相关,提示整个生命过程中肾脏易感性增加。然而,其在新生儿期之后与急性肾损伤(AKI)的关联尚未明确。出生时患有重大出生缺陷的个体可能因器官发育受损和早期合并症而尤为脆弱。本研究考察以出生体重对应胎龄衡量的胎儿生长受限,是否与伴或不伴重大出生缺陷个体从婴儿期至成年早期的AKI风险相关。这项全国性人群队列研究纳入丹麦1995年8月至2022年2月出生的所有活产个体。通过个人标识符链接国家健康登记和实验室数据库。出生体重对应胎龄分为小于胎龄(SGA,低于第10百分位)、适于胎龄(AGA,第10至90百分位)和大于胎龄(LGA,高于第90百分位)。AKI依据当前共识以血浆肌酐进行生化定义。结局包括25年AKI风险,以及按重大出生缺陷分层后Cox回归模型得出的校正风险比(aHR)。队列包括585,624名无出生缺陷个体和21,900名有出生缺陷个体。无缺陷者中,SGA、AGA和LGA的25年AKI风险分别为3.7%、3.2%和3.1%。与AGA相比,SGA与更高的AKI发生率相关(aHR 1.20;95%置信区间1.13-1.27)。有缺陷者中,SGA、AGA和LGA的风险分别为15.2%、9.9%和10.1%,SGA相对AGA的相应aHR为1.45(95%置信区间1.29-1.64)。小于胎龄出生与从婴儿期至成年早期AKI风险增加相关,在重大出生缺陷个体中尤为明显。提高临床认识可能有助于指导监测和预防,以保护生长受限个体的肾脏健康。
Remote ischemic preconditioning reduced the risk of contrast-associated AKI in patients undergoing coronary angiography or percutaneous coronary intervention. The benefits of remote ischemic preconditioning were consistent across coronary angiography, percutaneous coronary intervention, diabetes, and CKD subgroups. Remote ischemic preconditioning probably reduced in-hospital major adverse cardiovascular events, although there was no significant impact on 30-day kidney and cardiac outcomes. Remote ischemic preconditioning may prevent contrast-associated AKI and have cardioprotective effects in patients undergoing coronary angiographic procedures; however, results have been inconsistent. The aim of this systematic review and meta-analysis was to evaluate whether remote ischemic preconditioning lowers the risk of contrast-associated AKI and improves short-term kidney and cardiac outcomes in patients undergoing coronary angiography or percutaneous coronary intervention (PCI). We performed a comprehensive literature search using PubMed, Embase, and the Cochrane Central Register of Controlled Trials from inception through December 6, 2025. Randomized controlled trials (RCTs) comparing remote ischemic preconditioning with either sham remote ischemic preconditioning or usual care for kidney and/or cardiac outcomes in patients undergoing coronary angiography or PCI were included. Two independent reviewers screened studies, extracted data, and assessed risk of bias using the Cochrane Risk of Bias 2.0 tool. Outcomes studied were contrast-associated AKI, need for dialysis, in-hospital mortality, in-hospital major adverse cardiovascular events (MACE), 30-day mortality, 30-day MACE, and major adverse kidney events at 30 days. Data were pooled using a random-effects model and expressed as risk ratios (RR) with 95% confidence intervals (CI). Certainty of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation approach. Of the 5532 records identified, 36 RCTs encompassing 10,923 patients were included in this systematic review. Compared with sham remote ischemic preconditioning or usual care, remote ischemic preconditioning significantly reduced contrast-associated AKI (RR, 0.54; 95% CI, 0.45 to 0.65; 30 RCTs, 5078 participants; high-certainty evidence). Remote ischemic preconditioning probably reduced in-hospital MACE (RR, 0.51; 95% CI, 0.26 to 0.98; four RCTs, 1266 participants; moderate-certainty evidence). There were no differences in the need for dialysis, in-hospital mortality, 30-day mortality, and 30-day MACE. Remote ischemic preconditioning reduced the risk of contrast-associated AKI and in-hospital MACE in patients undergoing coronary angiography or PCI.
中文摘要:远程缺血预适应可降低接受冠状动脉造影或经皮冠状动脉介入治疗患者发生造影剂相关急性肾损伤的风险。其获益在冠状动脉造影、经皮冠状动脉介入治疗、糖尿病和慢性肾脏病亚组中保持一致。远程缺血预适应可能降低院内主要不良心血管事件,但对30天肾脏和心脏结局无显著影响。远程缺血预适应或可预防造影剂相关急性肾损伤,并在接受冠状动脉造影操作的患者中具有心脏保护作用,但现有结果并不一致。本系统评价和荟萃分析旨在评估远程缺血预适应是否降低接受冠状动脉造影或经皮冠状动脉介入治疗(PCI)患者的造影剂相关急性肾损伤风险,并改善短期肾脏和心脏结局。我们检索了PubMed、Embase和Cochrane中央对照试验注册库,检索时间从建库至2025年12月6日。纳入比较远程缺血预适应与模拟远程缺血预适应或常规治疗对接受冠状动脉造影或PCI患者肾脏和/或心脏结局影响的随机对照试验(RCT)。两名独立评价者筛选研究、提取数据,并使用Cochrane偏倚风险2.0工具评估偏倚风险。研究结局包括造影剂相关急性肾损伤、需要透析、院内死亡、院内主要不良心血管事件(MACE)、30天死亡、30天MACE和30天主要不良肾脏事件。采用随机效应模型合并数据,并以风险比(RR)及95%置信区间(CI)表示。使用推荐分级的评估、制定与评价方法评估证据确定性。在检索到的5532条记录中,36项RCT、共10923例患者纳入本系统评价。与模拟远程缺血预适应或常规治疗相比,远程缺血预适应显著降低造影剂相关急性肾损伤(RR,0.54;95% CI,0.45至0.65;30项RCT,5078例受试者;高确定性证据)。远程缺血预适应可能降低院内MACE(RR,0.51;95% CI,0.26至0.98;4项RCT,1266例受试者;中等确定性证据)。需要透析、院内死亡、30天死亡和30天MACE方面无差异。远程缺血预适应降低了接受冠状动脉造影或PCI患者的造影剂相关急性肾损伤风险和院内MACE风险。
eGFR discordance was associated with higher risk of AKI in allogeneic hematopoietic stem cell transplantation and adoptive T-cell therapies. Among hematopoietic stem cell transplantation recipients, eGFR discordance was associated with slower time-to-platelet engraftment. Among adoptive T-cell recipients, eGFR discordance was associated with prolonged cytopenia. Discordance between eGFR on the basis of serum creatinine (eGFR cr ) versus cystatin C (eGFR cys ) is associated with adverse outcomes in patients with and without cancer. We hypothesized that eGFR discordance is associated with AKI and death after hematopoietic stem cell transplantation (HSCT) or receipt of adoptive T-cell therapies. We conducted a multicenter study of adults receiving allogeneic HSCT and adoptive T-cell therapies who had paired serum creatinine and cystatin C values obtained in the 30 days preceding conditioning or lymphodepleting chemotherapy. The primary exposure was eGFR discordance, defined as eGFR cys ≥30% lower than eGFR cr . The primary outcome was a composite outcome of AKI (≥50% increase in serum creatinine or receipt of KRT) or death within 90 days after HSCT or adoptive T-cell infusion. Secondary outcomes included time-to-platelet engraftment in HSCT and prolonged cytopenia in adoptive T-cell recipients. We used multivariable logistic regression and cause-specific Cox regression with inverse probability weighting to adjust for confounders. Of 274 patients receiving HSCT (median age, 65 years; interquartile range, 52-71; 43% female), 86 (31%) had an eGFR discordance. Among 236 adoptive T-cell recipients (median age, 67 years; interquartile range, 60-74; 59% female), 78 (33%) had a discordance in eGFR. eGFR discordance was associated with higher odds of AKI or death in HSCT (odds ratio, 1.75; 95% confidence interval, 1.03 to 3.02) and adoptive T-cell recipients (odds ratio, 2.37; 95% confidence interval, 1.12 to 4.94). However, adjustment for eGFR cr-cys attenuated these associations in both cohorts. eGFR discordance was also associated with slower time-to-platelet engraftment in HSCT recipients and prolonged cytopenia after adoptive T-cell therapy. A pretreatment eGFR discordance was associated with AKI or death in HSCT and adoptive T-cell recipients; however, this association was attenuated after adjusting for eGFR cr-cys .
中文摘要:eGFR不一致与异基因造血干细胞移植和过继性T细胞治疗后更高的AKI风险相关。在造血干细胞移植受者中,eGFR不一致与血小板植入时间较慢相关。在过继性T细胞治疗受者中,eGFR不一致与持续性血细胞减少相关。基于血清肌酐的eGFR(eGFRcr)与基于胱抑素C的eGFR(eGFRcys)之间的不一致,在伴或不伴癌症的患者中均与不良结局相关。研究假设eGFR不一致与造血干细胞移植(HSCT)或接受过继性T细胞治疗后的AKI和死亡相关。研究为多中心研究,纳入接受异基因HSCT和过继性T细胞治疗的成人患者,这些患者在预处理或淋巴细胞清除化疗前30天内具有配对的血清肌酐和胱抑素C值。主要暴露为eGFR不一致,定义为eGFRcys较eGFRcr低至少30%。主要结局为HSCT或过继性T细胞输注后90天内AKI(血清肌酐升高至少50%或接受肾脏替代治疗)或死亡的复合结局。次要结局包括HSCT中的血小板植入时间和过继性T细胞治疗受者的持续性血细胞减少。采用多变量logistic回归和逆概率加权的病因特异性Cox回归校正混杂因素。274例接受HSCT的患者中(中位年龄65岁;四分位距52-71;43%女性),86例(31%)存在eGFR不一致。236例过继性T细胞治疗受者中(中位年龄67岁;四分位距60-74;59%女性),78例(33%)存在eGFR不一致。eGFR不一致与HSCT受者(比值比1.75;95%置信区间1.03至3.02)和过继性T细胞治疗受者(比值比2.37;95%置信区间1.12至4.94)AKI或死亡的更高 odds 相关。然而,校正eGFRcr-cys后,两个队列中的这些关联均减弱。eGFR不一致还与HSCT受者血小板植入时间较慢以及过继性T细胞治疗后持续性血细胞减少相关。治疗前eGFR不一致与HSCT和过继性T细胞治疗受者的AKI或死亡相关;但校正eGFRcr-cys后,该关联减弱。
Perioperative inflammation may result in organ injury, including acute kidney injury (AKI). Colchicine, an anti-inflammatory drug, may help protect the organs from inflammation. This clinical trial substudy examined whether colchicine reduced the risk of perioperative AKI compared with placebo. Prespecified substudy of a placebo-controlled randomized clinical trial. Patients aged 55 years or older undergoing major noncardiac thoracic surgery enrolled in the Colchicine for the Prevention of Perioperative Atrial Fibrillation (COP-AF) trial from 45 centers in 11 countries (2018-2023). Patients were excluded for a history of atrial fibrillation, for taking antiarrhythmic medication, or for a preoperative estimated glomerular filtration rate (eGFR) < 30 mL/min per 1.73 m2. Participants were randomized 1:1 to 0.5 mg oral colchicine or placebo, given twice daily for a total of 10 days. Patients, health care providers, data collectors, and outcome adjudicators were masked to the treatment assignment. Perioperative AKI, defined as an increase in serum creatinine concentration of either ≥0.3 mg/dL within 48 hours of surgery or ≥50% within 7 days of surgery. Alternative definitions of AKI were examined, as was effect modification by pre-existing chronic kidney disease (CKD). Among 3,209 patients enrolled in the main trial, 2,947 were included in this substudy (mean age, 68 years; mean eGFR, 83 mL/min/1.73 m2) and were randomly allocated to receive colchicine (n = 1,476) or placebo (n = 1,471). Perioperative AKI occurred in 67 participants (4.7%) in the colchicine group and in 63 participants (4.4%) in the placebo group (risk ratio [RR], 1.07 [95% CI, 0.76-1.50], P = 0.72; risk difference [RD], 0.3% [95% CI, -1.2% to 1.8%]). The RD of AKI in patients with CKD treated with colchicine versus placebo was -0.9%, and it was 0.5% in those without CKD (interaction P = 0.62). Limited statistical power to detect small clinically important effects on AKI treated with dialysis. Among patients undergoing noncardiac thoracic surgery, the risk of perioperative AKI did not differ between patients allocated to receive colchicine versus placebo. Grants from academic (Department of Medicine, Western University; Division of Cardiology, McMaster University), government (Canadian Institutes of Health Research; General Research Fund, Research Grants Council, Hong Kong Special Administrative Region, China), and not-for-profit (Accelerating Clinical Trials Consortium; Innovation Fund of the Alternative Funding Plan for the Academic Health Sciences Centres of Ontario; Population Health Research Institute; Hamilton Health Sciences; Hanela Foundation) sources. Registered at ClinicalTrials.gov with study number NCT03310125. Inflammation during and after surgery can lead to organ injury, including acute kidney injury (AKI). Colchicine, an anti-inflammatory drug, may help protect the organs from inflammation. This prespecified kidney substudy of the COP-AF trial (a placebo-controlled, randomized clinical trial of 3,209 patients aged 55 years and older having major noncardiac thoracic surgery), examined the effect of oral colchicine (0.5 mg tablet, taken twice daily starting within 4 hours before surgery for a total of 10 days) on the risk of perioperative AKI. The study found that the risk of perioperative AKI did not differ between patients assigned to receive colchicine versus placebo. The results were consistent for multiple definitions of AKI and in patients with pre-existing chronic kidney disease.
中文摘要:围术期炎症可能导致器官损伤,包括急性肾损伤(AKI)。抗炎药秋水仙碱可能有助于保护器官免受炎症影响。这项临床试验亚组研究比较秋水仙碱与安慰剂是否降低围术期AKI风险。该研究为安慰剂对照随机临床试验的预设亚组分析。研究纳入2018—2023年来自11个国家45个中心、参加秋水仙碱预防围术期心房颤动(COP-AF)试验、年龄55岁及以上并接受大型非心脏胸科手术的患者。排除有心房颤动病史、正在服用抗心律失常药物或术前估算肾小球滤过率(eGFR)低于30 mL/min/1.73 m2者。参与者按1:1随机接受0.5 mg口服秋水仙碱或安慰剂,每日两次,共10天。患者、医疗提供者、数据收集者和结局裁定者对治疗分配设盲。围术期AKI定义为术后48小时内血清肌酐浓度升高至少0.3 mg/dL,或术后7天内升高至少50%。研究还检查了AKI的其他定义,以及既存慢性肾脏病(CKD)对效应的修饰作用。主试验纳入3209例患者,本亚组纳入2947例(平均年龄68岁;平均eGFR 83 mL/min/1.73 m2),随机接受秋水仙碱(n=1476)或安慰剂(n=1471)。秋水仙碱组67例(4.7%)发生围术期AKI,安慰剂组63例(4.4%)发生围术期AKI(风险比[RR]1.07,95% CI 0.76-1.50,P=0.72;风险差[RD]0.3%,95% CI -1.2%至1.8%)。在CKD患者中,秋水仙碱与安慰剂相比AKI的RD为-0.9%,无CKD者为0.5%(交互作用P=0.62)。检测秋水仙碱对需透析AKI的较小但临床重要效应方面统计效能有限。在接受非心脏胸科手术的患者中,分配至秋水仙碱与安慰剂者的围术期AKI风险无差异。资助来源包括学术机构(Western University医学系;McMaster University心脏病学部)、政府(Canadian Institutes of Health Research;中国香港特别行政区研究资助局General Research Fund)和非营利机构(Accelerating Clinical Trials Consortium;Innovation Fund of the Alternative Funding Plan for the Academic Health Sciences Centres of Ontario;Population Health Research Institute;Hamilton Health Sciences;Hanela Foundation)。研究在ClinicalTrials.gov注册,注册号为NCT03310125。手术期间和术后炎症可导致器官损伤,包括AKI。抗炎药秋水仙碱可能有助于保护器官免受炎症影响。这项COP-AF试验的预设肾脏亚组研究(一项安慰剂对照随机临床试验,纳入3209例年龄55岁及以上接受大型非心脏胸科手术的患者)检查了口服秋水仙碱(0.5 mg片剂,术前4小时内开始,每日两次,共10天)对围术期AKI风险的影响。研究发现,分配至秋水仙碱与安慰剂者的围术期AKI风险无差异。多种AKI定义下以及既存CKD患者中结果一致。
基础研究 (5篇)
Acute kidney injury (AKI) is a prevalent condition with limited therapeutic options, in which sustained renal injury driven by inflammation remains a central pathological challenge. Here, we identify a specific subset of extracellular vesicles (EVs) as the critical link translating early myeloid inflammation into metabolically fuelled CD8+ T cell pathogenicity. Using single-EV surface proteomics via a proximity barcoding assay in a murine ischemia-reperfusion injury model, we mapped the renal EV landscape and discovered a myeloid-derived ITGAM+ EV subset with markedly increased abundance after injury. Using a CD63-PAGFPITGAM-KI reporter mouse that genetically enhances ITGAM+ EV release, we further validated that these EVs interact with CD8+ T cells in the renal lymphatic niche, driving their pro-inflammatory activation. Proteomic profiling pinpointed S100a9 as the functional cargo on these ITGAM+ EVs. Mechanistically, EV-delivered S100a9 stabilized the mitochondrial aspartate-glutamate carrier Slc25a12 in recipient CD8+ T cells, thereby enhancing glutamate metabolism to fuel a pathogenic transcriptional program. Pharmacological inhibition of S100a9 with tasquinimod, combined with genetic loss of S100a9 in bone marrow-derived myeloid cells, established the necessity of EV-associated S100a9 in driving CD8+ T cell activation. Our findings establish ITGAM+ EVs as essential mediators of pro-metabolic and pro-inflammatory signal in AKI and highlight the S100a9-Slc25a12 axis as a promising therapeutic target for intercepting sterile inflammation.
中文摘要:急性肾损伤(AKI)是一种常见疾病,治疗选择有限,炎症驱动的持续性肾损伤仍是核心病理难题。研究识别出一类特定细胞外囊泡(EVs),其将早期髓系炎症与代谢驱动的CD8+ T细胞致病性联系起来。在小鼠缺血再灌注损伤模型中,通过邻近条形码分析进行单EV表面蛋白质组学,描绘了肾脏EV图谱,发现损伤后丰度显著升高的髓系来源ITGAM+ EV亚群。使用CD63-PAGFPITGAM-KI报告小鼠(该小鼠经遗传学增强ITGAM+ EV释放),进一步验证这些EVs在肾脏淋巴微环境中与CD8+ T细胞相互作用,驱动其促炎活化。蛋白质组分析确定S100a9为这些ITGAM+ EVs上的功能性货物。机制上,EV递送的S100a9稳定受体CD8+ T细胞中的线粒体天冬氨酸-谷氨酸载体Slc25a12,从而增强谷氨酸代谢,为致病性转录程序供能。用tasquinimod药理学抑制S100a9,并结合骨髓来源髓系细胞中S100a9的遗传缺失,证实EV相关S100a9驱动CD8+ T细胞活化的必要性。研究结果确立ITGAM+ EVs是AKI中促代谢和促炎信号的重要介质,并提示S100a9-Slc25a12轴是拦截无菌性炎症的有前景治疗靶点。
Acute kidney injury (AKI) and its progression to chronic kidney disease (CKD) remain major unmet clinical challenges for which effective therapies are lacking. Although sensory neurons are recognized as key regulators of tissue injury and repair via neuroimmune crosstalk, their organization and function within the kidney are poorly understood. Here, we delineate a renal neuroimmune axis in which nociceptive neurons protect against ischemia-reperfusion (I/R)-induced kidney injury. Using whole-organ tissue clearing and three-dimensional imaging, we mapped an extensive network of nociceptive sensory fibers throughout the renal parenchyma. Ablation of TRPV1+ nociceptors aggravated renal dysfunction, tubular necrosis, and fibrosis after I/R, whereas chemogenetic activation conferred protection. Mechanistically, the sensory neuropeptide calcitonin gene-related peptide (CGRP), which is upregulated after injury, acts via the CALCRL-RAMP1 receptor complex on monocytes/macrophages, engaging the cAMP-PKA pathway to suppress pro-inflammatory cytokine and chemokine expression, thereby limiting myeloid infiltration and tubular injury. Importantly, we also found reduced renal CGRP abundance in kidneys from individuals with diabetes and older adults, who are at high risk for AKI and CKD, as well as in corresponding mouse models. In these vulnerable settings, exogenous CGRP more effectively reduced I/R-induced kidney injury. Our findings establish a dorsal root ganglia-kidney neuroimmune circuit that restrains I/R-induced renal inflammation and identify CGRP signaling as a potential therapeutic target to mitigate AKI and its progression to CKD, particularly in high-risk diabetic and elderly populations.
中文摘要:急性肾损伤(AKI)及其向慢性肾脏病(CKD)的进展仍是缺乏有效疗法的重大未满足临床挑战。感觉神经元被认为是组织损伤与修复的关键调控者,通过神经免疫交互发挥作用,但其在肾脏内的组织方式和功能仍不清楚。研究描绘了一条肾脏神经免疫轴,其中伤害性神经元对缺血再灌注(I/R)所致肾损伤具有保护作用。利用全器官组织透明化和三维成像,研究在肾实质内绘制出广泛的伤害性感觉纤维网络。消融TRPV1+伤害性感受器加重了I/R后的肾功能障碍、肾小管坏死和纤维化,而化学遗传学激活则产生保护作用。机制上,损伤后上调的感觉神经肽降钙素基因相关肽(CGRP)通过单核细胞/巨噬细胞上的CALCRL-RAMP1受体复合物发挥作用,激活cAMP-PKA通路,抑制促炎细胞因子和趋化因子表达,从而限制髓系细胞浸润和肾小管损伤。研究还发现,糖尿病个体和老年人肾脏以及相应小鼠模型肾脏中的CGRP丰度降低,这些人群是AKI和CKD的高危人群。在这些易感背景下,外源性CGRP更有效地减轻了I/R诱导的肾损伤。研究结果确立了一条背根神经节-肾脏神经免疫回路,可抑制I/R诱导的肾脏炎症,并提示CGRP信号是减轻AKI及其向CKD进展的潜在治疗靶点,尤其在糖尿病和老年高危人群中。
Severe or recurrent acute kidney injury (AKI) is a critical risk factor for chronic kidney disease (CKD) progression, characterized by irreversible fibrosis and limited therapeutic options. Maladaptive repair in proximal tubular epithelial cells (PTECs) during AKI-to-CKD progression is crucial, with the oxidative stress (OS)-ferroptosis axis emerging as a potential therapeutic target. Nuclear factor erythroid 2-related factor 2 (Nrf2), a key regulator of redox balance and ferroptosis, is essential for cellular homeostasis, but its role in PTECs maladaptive repair is unclear. In this study, we employed Nrf2 knockout (KO) mice to establish an AKI-to-CKD model through bilateral ischemia-reperfusion injury (bIRI). Nrf2 deficiency significantly exacerbated renal fibrosis, OS markers (H2O2, NOX4, 8-OHdG), and ferroptosis indicators (4-HNE, MDA, ACSL4), while concurrently suppressing antioxidant enzyme activity (SOD, GPx) and the expression of maladaptive repair-related genes (Vcam1, Irf8, etc.). Pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) were significantly elevated in KO mice. We found increased oxidative and inflammatory markers in CKD patients' serum and urine, highlighting the role of OS in disease progression. Treatment with 6K, a Kelch-like ECH-associated protein 1 (Keap1)-Nrf2 protein-protein interaction (PPI) inhibitor, markedly improved renal function, suppressed OS and ferroptosis, and upregulated adaptive repair-related genes and downregulated maladaptive repair-related genes in bIRI mice. Compound 6K exhibited a kidney-targeted distribution profile, with an area under the concentration-time curve (AUC) kidney/AUC blood ratio of 1.01, suggesting its potential for targeted treatment of kidney diseases. In human kidney-2 (HK-2) cells, 6K activated the Nrf2-GPX4 axis, thereby alleviated RSL3-induced suppression of GPX4 expression, reduced reactive oxygen species (ROS) accumulation and lipid peroxidation, and mitigated ferroptosis. Furthermore, 6K treatment significantly delayed fibrosis progression in bIRI and unilateral ureteral obstruction (UUO) models. In summary, our findings demonstrate that Nrf2 deficiency exacerbates AKI-CKD progression through redox imbalance and ferroptosis-mediated maladaptive repair. Targeting Keap1-Nrf2 with 6K protects against renal injury and fibrosis, highlighting its therapeutic potential for kidney diseases.
中文摘要:严重或反复发作的急性肾损伤(AKI)是慢性肾脏病(CKD)进展的重要危险因素,以不可逆纤维化和治疗选择有限为特征。AKI向CKD进展过程中,近端小管上皮细胞(PTEC)的适应不良性修复起关键作用,氧化应激(OS)-铁死亡轴成为潜在治疗靶点。核因子E2相关因子2(Nrf2)是氧化还原平衡和铁死亡的关键调控因子,对细胞稳态必不可少,但其在PTEC适应不良性修复中的作用尚不清楚。本研究采用Nrf2敲除(KO)小鼠,通过双侧缺血再灌注损伤(bIRI)建立AKI向CKD转化模型。Nrf2缺失显著加重肾纤维化、OS标志物(H2O2、NOX4、8-OHdG)和铁死亡指标(4-HNE、MDA、ACSL4),同时抑制抗氧化酶活性(SOD、GPx)及适应不良性修复相关基因(Vcam1、Irf8等)表达。KO小鼠促炎细胞因子(IL-1β、IL-6、TNF-α)显著升高。CKD患者血清和尿液中氧化及炎症标志物升高,提示OS在疾病进展中的作用。6K是一种Kelch样ECH相关蛋白1(Keap1)-Nrf2蛋白-蛋白相互作用(PPI)抑制剂,治疗bIRI小鼠可明显改善肾功能,抑制OS和铁死亡,上调适应性修复相关基因并下调适应不良性修复相关基因。化合物6K呈肾脏靶向分布,肾脏AUC/血液AUC比为1.01,提示其用于肾脏疾病靶向治疗的潜力。在人肾-2(HK-2)细胞中,6K激活Nrf2-GPX4轴,缓解RSL3对GPX4表达的抑制,减少活性氧(ROS)蓄积和脂质过氧化,减轻铁死亡。6K治疗还显著延缓bIRI和单侧输尿管梗阻(UUO)模型的纤维化进展。Nrf2缺失通过氧化还原失衡和铁死亡介导的适应不良性修复加重AKI-CKD进展。以6K靶向Keap1-Nrf2可减轻肾损伤和纤维化,显示其治疗肾脏疾病的潜力。
Susceptibility to ischemia-reperfusion-induced AKI was sexually dimorphic and associated with sex difference in KYNU expression and de novo NAD + flux. Androgen-dependent deficiency in kynureninase expression impaired NAD +de novo synthesis under stress, contributing to male mice susceptibility to kidney injury. Kynureninase deletion in female mice abrogated protection against ischemia‑reperfusion injury, which was rescued by nicotinamide mononucleotide treatment. Biological sex is recognized as a modulator of AKI, whereas the underlying molecular mechanisms remain incompletely understood. An ischemia-reperfusion injury-induced AKI model was established on adult male and female wild-type and female kynureninase ( Kynu ) knockout ( Kynu-/- ) mice. Prepubertal wild-type mice were gonadectomized and euthanized 5 weeks later. 13 C-tryptophan was administered by tail vein injection, and renal levels of NAD + and metabolites in the de novo pathway were examined using high-performance liquid chromatography. Quinolinic acid (QA) and nicotinamide mononucleotide were administered by oral gavage or intraperitoneal injection. Male mice were more susceptible to ischemic kidney injury, accompanied by a more pronounced decrease in NAD + levels compared with female mice. Further experiments demonstrated that the expression of KYNU, a central enzyme in the de novo NAD + biosynthetic pathway, was significantly downregulated in male kidneys. High-performance liquid chromatography analysis revealed that male mice exhibited significantly lower renal QA (a downstream metabolite of KYNU) and reduced tryptophan-derived NAD + after ischemia-reperfusion injury compared with females, reflecting impaired NAD +de novo biosynthesis. Notably, QA supplementation effectively alleviated the exacerbated kidney injury observed in male mice. In addition, castration markedly elevated renal Kynu expression to levels comparable with those in females, which decreased again after testosterone supplementation. Furthermore, genetic ablation of Kynu replicated the decreased renal QA and NAD + levels observed in male mice, accompanied by exacerbated kidney damage. Supplementation with nicotinamide mononucleotide, an NAD + precursor, significantly alleviated AKI in Kynu-/- mice. Androgen-dependent KYNU downregulation was found in the adult mouse kidney. Disrupted NAD +de novo biosynthesis caused by Kynu deficiency mediated the sex-biased susceptibility to AKI.
中文摘要:缺血再灌注诱导的急性肾损伤易感性存在性别二态性,并与KYNU表达及NAD+从头合成通量的性别差异相关。雄激素依赖的犬尿氨酸酶表达不足削弱应激状态下NAD+从头合成,促使雄性小鼠更易发生肾损伤。雌性小鼠敲除犬尿氨酸酶后失去对缺血再灌注损伤的保护,烟酰胺单核苷酸处理可恢复这种保护。生物学性别被认为是急性肾损伤的调节因素,但其分子机制仍未完全阐明。研究在成年雄性和雌性野生型小鼠及雌性犬尿氨酸酶基因敲除(Kynu-/-)小鼠中建立缺血再灌注损伤诱导的急性肾损伤模型。青春期前野生型小鼠行去势,5周后处死。经尾静脉注射13C标记色氨酸,采用高效液相色谱检测肾脏NAD+及从头合成通路代谢物水平。喹啉酸和烟酰胺单核苷酸分别经口灌胃或腹腔注射给药。雄性小鼠对缺血性肾损伤更敏感,NAD+水平下降较雌性小鼠更明显。进一步实验显示,NAD+从头合成通路核心酶KYNU在雄性肾脏中的表达显著下调。高效液相色谱分析显示,缺血再灌注损伤后雄性小鼠肾脏喹啉酸(KYNU下游代谢物)水平及色氨酸来源NAD+均显著低于雌性,反映NAD+从头合成受损。补充喹啉酸可有效减轻雄性小鼠加重的肾损伤。去势使肾脏Kynu表达明显升高至与雌性相当的水平,补充睾酮后再次下降。基因敲除Kynu可重现雄性小鼠肾脏喹啉酸和NAD+水平下降,并伴肾损伤加重。补充NAD+前体烟酰胺单核苷酸可显著减轻Kynu-/-小鼠的急性肾损伤。成年小鼠肾脏中存在雄激素依赖性KYNU下调。Kynu缺陷导致的NAD+从头合成受阻介导了急性肾损伤的性别偏倚易感性。
Platelet-activating factor receptor contributed to renal tubular epithelial cells G2/M arrest through suppressing mouse double minute 2-mediated p53 ubiquitin degradation in AKI-to-CKD transition. Phosphatidylethanolamine (18:0/18:1) served as a novel endogenous ligand of platelet-activating factor receptor, inducing the downstream signaling. WAY-639497, a small-molecule platelet-activating factor receptor antagonist identified by virtual screening, mitigated renal tubular epithelial cells G2/M arrest and AKI-to-CKD transition. AKI represents a critical clinical complication with a high propensity of progression to CKD, yet effective therapies remain limited. G protein-coupled receptors mediate diverse pathophysiological processes and are promising therapeutic targets. Here, we investigated the role of platelet-activating factor receptor (PTAFR), a lipophilic G protein-coupled receptor, in AKI-to-CKD transition. A mouse model of ischemia-reperfusion injury (IRI)-induced AKI was built by bilateral renal artery clamping. The phenotypic role of PTAFR in renal tubular epithelial cells (RTECs) after AKI was investigated in tubule-specific PTAFR-deficiency mice. The functional and molecular mechanisms were determined by transcriptomic profiling, flow cytometry, coimmunoprecipitation, Western blotting, and immunofluorescence. Lipidomic analysis and biological experiments were used to identify the endogenous ligand of PTAFR. The translational potential of PTAFR was evaluated by structure-based high-throughput virtual screening of a small-molecule inhibitor in vivo and in vitro assays. The expression of PTAFR was upregulated in RTECs after AKI in vivo and in vitro . Tubule-specific depletion of PTAFR alleviated IRI-induced RTEC injury and kidney fibrosis after AKI. Mechanistically, PTAFR promoted RTECs G2/M arrest by suppressing mouse double minute 2-mediated p53 ubiquitin degradation. Phosphatidylethanolamine (18:0/18:1) was identified as a novel PTAFR endogenous ligand inducing RTECs G2/M arrest. Urinary phosphatidylethanolamine (18:0/18:1) was correlated with kidney dysfunction and was able to effectively distinguish patients with AKI from healthy controls. High-throughput virtual screening identified WAY-639497, a small-molecule PTAFR antagonist, that was able to mitigate IRI-induced RTEC injury and kidney fibrosis after AKI. PTAFR promoted tubular epithelial cell G2/M arrest by inhibiting mouse double minute 2-mediated p53 ubiquitin degradation and further contributed AKI-to-CKD transition.
中文摘要:血小板激活因子受体通过抑制小鼠双微体2介导的p53泛素化降解,促进肾小管上皮细胞G2/M阻滞,参与AKI向CKD转化。磷脂酰乙醇胺(18:0/18:1)作为血小板激活因子受体的新型内源性配体,诱导下游信号。虚拟筛选发现的小分子血小板激活因子受体拮抗剂WAY-639497可减轻肾小管上皮细胞G2/M阻滞及AKI向CKD转化。AKI是临床重要并发症,易进展为CKD,有效治疗有限。G蛋白偶联受体介导多种病理生理过程,是有前景的治疗靶点。本研究探讨脂溶性G蛋白偶联受体血小板激活因子受体(PTAFR)在AKI向CKD转化中的作用。通过双侧肾动脉夹闭建立缺血再灌注损伤(IRI)诱导的AKI小鼠模型。在肾小管特异性PTAFR缺失小鼠中研究AKI后肾小管上皮细胞(RTEC)中PTAFR的表型作用。采用转录组分析、流式细胞术、免疫共沉淀、Western blot和免疫荧光确定功能和分子机制。利用脂质组学分析和生物学实验鉴定PTAFR内源性配体。通过基于结构的高通量虚拟筛选小分子抑制剂,并在体内外实验中评估PTAFR的转化潜力。AKI后RTEC中PTAFR表达在体内和体外均上调。肾小管特异性缺失PTAFR减轻IRI诱导的AKI后RTEC损伤和肾脏纤维化。机制上,PTAFR通过抑制小鼠双微体2介导的p53泛素化降解促进RTEC G2/M阻滞。磷脂酰乙醇胺(18:0/18:1)被鉴定为诱导RTEC G2/M阻滞的新型PTAFR内源性配体。尿磷脂酰乙醇胺(18:0/18:1)与肾功能障碍相关,能有效区分AKI患者与健康对照。高通量虚拟筛选鉴定出小分子PTAFR拮抗剂WAY-639497,可减轻IRI诱导的AKI后RTEC损伤和肾脏纤维化。PTAFR通过抑制小鼠双微体2介导的p53泛素化降解促进肾小管上皮细胞G2/M阻滞,并进一步参与AKI向CKD转化。
4肾移植 (7篇)
临床研究 (7篇)
Kidney transplantation faces persistent challenges in accurately evaluating donor organ quality and predicting long-term outcomes, with traditional assessment methods demonstrating limited predictive capacity. The increasing utilization of marginal-quality donor organs has intensified the need for sophisticated evaluation strategies. Machine perfusion technology has transformed organ preservation from mere static storage to a dynamic platform potentially enabling real-time monitoring, assessment, and interventions during the preservation period. Molecular profiling technologies such as genomics, transcriptomics, proteomics, and metabolomics could provide refined biomarkers for donor kidney assessment across several phases of kidney transplantation. The first window arises during donor evaluation. Techniques such as high-resolution molecular typing, genetic profiling, epigenomic markers, and artificial intelligence-enhanced imaging provide additional information compared to traditional scoring systems. During organ preservation, a second window emerges, allowing additional, isolated assessment of the organ after procurement but before transplantation. Machine perfusion systems enable sampling of perfusate and tissue for multi-omics analysis to characterize injury or function, although most candidate biomarkers remain at the discovery or early validation stage. After transplantation, donor-derived cell-free deoxyribonucleic acid, urinary chemokines, and advanced imaging modalities offer non-invasive early detection of graft injury. Clinical translation of these new techniques faces substantial challenges: most studies are single-center and have small sample sizes, assay standardization remains incomplete, and evidence linking biomarker-guided decisions to improved long-term graft survival is lacking. Machine learning may enhance risk stratification but remains largely unvalidated in prospective trials. Future progress requires a shift from short-term endpoint prediction to long-term outcome validation through multicenter studies, standardized protocols, and equitable implementation strategies.
中文摘要:肾移植在准确评估供体器官质量和预测长期结局方面持续面临挑战,传统评估方法的预测能力有限。边缘质量供体器官使用增加,使复杂评估策略的需求更为迫切。机器灌注技术使器官保存从单纯静态储存转变为动态平台,有望在保存期间实现实时监测、评估和干预。基因组学、转录组学、蛋白质组学和代谢组学等分子谱分析技术,可在肾移植多个阶段为供肾评估提供更精细的生物标志物。第一个窗口出现在供体评估阶段。高分辨率分子分型、遗传谱分析、表观基因组标志物以及人工智能增强成像等技术,相较传统评分系统可提供额外信息。器官保存期间出现第二个窗口,可在获取器官后、移植前对离体器官进行补充评估。机器灌注系统可采集灌注液和组织进行多组学分析,以刻画损伤或功能状态,尽管多数候选标志物仍处于发现或早期验证阶段。移植后,供体来源游离脱氧核糖核酸、尿液趋化因子和先进成像手段可实现移植物损伤的无创早期检测。这些新技术的临床转化面临重大挑战:多数研究为单中心、样本量小,检测标准化尚不完整,且缺乏将生物标志物指导决策与改善长期移植物存活相联系的证据。机器学习可能改进风险分层,但在前瞻性试验中大多尚未验证。未来进展需要从短期终点预测转向长期结局验证,通过多中心研究、标准化方案和公平实施策略实现。
A highly sensitized patient received a kidney transplant (KT) following imlifidase induction: we report an innovative diagnostic and therapeutic strategy for rejection management. On day 20 post-KT, the patient developed acute kidney injury, with donor-derived cell-free DNA (dd-cfDNA) increasing to 1.93%. Histology revealed isolated glomerulitis (g1) with C4d(2+) deposits along peritubular capillaries. Steroids and plasma exchanges were administered for suspected antibody-mediated rejection (AMR), despite no rebound of donor-specific anti-HLA antibodies (DSAs). Non-HLA anti-endothelial cell antibodies were positive, confirming AMR according to Banff 2022. Transcriptomic analysis showed overexpression of complement pathway-associated transcripts. C5 inhibition failed as serum creatinine further increased along with dd-cfDNA (3.96%). A second biopsy confirmed active AMR with increased expression of NK-related transcripts, leading to anti-CD38 treatment (daratumumab). At 6 months post-KT, the condition was controlled with stable creatinine at 20.4 μg/mL, dd-cfDNA decreased to 0.1%, microvascular inflammation resolved, non-HLA anti-endothelial cell antibodies became undetectable, still without HLA DSA rebound. Daratumumab is ongoing. Integrating dd-cfDNA, transcriptomic biopsy analysis, and non-HLA antibody assessment may optimize the management of highly sensitized KT recipients following imlifidase induction. However, long-term efficacy remains to be confirmed.
中文摘要:一名高度致敏患者在接受imlifidase诱导后接受肾移植(KT),本文报告一种用于排斥管理的创新诊断与治疗策略。KT后第20天,患者发生急性肾损伤,供者来源游离DNA(dd-cfDNA)升高至1.93%。组织学显示孤立性肾小球炎(g1),伴管周毛细血管C4d(2+)沉积。尽管供者特异性抗HLA抗体(DSA)未反弹,仍因疑似抗体介导排斥(AMR)给予激素和血浆置换。非HLA抗内皮细胞抗体阳性,按Banff 2022标准确认AMR。转录组分析显示补体通路相关转录本过表达。C5抑制失败,血清肌酐进一步升高,dd-cfDNA升至3.96%。第二次活检证实活动性AMR,NK相关转录本表达增加,遂给予抗CD38治疗(达雷妥尤单抗)。KT后6个月,病情得到控制,肌酐稳定在20.4 μg/mL,dd-cfDNA降至0.1%,微血管炎症消退,非HLA抗内皮细胞抗体转为检测不到,HLA DSA仍无反弹。达雷妥尤单抗仍在继续使用。整合dd-cfDNA、活检转录组分析和非HLA抗体评估,可能优化imlifidase诱导后高度致敏KT受者的管理。长期疗效仍有待确认。
Simultaneous pancreas-kidney transplantation (SPKTx) and kidney transplantation alone (KTx) are common treatment modalities for individuals with type 1 diabetes with end-stage kidney disease. This study compared metabolic and macrovascular disease outcomes between SPKTx and KTx in recipients with type 1 diabetes. We conducted a systematic search of the Embase, MEDLINE and Scopus databases (last searched 23 February 2025). We included retrospective and case-control studies, owing to a lack of randomised controlled trials in English, with adult patients. We excluded studies reporting on a return to dialysis post transplant, islet-kidney transplantation or separate pancreas-kidney transplants. Bias and study quality were assessed via the Newcastle-Ottawa scale for cohort studies. Demographic and outcome data were synthesised as both categorical and continuous data, with pooled means and summary statistics computed where applicable. Meta-analysis was performed on post-transplant outcomes in studies evaluating total cholesterol (TC), triglyceride (TG) level, HDL, LDL, blood pressure, HbA1c and renal function. Macrovascular outcomes included the frequency of new or adverse events associated with coronary artery disease (CAD), cerebrovascular disease (CeVD) and peripheral vascular disease (PVD). A total of 15 studies (n=564 SPKTx, 419 KTx) were included. Meta-analysis demonstrated lower post-transplant TC (mean difference -0.41 mmol/l [95% CI -0.60, -0.22], p<0.01, I2=37%), TG level (mean difference -0.76 mmol/l [95% CI -1.02, -0.49], p<0.01, I2=86%), LDL (mean difference -0.28 mmol/l [95% CI -0.42, -0.14], p<0.01, I2=15%), HbA1c (mean difference -28.79 mmol/mol [95% CI -35.75, -21.82], p<0.01, I2=98%; mean difference -2.61% [95% CI -3.05, -2.16], p<0.01) and creatinine levels (mean difference -21.54 μmol/l [95% CI -39.23, -3.85], p=0.02, I2=90%) following SPKTx compared with KTx. Mean antihypertensive agent use per participant decreased post SPKTx (1.0 vs 2.5 pre transplant; p<0.01), but was not significantly different from post-KTx groups. HbA1c increased following KTx (69 mmol/mol [8.5%]) compared with pre KTx (53 mmol/mol [7.0%], p<0.01). Progression of CAD, CeVD and PVD occurred across both groups post transplant. PVD showed more than a twofold increase in amputations and revascularisations post transplant. No difference was observed in the post-transplant frequency of CAD, CeVD or PVD between SPKTx and KTx. Evidence from this study was limited by a lack of subgroup data for analysis, a lack of randomised studies and a paucity of reported lifestyle factors influencing outcomes. SPKTx demonstrates a superior metabolic profile post transplant to that in KTx in recipients with type 1 diabetes. However, this does not translate into differences in the risk of CAD or PVD post transplant, with PVD accounting for the greatest burden of macrovascular disease. This protocol has been registered a priori on PROSPERO (CRD42024622408).
中文摘要:1型糖尿病合并终末期肾病患者常接受同期胰肾联合移植(SPKTx)或单纯肾移植(KTx)。该研究比较两类受者移植后代谢及大血管疾病结局。系统检索Embase、MEDLINE和Scopus数据库,末次检索日期为2025年2月23日。因缺乏英文随机对照试验,纳入成人回顾性研究和病例对照研究,排除移植后恢复透析、胰岛-肾移植以及胰肾分别移植的研究。采用纽卡斯尔-渥太华量表评估队列研究偏倚和研究质量。人口学与结局数据按分类和连续变量汇总,适用时计算合并均值和汇总统计量。对评估总胆固醇(TC)、甘油三酯(TG)、HDL、LDL、血压、HbA1c和肾功能的研究进行移植后结局meta分析。大血管结局包括冠心病(CAD)、脑血管病(CeVD)和外周血管病(PVD)新发事件或不良事件频率。共纳入15项研究(SPKTx n=564,KTx n=419)。Meta分析显示,与KTx相比,SPKTx移植后TC更低(均数差-0.41 mmol/l,95% CI -0.60至-0.22,p<0.01,I²=37%)、TG更低(均数差-0.76 mmol/l,95% CI -1.02至-0.49,p<0.01,I²=86%)、LDL更低(均数差-0.28 mmol/l,95% CI -0.42至-0.14,p<0.01,I²=15%)、HbA1c更低(均数差-28.79 mmol/mol,95% CI -35.75至-21.82,p<0.01,I²=98%;均数差-2.61%,95% CI -3.05至-2.16,p<0.01)且肌酐更低(均数差-21.54 μmol/l,95% CI -39.23至-3.85,p=0.02,I²=90%)。SPKTx后每名受者平均降压药使用量下降(移植前2.5降至移植后1.0,p<0.01),但与KTx移植后组无显著差异。KTx后HbA1c由移植前53 mmol/mol(7.0%)升至69 mmol/mol(8.5%),p<0.01。两组移植后均出现CAD、CeVD和PVD进展。PVD表现为移植后截肢和血运重建增加超过两倍。SPKTx与KTx移植后CAD、CeVD或PVD频率无差异。该研究证据受限于缺乏亚组数据、缺少随机研究以及影响结局的生活方式因素报告不足。SPKTx在1型糖尿病受者中显示出优于KTx的移植后代谢谱,但未转化为移植后CAD或PVD风险差异,PVD构成大血管疾病的最大负担。该方案已在PROSPERO预先注册(CRD42024622408)。
Expansion of living kidney donation is needed to meet the increasing global need for kidney replacement therapy. Advances in the understanding of postdonation health outcomes have confirmed that living donation in carefully selected donors is associated with a low absolute risk of kidney failure of 50 per 10,000 after 20 years. However, information about lifetime risks, heterogeneity of risk, and the long-term safety of donors with chronic kidney disease risk factors before or after donation remains incomplete. This uncertainty likely contributes to the global stagnation in living-donor kidney transplantation. This review outlines the evolution of living kidney donor risk assessment, including the exclusion of hyperfiltration injury as a significant contributor to kidney failure after donation and the importance of postdonation chronic kidney disease risk factors and acute kidney injury as key determinants of postdonation kidney health. Given the low absolute risk of kidney failure, the review will identify policy and practice considerations needed to safely expand living kidney donation. Dedicated funding for postdonation care to ensure the optimal management of conditions that might compromise postdonation kidney function and facilitate the ascertainment of information to better inform current and future living kidney donors should be prioritized.
中文摘要:为满足全球日益增长的肾脏替代治疗需求,需要扩大活体肾捐献。对捐献后健康结局认识的发展已证实,在严格筛选的捐献者中,活体捐献与较低的绝对肾衰竭风险相关,20年后为每万人50例。然而,关于终生风险、风险异质性以及捐献前或捐献后存在慢性肾脏病危险因素的捐献者长期安全性的信息仍不完整。这种不确定性可能促成全球活体供肾移植停滞。综述概述活体肾捐献者风险评估的演变,包括将高滤过损伤排除为捐献后肾衰竭的重要促成因素,以及捐献后慢性肾脏病危险因素和急性肾损伤作为捐献后肾脏健康关键决定因素的重要性。鉴于肾衰竭绝对风险较低,综述将提出安全扩大活体肾捐献所需的政策与实践考量。应优先为捐献后照护提供专门资金,以确保可能损害捐献后肾功能的状况得到最佳管理,并促进信息查明,从而更好地为当前和未来活体肾捐献者提供依据。
Microvascular inflammation (MVI) on kidney biopsy is associated with reduced graft survival following kidney transplantation (KT). CD38-targeting regimens, including the monoclonal antibody daratumumab, have recently emerged as a promising therapeutic strategy to counteract MVI and stabilize graft function. Here, we retrospectively collected data on eGFR, albuminuria, kidney allograft pathology, donor specific antibodies (DSA) and donor-derived cell-free DNA (dd-cfDNA) levels from 70 KT patients both prior to and after initiation of daratumumab treatment. Safety signals were also documented. The study cohort consisted of 59 patients diagnosed with antibody mediated rejection (AMR) and 11 patients showing DSA- and C4d-negative MVI. Median time between transplantation and diagnosis of MVI was 36 months. Daratumumab treatment was initiated at a median of 1.6 months following diagnosis of MVI. A mixed linear model showed stabilization of eGFR from -1.6 ml/min/1.73m2/month in the year prior to the diagnosis of MVI to +0.3 ml/min/1.73m2/month after starting daratumumab. Six patients lost their graft during follow-up. Median albuminuria and dd-cfDNA levels decreased early during treatment, whereas the effect on DSA was heterogeneous. Both the number of doses and treatment duration had no measurable impact on outcome. Our preliminary data suggest efficacy of daratumumab in stabilizing kidney function in KT recipients with MVI.
中文摘要:肾移植后肾活检发现微血管炎症(MVI)与移植物存活率下降相关。包括单克隆抗体达雷妥尤单抗在内的CD38靶向方案近期被视为对抗MVI并稳定移植物功能的有前景治疗策略。该研究回顾性收集了70例肾移植患者在开始达雷妥尤单抗治疗前后eGFR、白蛋白尿、移植肾病理、供者特异性抗体(DSA)及供者来源游离DNA(dd-cfDNA)水平的数据,并记录安全性信号。研究队列包括59例抗体介导排斥反应(AMR)患者和11例DSA及C4d阴性MVI患者。移植至MVI诊断的中位时间为36个月。达雷妥尤单抗在MVI诊断后中位1.6个月开始使用。混合线性模型显示,eGFR变化从MVI诊断前一年的-1.6 ml/min/1.73m2/月稳定至开始达雷妥尤单抗后的+0.3 ml/min/1.73m2/月。随访期间6例患者失去移植物。治疗早期白蛋白尿和dd-cfDNA中位水平下降,对DSA的影响不一致。给药次数和治疗持续时间对结局均无可测量影响。初步数据提示达雷妥尤单抗对伴MVI的肾移植受者具有稳定肾功能的作用。
We assessed whether an initial donor-derived cell-free DNA elevation during routine surveillance was associated with allograft dysfunction and loss in kidney transplant recipients. Intermediate and high donor-derived cell-free DNA states were independently associated with 3.7-fold and 6.4-fold higher risks of allograft loss, respectively. Persistently low donor-derived cell-free DNA levels were associated with low rates of rejection and allograft loss, identifying a low-risk population. Although donor-derived cell-free DNA (dd-cfDNA) correlates with histologic rejection and injury severity, its association with long-term graft outcomes has yet to be well established in kidney transplant recipients. We hypothesize that among patients monitored with dd-cfDNA, an initial elevation may be associated with subsequent allograft dysfunction and loss. The Kidney Allograft Outcomes AlloSure Registry is a prospective, multicenter cohort of 1743 adult kidney transplant recipients from 56 US centers; this analysis included 1258 patients who initiated dd-cfDNA surveillance 15-60 days post-transplant with up to 3-year follow-up. A multistate model was applied to characterize transitions from a low dd-cfDNA state (no elevations) to intermediate (0.5%-1.0% with ≥61% relative change value) or high (≥1.0%) dd-cfDNA states, and their unadjusted and covariate-adjusted associations with allograft loss or all-cause death were quantified using hazard regression models. Within 3 years, 36% of patients transitioned to an elevated dd-cfDNA state (intermediate n =216; high n =233). Allograft dysfunction by 36 months occurred significantly more often in patients with dd-cfDNA elevations despite preserved allograft function at the time of elevation (eGFR ≥60 ml/min per 1.73 m 2 in 42% of intermediate and 33% of high), consistent with subclinical injury. Transitions from low to elevated dd-cfDNA states were strongly associated with subsequent allograft loss (adjusted hazard ratios, 3.70 [95% confidence interval [CI], 1.38 to 9.90] for intermediate; 6.36 [95% CI, 2.80 to 14.42] for high), while mortality did not differ by dd-cfDNA state. Initial dd-cfDNA elevations exceeding established thresholds were independently associated with higher risks of allograft dysfunction and loss across both elevation categories, whereas patients who remained in the low dd-cfDNA state experienced favorable outcomes.
中文摘要:我们评估肾移植受者常规监测中首次供者来源游离DNA升高是否与移植物功能障碍和失功相关。中等和高供者来源游离DNA状态分别与移植物失功风险升高3.7倍和6.4倍独立相关。持续低水平供者来源游离DNA与较低的排斥反应和移植物失功发生率相关,可识别低危人群。供者来源游离DNA(dd-cfDNA)虽与组织学排斥反应及损伤严重程度相关,但其与长期移植物结局的关系在肾移植受者中尚未充分确立。我们假设在接受dd-cfDNA监测的患者中,首次升高可能与后续移植物功能障碍和失功相关。Kidney Allograft Outcomes AlloSure Registry是一项前瞻性、多中心队列,纳入美国56个中心的1743例成人肾移植受者;本分析包括1258例在移植后15-60天启动dd-cfDNA监测、随访至多3年的患者。采用多状态模型描述从低dd-cfDNA状态(无升高)向中等(0.5%-1.0%且相对变化值≥61%)或高(≥1.0%)dd-cfDNA状态的转换,并用风险回归模型量化其与移植物失功或全因死亡的未校正及协变量校正关联。3年内,36%的患者转换为dd-cfDNA升高状态(中等n=216;高n=233)。dd-cfDNA升高时移植物功能仍保留(中等状态42%、高状态33%的患者eGFR≥60 ml/min per 1.73 m²),但36个月时移植物功能障碍在dd-cfDNA升高患者中显著更常见,符合亚临床损伤。从低状态向升高状态的转换与后续移植物失功强相关(校正风险比:中等3.70[95%置信区间1.38至9.90];高6.36[95%置信区间2.80至14.42]),而不同dd-cfDNA状态的死亡率无差异。超过既定阈值的首次dd-cfDNA升高在两个升高类别中均与移植物功能障碍和失功风险升高独立相关,而持续处于低dd-cfDNA状态的患者结局良好。
De novo donor-specific anti-HLA antibody, microvascular inflammation, and T-cell-mediated rejection events frequently occurred concomitantly or serially, and their interconnectedness and complexity are underappreciated. Microvascular inflammation without donor-specific anti-HLA antibody did not independently worsen prognosis after adjustment for serial or concomitant T-cell-mediated rejection and de novo donor-specific anti-HLA antibody events in time-dependent models. HLA-DR/DQ alloimmune risk categories were multivariable correlates of microvascular inflammation-free survival, suggesting an association with HLA mismatch. Microvascular inflammation (sum of glomerulitis [g] and peritubular capillaritis [ptc] scores ≥2) frequently occurs without donor-specific anti-HLA antibodies (DSAs), often alongside T-cell-mediated rejection (TCMR), yet its independent prognostic significance remains uncertain. In a consecutive single-center cohort of 689 kidney transplant recipients (2004-2021), we examined the impact of first g+ptc≥2, TCMR, and de novo DSA (dnDSA) events on death-censored allograft loss using Cox models with time-dependent covariates to account for event timing and overlap. A first g+ptc≥2 occurred in 106/689 (15%) recipients, and 88% had concomitant or sequential TCMR and/or dnDSA. Most g+ptc≥2 biopsies were associated with TCMR (76%), including those with g=0. When assessed individually, the first g+ptc≥2 (hazard ratio [HR], 4.33; 95% confidence interval [CI], 2.5 to 7.5), TCMR (HR, 4.07; 95% CI, 2.3 to 7.1), and dnDSA (HR, 4.26; 95% CI, 2.2 to 8.3) events were each associated with death-censored allograft loss. However, in a combined time-dependent model, first TCMR (HR, 2.74; 95% CI, 1.4 to 5.4) and dnDSA (HR, 2.32; 95% CI, 1.1 to 5.1) remained independently associated with death-censored allograft loss, whereas g+ptc≥2 did not (HR, 1.77; 95% CI, 0.84 to 3.73). In a modern tacrolimus-based cohort, g+ptc≥2 without DSA was not associated with worse outcomes after adjustment for serial or concomitant TCMR and dnDSA events.
中文摘要:新生供体特异性抗HLA抗体、微血管炎症和T细胞介导的排斥事件常同时或序贯发生,其相互关联和复杂性未被充分认识。在时间依赖模型中校正序贯或同时发生的T细胞介导的排斥和新生供体特异性抗HLA抗体事件后,不伴供体特异性抗HLA抗体的微血管炎症并未独立加重预后。HLA-DR/DQ同种免疫风险分类是无微血管炎症生存的多变量相关因素,提示其与HLA错配相关。微血管炎症(肾小球炎[g]与管周毛细血管炎[ptc]评分之和≥2)常在不伴供体特异性抗HLA抗体(DSAs)时发生,并常与T细胞介导的排斥(TCMR)并存,但其独立预后意义仍不确定。在一项连续单中心队列中,纳入689例肾移植受者(2004—2021年),我们采用含时间依赖协变量的Cox模型分析首次g+ptc≥2、TCMR和新生DSA(dnDSA)事件对死亡删失的移植物丢失的影响,以考虑事件发生时间和重叠。106/689例(15%)受者发生首次g+ptc≥2,其中88%同时或序贯存在TCMR和/或dnDSA。多数g+ptc≥2活检与TCMR相关(76%),包括g=0者。单独评估时,首次g+ptc≥2(风险比[HR]为4.33;95%置信区间[CI]为2.5至7.5)、TCMR(HR为4.07;95%CI为2.3至7.1)和dnDSA(HR为4.26;95%CI为2.2至8.3)事件均与死亡删失的移植物丢失相关。然而,在联合时间依赖模型中,首次TCMR(HR为2.74;95%CI为1.4至5.4)和dnDSA(HR为2.32;95%CI为1.1至5.1)仍与死亡删失的移植物丢失独立相关,而g+ptc≥2则不然(HR为1.77;95%CI为0.84至3.73)。在以他克莫司为基础的现代队列中,不伴DSA的g+ptc≥2在序贯或同时发生的TCMR和dnDSA事件校正后,与更差结局无关。
5遗传性肾病/囊性 (5篇)
临床研究 (4篇)
A landmark study by Gibson and coworkers in 2021 estimated that one in 106 individuals carry a predicted pathogenic COL4A3 or COL4A4 variant, suggesting autosomal dominant Alport syndrome is massively underdiagnosed. However, pathogenicity of all triple-helical Glycine substitutions was inferred using in silico tools, which may overestimate prevalence. COL4A3, COL4A4, and COL4A5 variants were extracted from population database gnomADv4.1.1 (about 800,000 individuals, including UK Biobank) and from a clinical exome cohort of 29,055 patients (Eurofins Biomnis), stratified into a kidney disease group (KIDNEY) of 8663 individuals and 20,392 individuals of a non-kidney control group (NON-KIDNEY). Three curation strategies were compared: a ClinVar-dependent model, an in silico-driven model adapted from Gibson, and an Expert Strategy combining stringent allele frequency thresholds, high-confidence loss-of-function filtering, and with ClinVar validation for missense variants. Estimates were validated against the control group and replicated in the non-UKB Biobank subset. Applied to gnomADv4.1.1, the Gibson methodology yielded one in 221, a 52% reduction from the original one in 106 (gnomADv2). The Expert Strategy estimated one in 283, validated in the NON-KIDNEY group (one in 295; concordance ratio 0.96), whereas Gibson inflated the control rate by 91% (one in 154 vs. one in 295). Glycine substitutions (COL4A3 p.Gly1277Ser odds ratio 0.95; COL4A4 p.Gly999Glu odds ratio 1.01) were misclassified by all in silico tools. Expert Strategy variants were found in one in 44 KIDNEY patients (odds ratio 6.76). Enrichment was unchanged by high-confidence loss-of-function restriction. Autosomal dominant Alport syndrome affects one in 283 individuals, one to two orders of magnitude above classical clinical estimates (one in 5,000 to one in 53,000), confirming underdiagnosis, but substantially lower than the Gibson estimate. These findings argue for downgrading the PM2 rarity criterion in collagenopathies. Systematic COL4A3/COL4A4 screening in chronic kidney disease is justified by a diagnostic yield of one in 44.
中文摘要:Gibson等2021年的一项里程碑研究估计,每106人中就有1人携带预测致病的COL4A3或COL4A4变异,提示常染色体显性Alport综合征被大量漏诊。但所有三螺旋甘氨酸替换的致病性均通过计算机模拟工具推断,可能高估患病率。研究从人群数据库gnomADv4.1.1(约80万人,包括UK Biobank)和29,055例患者的临床外显子队列(Eurofins Biomnis)中提取COL4A3、COL4A4和COL4A5变异,并分为8,663人的肾脏病组(KIDNEY)和20,392人的非肾脏病对照组(NON-KIDNEY)。比较三种整理策略:依赖ClinVar的模型、改编自Gibson的计算机模拟驱动模型,以及结合严格等位基因频率阈值、高置信度功能缺失过滤和对错义变异进行ClinVar验证的专家策略。估计结果在对照组中验证,并在非UKB的Biobank子集中重复。应用于gnomADv4.1.1时,Gibson方法得到每221人中1人,较原始每106人中1人(gnomADv2)降低52%。专家策略估计每283人中1人,并在NON-KIDNEY组得到验证(每295人中1人;一致比0.96),而Gibson方法将对照率高估91%(每154人中1人 vs 每295人中1人)。甘氨酸替换(COL4A3 p.Gly1277Ser比值比0.95;COL4A4 p.Gly999Glu比值比1.01)被所有计算机模拟工具错误分类。专家策略变异在KIDNEY患者中为每44人中1人(比值比6.76)。高置信度功能缺失限制未改变富集。常染色体显性Alport综合征影响每283人中1人,比经典临床估计(每5,000至53,000人中1人)高一到两个数量级,证实漏诊,但显著低于Gibson估计。这些发现支持在胶原病中下调PM2罕见性标准。慢性肾脏病中系统筛查COL4A3/COL4A4有依据,诊断率为每44人中1人。
Autosomal dominant polycystic kidney disease risk stratification relies on total kidney volume, a validated marker of cyst burden and progression. Kremer et al.'s pilot study used rapid breath-hold magnetic resonance fingerprinting with radiomics to evaluate noncystic renal parenchyma in children and young adults. Quantitative T1/T2 texture features distinguished autosomal dominant polycystic kidney disease from controls independently of total kidney volume, cyst fraction, age, or body size, suggesting early tissue changes. Small, cross-sectional, unmatched data require longitudinal validation of reproducibility, prognostic value, and clinical utility.
中文摘要:常染色体显性多囊肾病风险分层依赖总肾脏体积,该指标是囊肿负荷和疾病进展的经验证标志物。Kremer等的初步研究采用快速屏气磁共振指纹成像结合影像组学,评估儿童和年轻成人非囊性肾实质。定量T1/T2纹理特征可将常染色体显性多囊肾病与对照区分,且独立于总肾脏体积、囊肿分数、年龄或体型,提示早期组织改变。数据样本小、为横断面且未匹配,需纵向验证可重复性、预后价值和临床效用。
This study investigated radiomic features extracted from magnetic resonance fingerprinting (MRF)-acquired T1 and T2 quantitative maps in children and young adults with autosomal dominant polycystic kidney disease (ADPKD) with normal kidney function and compared these features to those extracted from MRF images of healthy volunteers. Mean T1 and T2 relaxation times, along with additional radiomic features, were derived from MRF T1 and T2 maps in 11 healthy volunteers and 18 patients with ADPKD. Two radiomic feature schemes were investigated to differentiate between patients with ADPKD and a healthy cohort using features from either the non-cystic kidney parenchyma or the entire kidney: mean T1 and mean T2 relaxation times alone and feature selection to identify radiomic features from the MRF T1 and T2 maps. Clinical models based on age, height-corrected total kidney volume (htTKV), and body surface area corrected TKV (BSA-TKV) were also investigated. The area under the receiver operating characteristic curve (AUC) was used to evaluate classification performance. MRF-derived mean T1 and T2 relaxation times in the non-cystic kidney parenchyma and the entire kidney were significantly greater for patients with ADPKD than for healthy volunteers. Combining radiomic features allowed for promising differentiation of patients with ADPKD and healthy volunteers using the non-cystic kidney parenchyma (AUC values: 0.79-0.99) and the entire kidney (AUC values: 0.92-0.96). The clinical biomarkers BSA-TKV and htTKV achieved AUC values of 0.86 and 0.72, respectively. There was a strong ability to discriminate between patients with ADPKD and healthy volunteers using features from the non-cystic kidney parenchyma generated by MRF-based mean T2 and a combination of radiomic features extracted from either the MRF T1 or T2 map. Our study suggests that early alterations in non-cystic kidney parenchyma can detect the presence of ADPKD using radiomic features from MRF T1 and T2 maps.
中文摘要:该研究分析从磁共振指纹成像(MRF)获得的T1和T2定量图中提取的影像组学特征,对象为肾功能正常的儿童和年轻成人常染色体显性多囊肾病(ADPKD)患者,并将这些特征与健康志愿者MRF图像中提取的特征进行比较。研究从11名健康志愿者和18例ADPKD患者的MRF T1和T2图中获得平均T1和T2弛豫时间以及额外影像组学特征。研究采用两种影像组学特征方案区分ADPKD患者与健康队列,特征分别来自非囊性肾实质或整个肾脏:单独使用平均T1和平均T2弛豫时间,以及通过特征选择从MRF T1和T2图中识别影像组学特征。研究还评估基于年龄、身高校正总肾体积(htTKV)和体表面积校正总肾体积(BSA-TKV)的临床模型。采用受试者工作特征曲线下面积(AUC)评价分类性能。ADPKD患者非囊性肾实质和整个肾脏的MRF平均T1和T2弛豫时间均显著高于健康志愿者。联合影像组学特征在非囊性肾实质(AUC值0.79-0.99)和整个肾脏(AUC值0.92-0.96)中均可较好区分ADPKD患者与健康志愿者。临床生物标志物BSA-TKV和htTKV的AUC值分别为0.86和0.72。使用基于MRF的平均T2以及从MRF T1或T2图中提取的影像组学特征组合所生成的非囊性肾实质特征,对ADPKD患者与健康志愿者具有较强区分能力。该研究提示,非囊性肾实质的早期改变可通过MRF T1和T2图的影像组学特征用于检测ADPKD的存在。
In an observational cohort of mostly non-Hispanic White women, pregnancy was not associated with later-life accelerated kidney function decline. Pregnancy occurring during the HALT Progression of Polycystic Kidney Disease (HALT-PKD) trial was not associated with kidney disease progression relative to women who did not become pregnant. Prior evidence indicates that adverse pregnancy outcomes may be involved in autosomal dominant polycystic kidney disease progression; pregnant women should be closely monitored. Data are conflicting regarding whether pregnancy influences disease progression in women with autosomal dominant polycystic kidney disease (ADPKD). This study examined whether pregnancy or number of pregnancies was associated with kidney disease progression in women with ADPKD. Women with early- (study A) and late-stage (study B) ADPKD from the HALT Progression of Polycystic Kidney Disease (HALT-PKD) trial were included to examine the association between self-reported number of pregnancies (categorical predictor: no pregnancy versus 1-2 pregnancies and ≥3 pregnancies), annual slope of eGFR, annual percent change in total kidney volume (%ΔTKV), and a composite outcome (kidney failure, 50% decline in eGFR, or death) using multivariable linear regression and Cox proportional hazard models. In addition, women who became pregnant, had full-term pregnancies, and available data during study participation ( n =13) were propensity matched (1:4) to women who were not pregnant during study participation, and a mixed model was applied to determine the association of pregnancy with eGFR slope and %ΔTKV. Across all analyses, 455 women with a median age of 45 (interquartile range, 38-50) years and eGFR of 69±25 ml/min per 1.73 m 2 at baseline were included. One hundred ninety-nine women had 1-2 pregnancies, and 165 women had ≥3 pregnancies. There was no association of 1-2 pregnancies or ≥3 pregnancies (versus no pregnancies) with eGFR slope ( β -estimate [95% confidence interval (CI)]; 1-2 pregnancies: 0.22 [-0.44 to 0.89]; ≥3 pregnancies: -0.46 [-1.16 to 0.25]), %ΔTKV ( β -estimate [95% CI]; 1-2 pregnancies: 0.92 [-0.34 to 2.17]; ≥3 pregnancies: 0.69 [-0.67 to 2.04]), or time to composite outcome (hazard ratio [95% CI]; 1-2 pregnancies: 1.04 [0.56 to 1.93]; ≥3 pregnancies: 1.48 [0.78 to 2.77]) in adjusted models. Moreover, there was no difference in annual eGFR slope ( β -estimate: -0.14 [95% CI, -2.72 to 2.44]) and %ΔTKV ( β -estimate: 0.04 [95% CI, -3.74 to 3.82]) in women who became pregnant matched to women who did not became pregnant during their participation in the study. Pregnancy was not associated with ADPKD progression among women with early- and late-stage ADPKD enrolled in the HALT-PKD trial.
中文摘要:在一个以非西班牙裔白人女性为主的观察性队列中,妊娠与晚年肾功能加速下降无关。在HALT-PKD试验期间发生妊娠的女性,与未妊娠女性相比,妊娠与肾脏病进展无关。既往证据提示不良妊娠结局可能参与ADPKD进展;妊娠女性应密切监测。关于妊娠是否影响ADPKD女性疾病进展,现有数据存在矛盾。该研究考察妊娠或妊娠次数是否与ADPKD女性的肾脏病进展相关。纳入HALT-PKD试验中早期(研究A)和晚期(研究B)ADPKD女性,采用多变量线性回归和Cox比例风险模型,分析自我报告的妊娠次数(分类预测变量:未妊娠、1-2次妊娠和≥3次妊娠)与eGFR年斜率、总肾脏体积年百分比变化(%ΔTKV)以及复合结局(肾衰竭、eGFR下降50%或死亡)之间的关联。另外,研究参与期间妊娠、足月妊娠且有可用数据的女性(n=13)按1:4倾向性匹配至研究参与期间未妊娠的女性,并应用混合模型确定妊娠与eGFR斜率和%ΔTKV的关联。所有分析共纳入455名女性,基线中位年龄45岁(四分位距38-50岁),eGFR为69±25 ml/min/1.73 m²。199名女性有1-2次妊娠,165名女性有≥3次妊娠。在校正模型中,1-2次妊娠或≥3次妊娠(相对于未妊娠)与eGFR斜率(β估计值[95%置信区间(CI)];1-2次妊娠:0.22[-0.44至0.89];≥3次妊娠:-0.46[-1.16至0.25])、%ΔTKV(β估计值[95%CI];1-2次妊娠:0.92[-0.34至2.17];≥3次妊娠:0.69[-0.67至2.04])或至复合结局时间(风险比[95%CI];1-2次妊娠:1.04[0.56至1.93];≥3次妊娠:1.48[0.78至2.77])均无关联。研究参与期间妊娠的女性与匹配的未妊娠女性相比,eGFR年斜率(β估计值:-0.14[95%CI,-2.72至2.44])和%ΔTKV(β估计值:0.04[95%CI,-3.74至3.82])无差异。在HALT-PKD试验纳入的早期和晚期ADPKD女性中,妊娠与ADPKD进展无关。
基础研究 (1篇)
Unexpected nephrotoxicity during clinical stages of drug development, due to undetected toxicity in in vitro and in vivo settings, can lead to drug attrition and jeopardize drug development. The latter highlights the importance of in vitro renal toxicity testing that can safely be translated to humans. Two factors commonly overlooked in the latter are the continuous cell proliferation that occurs in regeneration processes after renal insult and the physiological O2 tension in the kidney. Autosomal Dominant Polycystic Kidney Disease is a genetic disorder characterized by the development of renal cysts and cellular changes, i.e. abnormal proliferation in conjunction with the Warburg effect. There is only one drug approved for the disease, tolvaptan, which, however, presents with liver toxicity and polyuria. In a quest for potential alternatives to tolvaptan, we compared the nephrotoxic and metabolic effects of four repurposed drugs, salicylic acid (up to 10 mM), birinapant (up to 100 µM), bardoxolone methyl (up to 1000 nM), and rapamycin (up to 160 nM) to tolvaptan (up to 100 µM) on human differentiated and proliferating (RPTEC/TERT1) and mouse proliferating (mProx24) renal proximal tubular epithelial cells at atmospheric (21%) and physiological (10%) O2 tensions. The focus was on improved interpretation of in vitro test results for the detection of potential adverse effects. We found that cell proliferation and O2 tension are major factors that determine the susceptibility of cells to compounds, while the drug effects on the metabolism and mitochondrial function provided further insight into the mechanisms underlying the observed in vitro toxicity.
中文摘要:药物开发临床阶段出现的意外肾毒性,源于体外和体内设置中未被检测到的毒性,可导致药物淘汰并危及药物开发。这凸显了可安全转化至人体的体外肾毒性测试的重要性。该测试常被忽视的两个因素,是肾损伤后再生过程中持续发生的细胞增殖,以及肾脏的生理氧张力。常染色体显性多囊肾病是一种遗传性疾病,以肾囊肿形成和细胞变化为特征,即异常增殖伴Warburg效应。该病仅有一种获批药物托伐普坦,但其存在肝毒性和多尿。为寻找托伐普坦的潜在替代方案,我们在常氧(21%)和生理(10%)氧张力下,比较了四种重定位药物水杨酸(最高10 mM)、birinapant(最高100 µM)、bardoxolone methyl(最高1000 nM)和雷帕霉素(最高160 nM)与托伐普坦(最高100 µM)对人分化和增殖RPTEC/TERT1细胞及小鼠增殖mProx24肾近端小管上皮细胞的肾毒性和代谢效应。重点在于改进体外测试结果的解释,以检测潜在不良效应。我们发现,细胞增殖和氧张力是决定细胞对化合物敏感性的主要因素,而药物对代谢和线粒体功能的影响进一步揭示了所观察到的体外毒性机制。
6急性肾损伤 (4篇)
基础研究 (4篇)
Acute kidney injury (AKI) is a clinical syndrome primarily attributed to mitochondrial dysfunction, characterized by disrupted mitochondrial balance. Impaired biogenesis leads to insufficient energy supply, while defective autophagy results in the accumulation of damaged mitochondria-both of which exacerbate injury to renal tubular epithelial cells. In this study, we developed melatonin/pioglitazone liposomes (MP@Lip) for AKI therapy via restoration of mitochondrial dynamic balance. When melatonin and pioglitazone was jointly delivered to damaged renal tubules, they activated mitochondrial autophagy and biogenesis, thereby bidirectionally restoring mitochondrial network homeostasis. Mechanistically, AMPK/SIRT3/PGC-1α-related signaling may be involved in the mitochondrial protection of MP@Lip. Upon AMPK phosphorylation, SIRT1/SIRT3 deacetylase activity is upregulated, the ratio of LC3B-II/LC3B-I increases, p62/SQSTM1 decreases, and autophagy is enhanced. PGC-1α enhances transcriptional activity and promotes the expression of mitochondrial biogenic markers (TOM20). This complementary degradation-synthesis loop gradually restores mitochondrial dynamic balance. In vitro experiments confirmed that MP@Lip reduces ROS production and apoptosis while restoring mitochondrial membrane potential. In vivo studies demonstrated improvement in renal function indicators, alleviation of inflammatory responses and histopathological damage, and no systemic toxicity. This strategy shifts AKI treatment from symptomatic support to ameliorating mitochondrial dysfunction, providing a targeted, complementary and relatively safe approach that may be applicable to other mitochondrial functional-related diseases.
中文摘要:急性肾损伤(AKI)是一种主要由线粒体功能障碍引起的临床综合征,其特征是线粒体平衡被破坏。线粒体生物发生受损导致能量供应不足,自噬缺陷则造成受损线粒体堆积,两者都会加重肾小管上皮细胞损伤。本研究开发了褪黑素/吡格列酮脂质体(MP@Lip),通过恢复线粒体动态平衡治疗AKI。褪黑素和吡格列酮共同递送至受损肾小管后,可激活线粒体自噬与生物发生,从而双向恢复线粒体网络稳态。机制上,AMPK/SIRT3/PGC-1α相关信号可能参与MP@Lip的线粒体保护。AMPK磷酸化后,SIRT1/SIRT3去乙酰化酶活性上调,LC3B-II/LC3B-I比值升高,p62/SQSTM1减少,自噬增强。PGC-1α增强转录活性并促进线粒体生物发生标志物TOM20表达。这一互补的降解-合成循环逐步恢复线粒体动态平衡。体外实验证实MP@Lip减少ROS产生和凋亡,同时恢复线粒体膜电位。体内研究显示肾功能指标改善,炎症反应和组织病理损伤减轻,且无全身毒性。该策略将AKI治疗从对症支持转向改善线粒体功能障碍,提供了一种靶向、互补且相对安全的方法,可能适用于其他线粒体功能相关疾病。
The epigenetic mechanisms driving the transition to ferroptosis in acute kidney injury (AKI) remain unclear. In this study, protein methyltransferase 5 (PRMT5) and its partner MEP50 were significantly upregulated in the renal tubules of AKI patients and murine models. Genetic silencing of PRMT5 via AAV-shRNA in vivo and siRNA in vitro improved renal function, attenuated mitochondrial damage, and suppressed ferroptotic tubular cell death. Mechanistically, PRMT5 promotes ACSL4 expression in a WDR5-dependent manner, facilitating tubular ferroptosis. Pharmacological inhibition of PRMT5 (GSK591) post-treatment or cloperastine hydrochloride prophylactic administration similarly improved renal function and limited ferroptotic cell death. These findings offer novel insights into the upstream epigenetic regulation of ACSL4-driven ferroptosis and suggest that PRMT5-ACSL4 axis might be a potential therapeutic target for AKI intervention.
中文摘要:驱动急性肾损伤(AKI)向铁死亡转变的表观遗传机制仍不清楚。蛋白甲基转移酶5(PRMT5)及其伙伴MEP50在AKI患者和小鼠模型的肾小管中显著上调。体内经AAV-shRNA、体外经siRNA沉默PRMT5可改善肾功能,减轻线粒体损伤,并抑制肾小管细胞铁死亡。机制上,PRMT5以依赖WDR5的方式促进ACSL4表达,推动肾小管铁死亡。PRMT5药理抑制剂(GSK591)后处理或盐酸氯哌斯汀预防性给药同样改善肾功能并限制铁死亡。这些结果揭示ACSL4驱动铁死亡的上游表观遗传调控,并提示PRMT5-ACSL4轴可能成为AKI干预的潜在治疗靶点。
Renal ischemia-reperfusion injury (IRI) is initiated by a burst of mitochondrial reactive oxygen species generated when ischemia-accumulated succinate is rapidly oxidised upon reperfusion, driving reverse electron transport and triggering lipid peroxidation-dependent tubular cell death. Here, we identify the mitochondrial matrix protease CLPP as an unexpected regulator of renal redox resilience. CLPP deficiency reduced succinate-driven mitochondrial H2O2 production and protected kidneys from functional decline, tubular necrosis, mitochondrial ultrastructural damage, and lipid peroxidation following IRI. Protection was most pronounced in females, in which CLPP loss established a constitutive antioxidant and detoxification programme prior to injury, characterised by increased glutathione and γ-glutamylcysteine abundance, enhanced NADPH-generating pentose phosphate pathway activity, sustained sulphur amino acid metabolism, and elevated capacity for lipid aldehyde detoxification. During reperfusion, these adaptations preserved thiol-redox buffering, limited 4-hydroxynonenal accumulation, and reduced oxidative modification of cysteine residues on proteins involved in complement, coagulation, fibrinolysis, and inflammatory signalling, thereby restricting ferroptotic lipid damage and downstream thrombo-inflammatory amplification. Although reduced reverse electron transport-derived ROS contributed to this phenotype, it was insufficient to account for the sex bias. While CLPP deficiency amplified an endogenous female antioxidant programme, male kidneys, lacking equivalent glutathione-centred preconditioning, showed only marginal benefit. These findings establish mitochondrial proteostasis as a determinant of sex-dependent redox adaptation and identify CLPP as a candidate target for preconditioning against predictable ischaemic insults, including kidney transplantation and cardiac surgery.
中文摘要:肾缺血再灌注损伤由再灌注时缺血蓄积的琥珀酸被迅速氧化所产生的一阵线粒体活性氧引发,推动反向电子传递并触发脂质过氧化依赖的肾小管细胞死亡。本研究发现线粒体基质蛋白酶CLPP是肾脏氧化还原韧性的一个意外调节因子。CLPP缺失减少了琥珀酸驱动的线粒体H2O2生成,并保护肾脏在缺血再灌注损伤后免于功能下降、肾小管坏死、线粒体超微结构损伤和脂质过氧化。这种保护在雌性中最为明显,CLPP缺失在损伤前即建立了一种组成性抗氧化和解毒程序,表现为谷胱甘肽和γ-谷氨酰半胱氨酸丰度增加、生成NADPH的戊糖磷酸途径活性增强、硫氨基酸代谢维持以及脂质醛解毒能力升高。再灌注期间,这些适应维持了硫醇氧化还原缓冲,限制了4-羟基壬烯醛蓄积,并减少了补体、凝血、纤溶和炎症信号相关蛋白上半胱氨酸残基的氧化修饰,从而限制铁死亡性脂质损伤及下游血栓炎症放大。尽管反向电子传递来源的活性氧减少参与该表型,但不足以解释性别差异。CLPP缺失放大了雌性内源性抗氧化程序,而雄性肾脏缺乏同等以谷胱甘肽为中心的前处理,仅显示边缘获益。这些发现确立线粒体蛋白稳态是性别依赖氧化还原适应的决定因素,并将CLPP确定为针对可预测缺血性打击(包括肾移植和心脏手术)进行前处理的候选靶点。
Early detection of Acute Kidney Injury (AKI) remains a clinical challenge, requiring rapid and sensitive monitoring of biomarkers like Neutrophil Gelatinase-Associated Lipocalin (NGAL). This study presents a flow-enhanced electrochemical aptamer-based (E-AB) biosensor designed for the nanomolar detection of NGAL in complex matrices. By integrating optimised hydrodynamic flow (35 μL/min) with miniaturised gold microelectrodes, we leveraged enhanced mass transport and radial diffusion to significantly improve analyte flux and binding kinetics. A critical finding was the role of the protein matrix in surface passivation; the inclusion of 4% BSA resulted in a >20-fold sensitivity improvement compared to standard PBS buffer, attributed to additional passivation during measurement. This synergistic approach enabled a limit of detection (LOD) of 0.2 nM with a dynamic range spanning 0.2-24 nM. As a preliminary proof-of-concept, the clinical utility was validated using unprocessed human plasma samples from AKI patients, demonstrating a moderate correlation (R2 = 0.7731) with gold-standard ELISA measurements and accuracy in clinical risk stratification. These results highlight the potential of flow-enhanced E-AB sensors for continuous, near-real-time monitoring of critical biomarkers in clinical settings.
中文摘要:急性肾损伤(AKI)的早期发现仍是临床难题,需要对中性粒细胞明胶酶相关脂质运载蛋白(NGAL)等生物标志物进行快速、灵敏的监测。本研究提出一种流增强电化学适配体(E-AB)生物传感器,用于复杂基质中NGAL的纳摩尔级检测。通过将优化的流体动力流(35 μL/min)与微型化金微电极结合,利用增强的质量传递和径向扩散显著提高分析物通量和结合动力学。一个关键发现是蛋白基质在表面钝化中的作用;与标准PBS缓冲液相比,加入4% BSA使灵敏度提高超过20倍,这归因于测量过程中额外的钝化作用。该协同方法实现了0.2 nM的检测限(LOD),动态范围为0.2-24 nM。作为初步概念验证,使用AKI患者未处理的人血浆样本验证了临床实用性,与金标准ELISA测量呈中度相关(R2 = 0.7731),并在临床风险分层中表现准确。这些结果凸显了流增强E-AB传感器在临床环境中对关键生物标志物进行连续、近实时监测的潜力。
7透析 (4篇)
临床研究 (3篇)
Large, pragmatic, randomized trials are needed to identify which components of routine hemodialysis care improve outcomes, but conventional processes, including individual written consent for every eligible patient, can make some trials infeasible. Alterations to the consent process refer to departures from the usual written informed consent requirements: Consent may be waived for a specific trial element, the process may be modified through notification with an opt-out, preferences may be documented in usual clinical records, or separate consent may be used for selected data collection. These alterations may be ethically acceptable when the research poses no more than minimal incremental risk beyond usual care, usual written consent is impracticable or would compromise the validity of the trial, participant welfare is maintained, and communication with participants remains appropriate. We describe our experience with 5 pragmatic randomized trials of hemodialysis care interventions, including trials of dialysate temperature, magnesium, bicarbonate, expanded solute removal, and transplant access. These trials used different approaches to consent for trial participation, receipt of the allocated intervention, and use of routinely collected data. When designed with patient notification, opt-out opportunities, independent oversight, attention to vulnerability and inclusivity, and acceptable intervention delivery, alterations to the consent process can remain respectful, transparent, and attentive to patients' interests, while enabling rigorous trials that might otherwise not be conducted.
中文摘要:需要大型实用性随机试验来确定常规血液透析照护中哪些组成部分能改善结局,但要求每名符合条件患者均签署个体化书面同意等常规流程,可能使部分试验无法实施。同意流程的调整指偏离通常的书面知情同意要求:可对某一特定试验要素免除同意,可通过通知并允许退出修改流程,可将偏好记录于常规临床记录,也可对选定的数据收集另行取得同意。当研究相较于常规照护仅带来不超过最小程度的额外风险、通常的书面同意不可行或会损害试验有效性、参与者福祉得到维护且与参与者的沟通仍然适当时,这些调整在伦理上可能可以接受。我们描述在5项血液透析照护干预的实用性随机试验中的经验,涉及透析液温度、镁、碳酸氢盐、扩展溶质清除和移植可及性。这些试验对试验参与、接受分配干预以及使用常规收集数据采用了不同的同意方式。设计时加入患者通知、退出机会、独立监督、对脆弱性和包容性的关注以及可接受的干预实施方式,同意流程的调整仍可保持尊重、透明并关注患者利益,同时使原本可能无法开展的严谨试验得以进行。
Many major adverse cardiovascular events happen within the first 6 months after hemodialysis initiation. Using nondialyzable β -blockers at hemodialysis initiation was associated with fewer cardiovascular events than dialyzable β -blockers. How β -blocker dialyzability affects cardiovascular outcomes in patients receiving hemodialysis remains unclear. Previous observational studies show conflicting results, and conducting clinical trials in this population has proven challenging. This uncertainty has contributed to substantial variation in β -blocker prescribing patterns across regions and clinicians. Using data from the United States Renal Data System, we identified patients receiving β -blockers on the day of starting hemodialysis and classified them into nondialyzable and dialyzable exposure groups. Geographical variations in nondialyzable and dialyzable β -blocker prescription rates across neighboring regions in each state were leveraged as an instrumental variable. The treatment effect of nondialyzable versus dialyzable β -blockers on major adverse cardiovascular events (MACE) at 6 months, 1 year, and 3 years was evaluated using instrumental variable g -estimation methods for survival outcomes. MACE comprised myocardial infarction, stroke, and all-cause mortality. The cohort of 40,313 participants from 41 US states experienced 25,720 MACE over the 3-year follow-up period (median years [interquartile range], 1.4 [0.4-3.0]), with more than 42% occurring during the first 6 months after hemodialysis initiation. The instrumental variable met all statistical assumptions. Nondialyzable β -blockers were associated with significantly lower risk of MACE at all three follow-up time points compared with dialyzable β -blockers (hazard ratios [95% confidence intervals], 0.82 [0.74 to 0.90], 0.85 [0.79 to 0.92], and 0.90 [0.85 to 0.96], respectively). Similar patterns were observed for each separate component of MACE. The use of nondialyzable β -blockers compared with dialyzable β -blockers was associated with a lower risk of MACE during all time points, including the early, high-risk period in the 6 months following hemodialysis initiation.
中文摘要:许多主要不良心血管事件发生在开始血液透析后的前6个月内。开始血液透析时使用不可透析清除的β受体阻滞剂与使用可透析清除的β受体阻滞剂相比,与更少的心血管事件相关。β受体阻滞剂的透析清除特性如何影响接受血液透析患者的心血管结局仍不清楚。既往观察性研究结果相互矛盾,且在该人群中开展临床试验已被证明具有挑战性。这种不确定性导致不同地区和临床医生之间β受体阻滞剂处方模式存在较大差异。利用美国肾脏数据系统数据,我们识别了在开始血液透析当天接受β受体阻滞剂的患者,并将其分为不可透析清除暴露组和可透析清除暴露组。各州相邻地区之间不可透析清除与可透析清除β受体阻滞剂处方率的地理差异被用作工具变量。采用针对生存结局的工具变量g估计方法,评估不可透析清除与可透析清除β受体阻滞剂对6个月、1年和3年主要不良心血管事件(MACE)的治疗效应。MACE包括心肌梗死、卒中和全因死亡。来自美国41个州的40,313名参与者组成的队列在3年随访期间发生25,720例MACE(中位随访1.4年[四分位距0.4-3.0]),其中超过42%发生在开始血液透析后的前6个月内。工具变量满足所有统计假设。与可透析清除的β受体阻滞剂相比,不可透析清除的β受体阻滞剂在三个随访时间点均与显著更低的MACE风险相关(风险比[95%置信区间]分别为0.82[0.74至0.90]、0.85[0.79至0.92]和0.90[0.85至0.96])。MACE各单独组分也观察到相似模式。与可透析清除的β受体阻滞剂相比,使用不可透析清除的β受体阻滞剂在所有时间点均与更低的MACE风险相关,包括开始血液透析后6个月内的早期高风险阶段。
Dialysis care for patients with End-Stage Kidney Disease (ESKD) has seen minimal improvement in outcomes over the past decade, despite substantial advancements in other chronic disease fields. This article explores enduring challenges and future opportunities in outpatient dialysis care from a policy-innovation perspective. The current landscape is defined by clinical limitations and a profound economic strain on the healthcare system. However, a period of cautious optimism may be emerging. This is driven by promising innovations, including the development of wearable and implantable artificial kidneys, advanced hemodiafiltration techniques, biologically inspired therapies like bioartificial kidneys, and the integration of artificial intelligence for personalized care. Realizing the full potential of these advancements requires a multi-pronged approach involving a greater emphasis on the patient's voice, payment reforms that incentivize value over volume throughout a person's journey with kidney disease, and supportive policy changes. Yet, hurdles remain, including supply chain vulnerabilities, a growing nephrology workforce crisis, and the need to ensure equitable access to new technologies to avoid amplifying existing health disparities. A collaborative effort is essential to move toward a future where dialysis is less burdensome and facilitates a better quality of life for all people with kidney diseases.
中文摘要:过去十年,终末期肾病(ESKD)患者的透析照护结局改善甚微,尽管其他慢性病领域取得了实质性进展。文章从政策创新视角探讨门诊透析照护的长期挑战与未来机会。当前格局由临床局限和对医疗系统的沉重经济负担所界定。不过,一个谨慎乐观的时期可能正在出现。这得益于有前景的创新,包括可穿戴和植入式人工肾的研发、先进血液透析滤过技术、生物人工肾等受生物学启发的疗法,以及人工智能用于个体化照护的整合。要实现这些进展的全部潜力,需要多管齐下的路径,包括更重视患者声音、在患者整个肾病历程中激励价值而非数量的支付改革,以及支持性政策变化。障碍仍然存在,包括供应链脆弱性、日益严重的肾脏病专业人才队伍危机,以及需要确保新技术公平可及,避免扩大现有健康差距。协作努力至关重要,以迈向透析负担更轻、并促进所有肾病患者获得更好生活质量的未来。
基础研究 (1篇)
Olivine-based ocean alkalinity enhancement (OAE) is a promising carbon dioxide removal technology; however, the geochemical fate of olivine-derived toxic metals, particularly nickel (Ni) and chromium (Cr) at marine sediment interfaces, remains poorly constrained. We employed dialysis-membrane microcosms to isolate olivine from Mn oxides, allowing only dissolved species to diffuse and react under three olivine loadings (1, 5, and 10 g L-1) in seawater for 60 days. Results revealed that (1) Ni was preferentially sequestered by the Mn oxides, with δ-MnO2 showing higher uptake capacity than birnessite, (2) Cr was co-sequestered with secondary Fe(III) (oxyhydr)oxides rather than adsorbing directly onto Mn oxides, and (3) synergistic Ni2+ isomorphic substitution and Fe(II)-driven Mn(III) reduction rearranged δ-MnO2 into a more stable hexagonal layered framework. Consequently, both δ-MnO2 and birnessite act as long-term Ni sinks, preventing Ni remobilization via desorption or diagenetic phase transitions. These findings support a proposed "spatial decoupling" OAE strategy, where olivine is pre-dissolved in land- or ship-based reactors to remove Cr via Fe co-precipitation. Subsequent discharge of the Ni-bearing alkaline effluent into shallow coastal regions allows benthic Mn oxides to scavenge Ni, reducing toxicity risks associated with direct mineral contact.
中文摘要:基于橄榄石的海洋碱度增强(OAE)是一种有前景的二氧化碳去除技术,但橄榄石释放的有毒金属尤其是镍(Ni)和铬(Cr)在海洋沉积物界面的地球化学归趋仍缺乏约束。我们采用透析膜微宇宙将橄榄石与锰氧化物隔离,仅允许溶解态组分扩散并反应,在海水中设置三种橄榄石投加量(1、5和10 g L-1),运行60天。结果表明:(1)Ni优先被锰氧化物固定,δ-MnO2的摄取容量高于水钠锰矿;(2)Cr与次生Fe(III)(氢)氧化物共沉淀固定,而非直接吸附于锰氧化物;(3)Ni2+同晶置换与Fe(II)驱动的Mn(III)还原协同作用,使δ-MnO2重排为更稳定的六方层状结构。因此,δ-MnO2和水钠锰矿均可作为长期Ni汇,阻止Ni通过解吸或成岩相变再活化。这些发现支持所提出的「空间解耦」OAE策略:在陆基或船基反应器中预溶解橄榄石,通过Fe共沉淀去除Cr;随后将含Ni碱性出流排入浅海沿岸区域,使底栖锰氧化物捕获Ni,降低与矿物直接接触相关的毒性风险。
8高血压/电解质/酸碱 (3篇)
临床研究 (3篇)
The best management approach for renin-angiotensin system (RAS) inhibitor use before surgery is controversial. Some studies have suggested that continuation could increase the risk of clinically significant peri-operative hypotension and, thus, organ injury. By contrast, others believe that withholding them significantly increases the risk of severe hypertension and heart failure. To determine the most effective strategy, this systematic review and meta-analysis of randomized controlled trials compared discontinuation vs continuation of RAS inhibitors in patients undergoing non-cardiac and non-vascular surgeries. PubMed, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) databases were searched for randomized controlled trials that compared discontinuation vs continuation of RAS inhibitors in patients undergoing non-cardiac and non-vascular surgery. Five randomized controlled trials (n = 10 773 patients; 5388 randomized to discontinuation) were included. Discontinuation of an RAS inhibitor probaby reduced peri-operative hypotension (27.66% vs 34.06%; risk ratio [RR] 0.81, 95% confidence interval [CI] 0.73-0.89; moderate certainty). The evidence is very uncertain about effects on peri-operative hypertension (9.46% vs 8.05%; RR 1.38, 95% CI 0.66-2.89; very low certainty). For major clinical outcomes, discontinuation suggested little to no difference in acute kidney injury (10.45% vs 10.69%; RR 0.98, 95% CI 0.66-1.45; low certainty), acute heart failure (5.38% vs 5.32%; RR 1.00, 95% CI 0.76-1.31; low certainty), myocardial infarction (1.22% vs 1.00%; RR 1.19, 95% CI 0.60-2.39; low certainty), stroke (0.42% vs 0.40%; RR 1.04, 95% CI 0.56-1.93; low certainty), and arrhythmias (1.80% vs 1.40%; RR 1.28, 95% CI 0.69-2.38; low certainty). These findings suggest that discontinuation of RAS inhibitors is likely to reduce peri-operative hypotension in patients undergoing non-cardiac, non-vascular surgery, but the evidence is very uncertain about effects on peri-operative hypertension and major clinical outcomes.
中文摘要:肾素-血管紧张素系统(RAS)抑制剂在术前的管理方式尚无定论。部分研究提示继续用药可能增加有临床意义的围手术期低血压、并由此带来器官损伤风险;另一些观点则认为停药会明显增加重度高血压和心力衰竭的风险。为明确更有效的策略,本系统评价与荟萃分析纳入随机对照试验,比较接受非心脏、非血管手术的患者中停用与继续使用RAS抑制剂的差异。检索PubMed、Embase和Cochrane对照试验中心注册库(CENTRAL),纳入比较非心脏、非血管手术患者停用与继续使用RAS抑制剂的随机对照试验。共纳入5项随机对照试验(n=10773例患者,其中5388例随机分入停药组)。停用RAS抑制剂可能降低围手术期低血压(27.66% vs 34.06%;风险比[RR] 0.81,95%置信区间[CI] 0.73-0.89;中等确定性)。对围手术期高血压的影响,证据极不确定(9.46% vs 8.05%;RR 1.38,95% CI 0.66-2.89;极低确定性)。在主要临床结局方面,停药对急性肾损伤(10.45% vs 10.69%;RR 0.98,95% CI 0.66-1.45;低确定性)、急性心力衰竭(5.38% vs 5.32%;RR 1.00,95% CI 0.76-1.31;低确定性)、心肌梗死(1.22% vs 1.00%;RR 1.19,95% CI 0.60-2.39;低确定性)、卒中(0.42% vs 0.40%;RR 1.04,95% CI 0.56-1.93;低确定性)及心律失常(1.80% vs 1.40%;RR 1.28,95% CI 0.69-2.38;低确定性)提示几乎没有差异。上述结果提示,在非心脏、非血管手术患者中停用RAS抑制剂可能减少围手术期低血压,但对围手术期高血压和主要临床结局的影响,证据很不确定。
Hyperkalemia is a common complication of kidney disease and incidence increases as kidney function declines. Renin angiotensin system blockade, which improves renal and cardiovascular outcomes, increases the risk of hyperkalemia. Unfortunately, hyperkalemia often leads to discontinuation of these medications, which can increase adverse outcomes. Treatment of chronic hyperkalemia includes diet and pharmacologic interventions. However, the association is weak of dietary potassium intake with serum potassium levels and does not consider important internal and external balance factors that affect serum levels. Traditional dietary interventions that limit dietary potassium can lead to a restrictive diet that limits fruits and vegetables, whole grains, and plant-based proteins. This restrictive approach may unnecessarily limit dietary quality and variety in a population already at risk for poor nutritional status and complications of chronic kidney disease. The management of hyperkalemia requires a comprehensive, individualized approach that moves beyond blanket dietary restrictions. The objective of this review is to describe the role of diet and pharmacologic approaches to manage hyperkalemia, highlighting newer dietary approaches.
中文摘要:高钾血症是肾脏疾病的常见并发症,其发生率随肾功能下降而升高。肾素-血管紧张素系统阻断可改善肾脏和心血管结局,但会增加高钾血症风险。高钾血症常导致这类药物停用,从而可能增加不良结局。慢性高钾血症的治疗包括饮食和药物干预。然而,膳食钾摄入与血清钾水平的关联较弱,且未考虑影响血清钾的重要内外平衡因素。限制膳食钾的传统饮食干预可能导致限制性饮食,减少水果、蔬菜、全谷物和植物蛋白的摄入。这种限制性做法可能不必要地限制本已面临营养状态不佳和慢性肾脏病并发症风险人群的饮食质量和多样性。高钾血症管理需要综合、个体化的方法,超越一概而论的饮食限制。本综述旨在描述饮食和药物方法在高钾血症管理中的作用,并重点介绍较新的饮食策略。
Hypertension affects over 1.3 billion people worldwide and is the leading modifiable cause of cardiovascular morbidity and mortality. Approximately one-third of individuals with hypertension exhibit a low-renin phenotype, a clinically heterogeneous subgroup in whom the underlying etiology remains uncharacterized in most cases. Among its mechanistic contributors, non-classical apparent mineralocorticoid excess (NC-AME), defined by partial insufficiency of 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2), represents a prevalent and underrecognized cause of cortisol-mediated mineralocorticoid receptor overactivation that has, to date, lacked a formal clinical definition, standardized diagnostic criteria, or evidence-based therapeutic framework. This Scientific Statement addresses that gap. The panel formally defines NC-AME as a syndrome of partial 11β-HSD2 insufficiency occurring in the absence of biallelic HSD11B2 variants, biochemically characterized by an elevated cortisol-to-cortisone (F/E) ratio and low cortisone concentration, and typically associated with low plasma renin, normal-to-low aldosterone, and elevated blood pressure. The Statement consolidates evidence across three mechanistic domains, genetic and epigenetic dysregulation of HSD11B2, endogenous and exogenous enzyme inhibition, and patient-specific alterations (i.e. age, sex, renal function), and proposes both a structured, an LC-MS/MS-based diagnostic algorithm, and a resource-adapted diagnostic approach. Mineralocorticoid receptor antagonists are endorsed as mechanism-directed first-line therapy, with blood pressure and renin normalization as co-primary treatment targets. Acquired and reversible causes are classified separately to guide clinical management. A research agenda is advanced to drive threshold standardization, multicenter validation, and integration of NC-AME into hypertension guidelines across endocrinology, cardiology, and nephrology.
中文摘要:高血压影响全球超过13亿人,是心血管疾病发病和死亡最主要的可干预原因。约三分之一高血压患者表现为低肾素表型,这一临床异质性亚组多数病例的潜在病因仍未明确。在相关机制中,非经典表观盐皮质激素过多综合征(NC-AME)由11β-羟类固醇脱氢酶2型(11β-HSD2)部分不足所定义,是皮质醇介导的盐皮质激素受体过度激活的常见但未被充分认识的原因,迄今缺乏正式临床定义、标准化诊断标准或循证治疗框架。本科学声明填补这一空白。专家组将NC-AME正式定义为不存在双等位基因HSD11B2变异时发生的部分11β-HSD2不足综合征,生化特征为皮质醇/可的松(F/E)比值升高和可的松浓度降低,通常伴血浆肾素降低、醛固酮正常至降低和血压升高。声明整合了三个机制领域的证据:HSD11B2的遗传与表观遗传调控异常、内源性与外源性酶抑制、患者特异性改变(即年龄、性别、肾功能),并提出基于LC-MS/MS的结构化诊断算法和资源适配的诊断路径。盐皮质激素受体拮抗剂被推荐为机制导向的一线治疗,血压和肾素正常化作为共同主要治疗目标。获得性和可逆性病因被单独分类以指导临床管理。声明提出研究议程,以推动阈值标准化、多中心验证,并将NC-AME纳入内分泌学、心脏病学和肾脏病学的高血压指南。
9基础/转化研究 (3篇)
基础研究 (3篇)
Low-molecular weight heparin (LMWH) remains clinically indispensable for the prevention and treatment of thrombosis in cardiovascular surgery, hemodialysis, and other critical care settings. However, LMWH is constrained by heparin-induced thrombocytopenia (HIT) and supply chain vulnerabilities of animal-derived sources. This study used chemoenzymatic synthesis to engineer homogeneous dodecasaccharide 12G-2, decoupling anticoagulant efficacy from HIT risk via dual structural modulation. Substitution with 2-O-sulfated glucuronic acid conferred conformational rigidity, and engineered sulfation attenuated platelet factor 4 (PF4) binding, whereas the antithrombin-binding domain remained intact. 12G-2 exhibited nanomolar anti-Factor Xa (FXa) activity in vitro, enoxaparin-equivalent venous antithrombotic efficacy, and superior arterial antithrombotic activity in murine thrombosis models, and it showed diminished PF4 binding, attenuated pathological β sheet formation, and minimal recognition by HIT-related antibodies in vitro. Both in vitro and in a murine tail-bleeding model, 12G-2 demonstrated high protamine reversibility, exceeding standard LMWH enoxaparin neutralization efficiency. In washed human platelets, 12G-2-PF4 complexes with the HIT-mimicking antibody KKO failed to induce integrin αIIbβ3 activation or P-selectin release and elicited minimal platelet spreading comparable to resting controls. Safety assessments in mice showed no hepatotoxicity at tested doses and low immunogenicity in a murine PF4-heparin immunization model. In PF4-heparin antibody-positive mice, 12G-2 attenuated platelet activation while exerting stronger FXa inhibition than enoxaparin. These findings established 12G-2 as an alternative to LMWH.
中文摘要:低分子量肝素(LMWH)在心血管手术、血液透析及其他重症监护场景中预防和治疗血栓仍不可替代,但其应用受制于肝素诱导的血小板减少症(HIT)以及动物源原料供应的脆弱性。本研究采用化学酶法合成制备结构均一的十二糖12G-2,通过双重结构调控将抗凝效力与HIT风险解耦。引入2-O-硫酸化葡萄糖醛酸使分子构象趋于刚性,经改造的硫酸化模式减弱了与血小板因子4(PF4)的结合,而抗凝血酶结合结构域保持完整。12G-2在体外表现纳摩尔级抗Xa因子(FXa)活性,在小鼠血栓模型中具有与依诺肝素相当的静脉抗血栓效力及更强的动脉抗血栓活性;体外实验中其PF4结合减少、病理性β折叠形成减弱,且HIT相关抗体对其识别很低。体外及小鼠尾部出血模型中,12G-2均显示较高的鱼精蛋白可逆性,中和效率优于标准LMWH依诺肝素。在洗涤人血小板中,12G-2与PF4形成的复合物即使与HIT模拟抗体KKO结合,也未能诱导整合素αIIbβ3活化或P-选择素释放,血小板铺展程度极低,与静息对照相当。小鼠安全性评估显示在所试剂量下无肝毒性,在小鼠PF4-肝素免疫模型中免疫原性低。在PF4-肝素抗体阳性小鼠中,12G-2减轻血小板活化,同时FXa抑制作用强于依诺肝素。这些结果确立12G-2可作为LMWH的替代选择。
Chronic diseases can continue to progress after the initiating insult has subsided, indicating that injured tissues may retain a persistent imprint of failed repair. Here, senescent repair memory refers to a tissue state in which transient repair-associated senescence fails to resolve and is maintained by persistent senescent cells, altered secretory and metabolic programmes, defective immune clearance, epigenetic stabilization and spatial niche interactions. Once established beyond the adaptive repair window, this state can perpetuate inflammation, fibrosis and functional decline even after the original injury has diminished. This Review examines how failed resolution may contribute to chronic kidney disease, cardiovascular disease, pulmonary fibrosis, metabolic liver disease, neurodegeneration and osteoarthritis. Evidence is strongest in kidney disease, pulmonary fibrosis and metabolic liver disease. Cardiovascular disease and osteoarthritis are supported mainly by experimental or associative studies, whereas the application of this model to neurodegeneration remains largely indirect. Senescent repair memory is therefore presented not as a new molecular pathway or a universal explanation for chronic disease, but as a testable framework linking the persistence, maintenance, spatial organization and functional consequences of unresolved senescence. By distinguishing adaptive repair from disease-sustaining senescence, this perspective may inform the development of stage- and tissue-specific biomarkers and interventions.
中文摘要:慢性疾病在初始损伤消退后仍可继续进展,提示受损组织可能保留了修复失败的持续印记。衰老性修复记忆指一种组织状态:短暂的修复相关衰老未能消退,并由持续存在的衰老细胞、改变了的分泌与代谢程序、缺陷的免疫清除、表观遗传稳定化以及空间微环境相互作用所维持。一旦在适应性修复窗口之后确立,该状态即使在原始损伤减弱后仍可延续炎症、纤维化和功能衰退。本综述探讨修复失败如何参与慢性肾脏病、心血管疾病、肺纤维化、代谢性肝病、神经退行性疾病和骨关节炎。证据在肾病、肺纤维化和代谢性肝病中最强。心血管疾病和骨关节炎主要由实验性或关联性研究支持,而该模型在神经退行性疾病中的应用在很大程度上仍是间接的。因此,衰老性修复记忆并非作为新的分子通路或慢性疾病的普遍解释提出,而是作为一个可检验的框架,连接未消退衰老的持续性、维持、空间组织和功能后果。通过区分适应性修复与维持疾病的衰老,这一视角可能为分期和组织特异性生物标志物及干预措施的开发提供信息。
Transcutaneous fluorescein isothiocyanate (FITC)-sinistrin fluorescence enables convenient, minimally invasive estimation of the glomerular filtration rate (GFR) in rodents. However, the commonly used fixed-factor conversions (i.e., GFR/BW = conversion factor (21.33)/HL, where HL is sinistrin half-life and BW is body weight) assume the volume of distribution scales proportionally with BW. This assumption can bias GFR estimates when body composition shifts with growth or when extracellular fluid volume expands under high-salt intake. Here, we quantified these errors and developed improved HL-to-GFR conversion methods. Male and female Dahl salt-sensitive rats with chronically implanted venous catheters underwent simultaneous measurements of serum and transcutaneous FITC-sinistrin fluorescence. Serum clearance provided reference GFR and serum-derived HL, and the transcutaneous signal provided transcutaneous HL. In separate cohorts, body composition and extracellular fluid were assessed by Nuclear Magnetic Resonance-Bioimpedance Spectroscopy. A regression of GFR×HL was performed using BW, age, sex, and salt intake. In low-salt fed rats, sex-specific BW-based models explained much of the variability in GFR×HL (females: 97.81×BW0.385; males: 203.0×BW0.855; BW in kg). Separately, using data from all rats across salt conditions, we derived a salt-dependent conversion to allow for temporal salt effects. The corrected model detected the transient increase in GFR on high-salt day 3 that was missed by a fixed factor. GFR scaled sub-linearly with BW (exponent 0.744). Allowing the sinistrin HL-to-GFR conversion to vary with BW and salt condition moderately improves the accuracy of HL-based FITC-sinistrin GFR estimates compared with a single fixed conversion factor and captures the transient GFR increase after salt loading. Sub-linear scaling of GFR supports allometric size adjustment (BW0.744) to reduce size-dependent bias and better reflect true GFR in growing rats.
中文摘要:经皮FITC-sinistrin荧光可在啮齿类动物中便捷、微创地估测肾小球滤过率(GFR)。常用固定因子换算(GFR/BW = 换算因子21.33/HL,HL为sinistrin半衰期,BW为体重)假定分布容积随BW成比例变化。当生长导致体成分改变或高盐摄入引起细胞外液容量扩张时,这一假定会使GFR估测产生偏倚。本研究量化了这些误差并建立改进的HL-to-GFR换算方法。长期植入静脉导管的雄性和雌性Dahl盐敏感大鼠同步测定血清与经皮FITC-sinistrin荧光。血清清除率提供参考GFR和血清来源HL,经皮信号提供经皮HL。在独立队列中,用核磁共振-生物阻抗谱评估体成分和细胞外液。对GFR×HL以BW、年龄、性别和盐摄入进行回归。低盐喂养大鼠中,性别特异性BW模型解释了GFR×HL的大部分变异(雌性:97.81×BW^0.385;雄性:203.0×BW^0.855;BW单位为kg)。另用全部盐条件下大鼠数据推导盐依赖性换算,以纳入盐摄入的时间效应。校正模型检测到高盐第3天GFR的短暂升高,而固定因子未能发现。GFR随BW呈亚线性缩放(指数0.744)。使sinistrin HL-to-GFR换算随BW和盐条件变化,与单一固定换算因子相比可中度提高基于HL的FITC-sinistrin GFR估测准确性,并捕捉盐负荷后的短暂GFR升高。GFR的亚线性缩放支持用异速生长尺寸校正(BW^0.744)减少尺寸相关偏倚,并更好反映生长中大鼠的真实GFR。
10代谢性肝病 (3篇)
临床研究 (2篇)
Metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with adverse liver and non-liver outcomes, but the impact of coexisting sarcopenia-related abnormalities (e.g., low muscle strength [MS], muscle mass, and physical performance) remains unclear. In a prospective UK Biobank cohort (n = 438,748), we evaluated their joint associations with incidence and risks of all-cause mortality, cirrhosis, hepatocellular carcinoma (HCC), cardiovascular disease (CVD), chronic kidney disease (CKD), non-liver cancers, and obesity-related cancers across MASLD and sarcopenia-related abnormality status. Over a median follow-up of 13.8 years, 401 HCC, 1714 cirrhosis, 39,534 CVD, 19,637 CKD, 38,240 non-liver cancers, 12,536 obesity-related cancers, and 34,801 deaths occurred. A stepwise increase in both incidence and adjusted risk of liver and non-liver outcomes was observed across MASLD and sarcopenia strata. Within the coexistence group, the obesity (vs. non-obesity) subgroup generally had higher risks. For example, for cirrhosis, adjusted hazard ratios increased from 3.93 to 7.36 then 8.48 with MASLD alone, coexisting MASLD with low MS overall and coexisting MASLD, low MS and obesity, respectively. Similar findings were observed in external validation analyses using the 2011-2018 US National Health and Nutrition Examination Survey cohort. Together, these observations inform risk stratification strategy and management of MASLD to include sarcopenia assessment.
中文摘要:代谢功能障碍相关脂肪性肝病(MASLD)与不良肝脏及非肝脏结局相关,但合并肌少症相关异常(如低肌肉力量[MS]、肌肉量和身体表现)的影响仍不清楚。在一项前瞻性UK Biobank队列(n=438,748)中,我们评估了其与全因死亡、肝硬化、肝细胞癌(HCC)、心血管疾病(CVD)、慢性肾脏病(CKD)、非肝脏癌症及肥胖相关癌症的发生率和风险的联合关联,按MASLD和肌少症相关异常状态分层。中位随访13.8年间,发生401例HCC、1714例肝硬化、39,534例CVD、19,637例CKD、38,240例非肝脏癌症、12,536例肥胖相关癌症和34,801例死亡。随着MASLD和肌少症分层增加,肝脏和非肝脏结局的发生率及校正风险呈阶梯式升高。在共存组内,肥胖(相对于非肥胖)亚组通常风险更高。例如,肝硬化方面,校正风险比从单纯MASLD的3.93升至MASLD合并低MS的7.36,再升至MASLD、低MS和肥胖共存的8.48。使用2011-2018年美国国家健康与营养检查调查队列的外部验证分析观察到相似结果。这些观察结果提示,MASLD的风险分层策略和管理应纳入肌少症评估。
Metabolic dysfunction-associated steatotic liver disease (MASLD) includes a spectrum of progressive liver conditions ranging from isolated steatosis to metabolic dysfunction-associated steatohepatitis (MASH), advanced fibrosis and cirrhosis. Currently, MASLD is the leading cause of chronic liver disease worldwide. MASLD is strongly associated with type 2 diabetes, cardiovascular disease, chronic kidney disease and certain extrahepatic cancers. MASLD shares a common pathogenesis with cardiometabolic diseases, especially type 2 diabetes, primarily driven by unhealthy dietary habits, dysfunctional adipose tissue, insulin resistance and low-grade inflammation. Substantial heterogeneity in the pathophysiology of MASLD may influence its rate of progression, its relationship with cardiometabolic diseases and its treatment response. In addition to lifestyle interventions, including a healthy low-energy diet and increased physical activity levels, pharmacological treatment of MASLD/MASH is recommended. For individuals with type 2 diabetes and MASLD/MASH, treatment should preferably include glucagon-like peptide-1 (GLP-1) receptor agonist-based therapies and sodium-glucose cotransporter 2 (SGLT2) inhibitors, which have been shown to improve MASLD/MASH and provide established cardiorenal benefits. In this narrative review, we assess the efficacy of these pharmacotherapies and discuss other treatment approaches for MASLD/MASH, with a focus on their metabolic benefits.
中文摘要:代谢功能障碍相关脂肪性肝病(MASLD)涵盖从孤立性脂肪变性到代谢功能障碍相关脂肪性肝炎(MASH)、晚期纤维化和肝硬化的进展性肝病谱系。目前,MASLD是全球慢性肝病的首要病因。MASLD与2型糖尿病、心血管疾病、慢性肾脏病和某些肝外癌症密切相关。MASLD与心脏代谢疾病尤其是2型糖尿病具有共同发病机制,主要由不健康饮食习惯、脂肪组织功能障碍、胰岛素抵抗和低度炎症驱动。MASLD病理生理学存在显著异质性,可能影响其进展速度、与心脏代谢疾病的关系以及治疗反应。在生活方式干预之外,包括健康低能量饮食和增加体力活动,推荐对MASLD/MASH进行药物治疗。对于合并2型糖尿病的MASLD/MASH个体,治疗最好包括基于胰高血糖素样肽-1(GLP-1)受体激动剂的疗法和钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂,这些药物已显示可改善MASLD/MASH,并具有已确立的心肾获益。该叙述性综述评估这些药物的疗效,并讨论MASLD/MASH的其他治疗方法,重点在其代谢获益。
基础研究 (1篇)
Recent awareness that metabolic dysfunction-associated steatotic liver disease (MASLD) is a common liver condition in individuals with type 2 diabetes and carries a significant risk of cirrhosis and extrahepatic disease has called for an examination of its relationship with diabetes-related complications. MASLD, especially at-risk steatohepatitis (metabolic dysfunction-associated steatohepatitis [MASH]) with significant fibrosis ≥F2, shares many metabolic abnormalities with type 2 diabetes, including insulin resistance, gluco- and lipotoxicity, chronic subclinical inflammation and mitochondrial impairment. In addition, many cross-sectional and longitudinal observational studies suggest an association between MASLD and micro- and macrovascular complications of type 1 and type 2 diabetes. However, a causal pathogenic relationship has been difficult to confirm given the overlap of cardiometabolic risk factors (CMRFs) in MASLD and type 2 diabetes. Complicating matters further, most of the available evidence has significant limitations. These include shortcomings in participant selection, heterogeneity in study design, use of diagnostic tools with low sensitivity for liver disease and diabetes-related complications, inadequate control for alcohol consumption or CMRFs, and lack of repeat measurements during longitudinal studies. Nevertheless, current evidence suggests that MASLD is a 'risk enhancer' for both micro- and macrovascular disease in diabetes, rather than an independent risk factor. Here, we review the underlying mechanistic pathways and clinical evidence that appear to link both conditions and identify knowledge gaps in need of future research. Until more robust evidence emerges, we hope that a greater awareness about the link between MASLD and diabetes-related micro- and macrovascular complications will prompt clinicians to educate their patients and peers on the potentially heightened health risks of MASLD and encourage clinicians to take a more proactive approach to risk stratification and intervention.
中文摘要:近期认识到,代谢功能障碍相关脂肪性肝病(MASLD)是2型糖尿病患者常见的肝脏疾病,并带来肝硬化和肝外疾病的显著风险,这促使人们审视其与糖尿病相关并发症的关系。MASLD,尤其是伴显著纤维化≥F2的高危脂肪性肝炎(代谢功能障碍相关脂肪性肝炎[MASH]),与2型糖尿病共享多种代谢异常,包括胰岛素抵抗、糖毒性和脂毒性、慢性亚临床炎症及线粒体损伤。许多横断面和纵向观察性研究提示,MASLD与1型和2型糖尿病的微血管和大血管并发症存在关联。由于MASLD与2型糖尿病中心血管代谢危险因素(CMRFs)重叠,致病性因果关系难以确认。现有证据多数存在明显局限,使问题更复杂:参与者选择有缺陷、研究设计异质、所用诊断工具对肝病和糖尿病相关并发症敏感性低、对饮酒或CMRFs控制不足,以及纵向研究缺乏重复测量。但当前证据提示MASLD是糖尿病微血管和大血管疾病的「风险增强因素」,而非独立危险因素。综述梳理连接这两种情况的潜在机制通路和临床证据,并指出未来研究需要填补的知识空白。在更可靠证据出现之前,希望提高对MASLD与糖尿病相关微血管和大血管并发症联系的认识,能促使临床医生教育患者和同行了解MASLD可能带来的更高健康风险,并鼓励临床医生更主动地进行风险分层和干预。
11糖尿病肾病 (2篇)
基础研究 (2篇)
To establish a comprehensive theranostic framework for early-stage diabetic kidney disease (DKD) by validating serum S100A8/A9 as a highly sensitive diagnostic biomarker and exploring therapeutic strategies targeting the S100A9/transmembrane protein 24 (TMEM24) signaling axis to restore podocyte autophagy. A clinical cohort and machine learning algorithms (Random Forest/Neural Networks) were employed to evaluate the diagnostic performance of S100A8/A9. In vivo (db/db mice) and in vitro (HG-stimulated podocytes) models were used to investigate the molecular mechanisms. Co-IP-LC/MS and protein truncation assays identified S100A9-interacting partners. Structure-based virtual screening was utilized to identify Shikonin as a novel TMEM24-targeting ligand, and its renoprotective effects were rigorously validated. Serum S100A8/A9 levels were significantly elevated in early DKD, outperforming conventional markers in machine learning models (AUC up to 0.978). Mechanistically, S100A9 interacts with Transmembrane Protein 24 (TMEM24) through its SMP and C2 domains, hyperactivating the PI3K/AKT/mTOR pathway and impairing podocyte autophagy. Shikonin, identified through virtual screening, demonstrated a strong binding affinity for TMEM24. Administration of Shikonin dose-dependently inhibited the TMEM24-mediated PI3K/AKT/mTORC1 signaling, thereby restoring autophagic flux and ameliorating podocyte injury, glomerular basement membrane thickening, and renal fibrosis. This study defines S100A8/A9 as a pivotal biomarker and therapeutic target, offering a theranostic strategy where Shikonin serves as a potent agent to ameliorate DKD progression by targeting the TMEM24-autophagy axis.
中文摘要:为建立早期糖尿病肾脏病(DKD)的一体化诊疗框架,验证血清S100A8/A9作为高灵敏诊断生物标志物,并探索靶向S100A9/跨膜蛋白24(TMEM24)信号轴以恢复足细胞自噬的治疗策略。采用临床队列与机器学习算法(随机森林/神经网络)评估S100A8/A9的诊断效能。使用体内(db/db小鼠)与体外(高糖刺激足细胞)模型研究分子机制。Co-IP-LC/MS与蛋白截短实验鉴定S100A9的相互作用蛋白。基于结构的虚拟筛选发现紫草素(Shikonin)为新的TMEM24靶向配体,并对其肾脏保护作用进行严格验证。早期DKD患者血清S100A8/A9水平显著升高,在机器学习模型中优于传统标志物(AUC最高达0.978)。机制上,S100A9通过其SMP与C2结构域与TMEM24结合,过度激活PI3K/AKT/mTOR通路并损害足细胞自噬。虚拟筛选获得的紫草素对TMEM24具有强结合亲和力。给予紫草素可剂量依赖性抑制TMEM24介导的PI3K/AKT/mTORC1信号,从而恢复自噬流,改善足细胞损伤、肾小球基底膜增厚与肾脏纤维化。本研究将S100A8/A9确定为关键生物标志物与治疗靶点,提出一种诊疗一体化策略:紫草素作为靶向TMEM24-自噬轴的有效药物,延缓DKD进展。
Diabetic nephropathy is a leading cause of end-stage renal disease, with podocyte loss being a critical event in its progression. However, the dominant molecular mechanism driving podocyte loss remains elusive, hindering targeted therapy. We aimed to identify the key pathways of podocyte failure in human diabetic nephropathy and investigate metformin's therapeutic potential. We employed an integrative multi-omics approach, including single-nucleus RNA-seq (snRNA-seq) of 156,043 human kidney nuclei from individuals with diabetic nephropathy and healthy control individuals, db/db mouse models of diabetic nephropathy, spatial metabolomics, in vitro podocyte cultures, and targeted urinary metabolomics in individuals with diabetic nephropathy and healthy control individuals. snRNA-seq identified ferroptosis and fatty acid metabolic dysregulation as the most enriched pathways within podocytes, mechanistically linked to the MAPK14-solute carrier family 7 member 11 (SLC7A11)-glutathione peroxidase 4 (GPX4) axis. In murine diabetic nephropathy models and in vitro, metformin directly inhibited this MAPK14-SLC7A11-GPX4 axis, suppressed podocyte ferroptosis (including restoration of GPX4 and SLC7A11 expression and reduction of p-p38 and lipid peroxidation) and restored compartment-specific renal lipid accumulation as shown by spatial metabolomics. Clinically, we identified and validated a urinary fatty acid signature, with palmitoylcarnitine as a key biomarker (AUC 0.974, calculated from receiver operating characteristic curves), correlating with disease indices including blood glucose, eGFR, serum creatinine and blood urea nitrogen. Our study reveals podocyte ferroptosis to be a central pathogenic event in human diabetic nephropathy, repositioning metformin as a direct ferroptosis inhibitor that preserves podocyte integrity via the MAPK14-SLC7A11-GPX4 axis. Furthermore, we provide a high-performance urinary biomarker, offering a direct translational link toward targeted anti-ferroptosis therapies and non-invasive diagnostics for diabetic nephropathy.
中文摘要:糖尿病肾病是终末期肾病的主要原因,足细胞丢失是其进展中的关键事件。驱动足细胞丢失的主要分子机制仍不明确,限制了靶向治疗。研究旨在识别人类糖尿病肾病中足细胞衰竭的关键通路,并探讨二甲双胍的治疗潜力。研究采用整合多组学方法,包括对156043个来自糖尿病肾病患者和健康对照者的人肾细胞核进行单核RNA测序,使用db/db糖尿病肾病小鼠模型、空间代谢组学、体外足细胞培养,以及对糖尿病肾病患者和健康对照者进行靶向尿液代谢组学分析。单核RNA测序发现,铁死亡和脂肪酸代谢失调是足细胞内最富集的通路,机制上与MAPK14-溶质载体家族7成员11(SLC7A11)-谷胱甘肽过氧化物酶4(GPX4)轴相关。在小鼠糖尿病肾病模型和体外实验中,二甲双胍直接抑制该MAPK14-SLC7A11-GPX4轴,抑制足细胞铁死亡,包括恢复GPX4和SLC7A11表达、降低p-p38和脂质过氧化,并通过空间代谢组学恢复区室特异性肾脏脂质蓄积。临床方面,研究识别并验证了尿液脂肪酸特征,其中棕榈酰肉碱为关键生物标志物,AUC为0.974,由受试者工作特征曲线计算得出,并与血糖、eGFR、血清肌酐和血尿素氮等疾病指标相关。研究揭示足细胞铁死亡是人类糖尿病肾病中的核心致病事件,并将二甲双胍重新定位为通过MAPK14-SLC7A11-GPX4轴维持足细胞完整性的直接铁死亡抑制剂。研究还提供了一种高性能尿液生物标志物,为靶向抗铁死亡治疗和糖尿病肾病无创诊断提供了直接转化联系。
12遗传性肾病 (2篇)
临床研究 (2篇)
While a few studies have investigated renal manifestations associated with mitochondrial DNA (mtDNA) variants, detailed renal histopathological changes and long-term outcomes remain poorly characterized. This study reported a family in which all 5 siblings presented with hyperuricemia and chronic kidney disease (CKD); the proband died of end-stage kidney disease at 16 years of age, while both parents were unaffected. Renal histology from 3 siblings revealed multiple foci of sclerotic and atubular glomeruli, as well as focal tubular atrophy, making early pathologic diagnosis challenging. Ten years later, whole exome sequencing identified an m.616T>C variant in the MT-TF gene of mtDNA, confirming the diagnosis of mitochondrial tubulointerstitial kidney disease and demonstrating mitochondrial abnormalities in the distal tubules and collecting duct. Over a 12-year follow-up period, 1 patient died of end-stage kidney disease, 1 required dialysis, 2 progressed from CKD stage G2 to G4, and 1 remained stable at CKD stage G3. This 12-year study of a family with MT-TF m.616T>C-associated mitochondrial tubulointerstitial kidney disease highlights the relative homogeneity of renal pathology alongside marked heterogeneity in long-term outcomes, despite an identical genetic background.
中文摘要:尽管已有少数研究探讨线粒体DNA(mtDNA)变异相关的肾脏表现,但详细的肾脏组织病理学改变和长期结局仍缺乏充分描述。本研究报道一个家庭,5名同胞均表现为高尿酸血症和慢性肾脏病(CKD);先证者16岁时死于终末期肾病,父母均未受累。3名同胞的肾脏组织学显示多灶性硬化性和无小管肾小球,以及局灶性肾小管萎缩,使早期病理诊断具有挑战性。10年后,全外显子测序在mtDNA的MT-TF基因中鉴定出m.616T>C变异,确诊线粒体肾小管间质性肾病,并显示远端小管和集合管存在线粒体异常。在12年随访期间,1例患者死于终末期肾病,1例需要透析,2例从CKD G2期进展至G4期,1例稳定在CKD G3期。这项对MT-TF m.616T>C相关线粒体肾小管间质性肾病家庭的12年研究强调,尽管遗传背景相同,肾脏病理相对一致,但长期结局存在显著异质性。
The molecular diagnosis of autosomal dominant tubulointerstitial kidney disease due to MUC1 variants (ADTKD-MUC1) using high-throughput (short-read) sequencing methods remains challenging due to the presence of a coding long variable-number tandem repeat (VNTR) region wherein most known pathogenic variants are located. Here, we used targeted amplicon long-read sequencing to study the MUC1 VNTR in a retrospective cohort study of 78 individuals. Using a bioinformatic pipeline including newly developed specialized software, VNTRtools, we reconstructed patient-specific complete VNTR haplotypes, generated a synthetic VNTR reference, performed long-read realignment to this reference, and finally performed variant calling. VNTRtools proved efficient, requiring seconds or minutes per sample to accurately identify all pathogenic MUC1 frameshift variants in positive controls, including atypical variants. Ten new diagnoses of ADTKD-MUC1 were made. Furthermore, we report a confirmed de novo case of ADTKD-MUC1 in a 32-year-old patient. We were able to structurally resolve and phase the interindividually highly variable VNTRs in most probands, enabling the high-confidence detection of pathogenic frameshift variants in 24 individuals. We also detected 18 previously unreported VNTR repeat unit types, demonstrating the highly polymorphic nature of MUC1's VNTR. We propose a combined approach in which short-read VNTR analysis using the published alignment-free bioinformatic tools is used as a first-line test, followed by targeted long-read sequencing with VNTRtools analysis for confirmatory testing and in-depth VNTR characterization. This combined approach will lead to a higher diagnostic confidence in ADTKD-MUC1-especially in sporadic cases. Complete VNTR haplotype information will likely enable a better genetic understanding of this currently underdiagnosed disorder and may become relevant for future therapeutic approaches like targeted silencing of the pathogenic MUC1 allele.
中文摘要:由于编码区长可变数目串联重复(VNTR)区域存在,且多数已知致病变异位于其中,使用高通量短读长测序对MUC1变异所致常染色体显性肾小管间质性肾病(ADTKD-MUC1)进行分子诊断仍具挑战。我们在78人的回顾性队列中采用靶向扩增子长读长测序研究MUC1 VNTR。利用包含新开发专用软件VNTRtools的生物信息流程,重建患者特异性完整VNTR单倍型,生成合成VNTR参考序列,将长读长数据回贴至该参考序列,最后进行变异检出。VNTRtools效率较高,每份样本仅需数秒至数分钟,即可在阳性对照中准确识别所有致病性MUC1移码变异,包括非典型变异。研究新增10例ADTKD-MUC1诊断。另报告一例经确认的新发ADTKD-MUC1,患者32岁。我们能在多数先证者中从结构上解析并定相个体间高度变异的VNTR,从而在24人中高置信度检出致病性移码变异。还发现18种此前未报告的VNTR重复单元类型,显示MUC1 VNTR高度多态。我们提出联合策略:先用已发表的免比对生物信息工具进行短读长VNTR分析作为一线检测,随后用VNTRtools分析靶向长读长测序作确认检测和深入VNTR表征。该联合策略将提高ADTKD-MUC1诊断信心,尤其对散发病例。完整VNTR单倍型信息有望增进对这种目前诊断不足疾病遗传学理解,并可能对未来靶向沉默致病MUC1等位基因的治疗方法有意义。
13急诊普外科 (1篇)
临床研究 (1篇)
The Emergency General Surgery Verification Program was designed and launched in 2023 by the American College of Surgeons to standardize and improve EGS care through 43 standards that support hospital structure, care processes, and outcome surveillance. To evaluate the association between EGS verification and hospital length of stay (LOS), acute kidney injury (AKI), and 30-day mortality and to assess whether changes in care processes contribute to effects. This quasi-experimental difference-in-differences cohort study with staggered adoption used data from the ACS National Surgical Quality Improvement Program EGS Targeted Dataset. Patients with operatively managed EGS diagnoses from July 1, 2023, through December 31, 2024, at 50 control and 5 verified hospitals were evaluated. Data were analyzed from July 2025 through February 2026. Hospital EGS verification status. Primary outcomes were mean LOS, 30-day mortality rate, and AKI rate. These were calculated adjusted and unadjusted. Average treatment effects on the treated were estimated with hospital-clustered bootstrap standard errors. The final cohort included 21 858 patients at 55 hospitals. Median (IQR) patient age was 53.2 (36.5-68.5) years, and 12 366 patients (56.6%) were female. Prior to verification, verified hospitals treated higher-acuity patients and had higher predicted mortality and AKI rates. Verification was associated with absolute reductions in LOS (-1.31 days; 95% CI, -1.95 to -0.67), AKI (-1.23 percentage points; 95% CI, -2.00 to -0.46), and mortality (-1.63 percentage points; 95% CI, -2.55 to -0.71), corresponding to relative reductions of 19.7%, 29.0%, and 28.8%, respectively. These results held after risk adjustment and Bonferroni correction. Verification was also associated with improved care processes, including increased admission to surgical services (74.8% to 85.7%; P < .001), decreased failure of nonoperative management (25.5% to 19.0%; P < .001), and shorter time to operation (-10.7 hours; P < .001). All processes were independently associated with improvements in all 3 primary outcomes. In this cohort study, early adoption of ACS EGS verification was associated with clinically meaningful reductions in LOS, AKI, and 30-day mortality among participating hospitals. These findings demonstrate the EGS verification likely drives systems-level improvements in emergency surgical care, which may be partially explained by improvements in performance on hospital process measures.
中文摘要:急诊普外科认证项目由美国外科医师学会于2023年设计并启动,通过43项支持医院结构、诊疗流程和结局监测的标准来规范和改善急诊普外科诊疗。评估急诊普外科认证与医院住院时间、急性肾损伤和30天死亡率之间的关联,并评估诊疗流程变化是否促成这些效应。这项采用交错实施的准实验双重差分队列研究使用美国外科医师学会国家外科质量改进项目急诊普外科定向数据集的数据。评估2023年7月1日至2024年12月31日期间在50家对照医院和5家认证医院接受手术治疗的急诊普外科诊断患者。数据分析时间为2025年7月至2026年2月。医院急诊普外科认证状态。主要结局为平均住院时间、30天死亡率和急性肾损伤发生率,计算调整和未调整结果。采用医院聚类自助法标准误估计处理组的平均处理效应。最终队列包括55家医院的21858例患者。患者年龄中位数(IQR)为53.2(36.5-68.5)岁,12366例(56.6%)为女性。认证前,认证医院收治的患者病情更重,预测死亡率和急性肾损伤发生率更高。认证与住院时间(-1.31天;95% CI,-1.95至-0.67)、急性肾损伤(-1.23个百分点;95% CI,-2.00至-0.46)和死亡率(-1.63个百分点;95% CI,-2.55至-0.71)的绝对下降相关,相对降幅分别为19.7%、29.0%和28.8%。这些结果在风险调整和Bonferroni校正后仍然成立。认证还与诊疗流程改善相关,包括收入外科服务比例增加(74.8%至85.7%;P < .001)、非手术治疗失败减少(25.5%至19.0%;P < .001)和至手术时间缩短(-10.7小时;P < .001)。所有流程均与3项主要结局的改善独立相关。在这项队列研究中,早期采用美国外科医师学会急诊普外科认证与参与医院住院时间、急性肾损伤和30天死亡率的具有临床意义的下降相关。这些发现表明急诊普外科认证可能推动急诊外科诊疗的系统层面改善,部分可由医院流程指标表现改善解释。
14环境与慢性病 (1篇)
临床研究 (1篇)
Ambient air pollutants have been associated with increased risks of mortality and chronic diseases; however, population-based evidence on their shared versus pollutant- and outcome-specific molecular mechanisms remains unclear. Leveraging proteomics data from 48,645 participants in the UK Biobank, we characterized proteomic signatures related to overall and individual air pollutants, including particulate matter (PM2.5 and PM10), nitrogen dioxide (NO2) and nitrogen oxides (NOx), and examined their associations with risks of mortality and major chronic diseases. Subsequently, we investigated potential mediating proteins underlying these associations to determine relevant biological mechanisms through functional annotation analyses. Plasma proteins jointly associated with four air pollutants were commonly enriched in immune regulatory pathways, while proteins uniquely associated with PM2.5, PM10, NO2, and NOx were enriched in pollutant-specific pathways of vascular dysfunction, DNA damage, apoptosis signaling, and extracellular matrix remodeling, respectively. Proteomic signatures of air pollutants captured biological processes underlying mortality and major chronic diseases. Mediation analyses and Mendelian randomization identified mediating proteins causally associated with their respective health outcomes, highlighting shared mechanisms of inflammation and immune response as well as outcome-specific pathways such as vascular remodeling for cardiovascular disease, oxidative stress for chronic kidney disease, and cell adhesion for dementia. Specifically, cell-type and tissue enrichment annotation revealed outcome-relevant specificity of advanced glycosylation end product-specific receptor (AGER) for chronic respiratory disease and lung cancer. This study dissects the relationship between ambient air pollutants and adverse health outcomes by revealing both shared and divergent mechanisms and representing potential targets such as AGER for disease prevention and therapeutic intervention.
中文摘要:环境空气污染物与死亡和慢性病风险升高相关,但其共同及污染物特异、结局特异的分子机制仍缺乏人群证据。研究利用英国生物银行48,645名参与者的蛋白质组学数据,刻画与总体及单个空气污染物相关的蛋白质组特征,污染物包括PM2.5、PM10、二氧化氮(NO2)和氮氧化物(NOx),并分析这些特征与死亡和主要慢性病风险的关联。随后探讨这些关联背后的潜在中介蛋白,并通过功能注释分析确定相关生物学机制。与四种空气污染物共同相关的血浆蛋白主要富集于免疫调节通路,而与PM2.5、PM10、NO2和NOx分别独特相关的蛋白则富集于血管功能障碍、DNA损伤、凋亡信号和细胞外基质重塑等污染物特异通路。空气污染物的蛋白质组特征捕捉了死亡和主要慢性病背后的生物学过程。中介分析和孟德尔随机化识别出与相应健康结局存在因果关联的中介蛋白,凸显炎症和免疫反应的共同机制,以及心血管病的血管重塑、慢性肾脏病的氧化应激、痴呆的细胞黏附等结局特异通路。细胞类型和组织富集注释显示,晚期糖基化终产物特异性受体(AGER)对慢性呼吸系统疾病和肺癌具有与结局相关的特异性。该研究揭示空气污染物与不良健康结局之间的共同和分化机制,并提出AGER等可用于疾病预防和治疗干预的潜在靶点。
15糖尿病并发症 (1篇)
临床研究 (1篇)
Nearly 40% of African adults with type 2 diabetes are lean (BMI <25 kg/m2). Emerging evidence suggests that type 2 diabetes in African individuals who are lean may represent a distinct phenotype driven by impaired insulin secretion rather than insulin resistance, raising concerns about treatment mismatch and divergent disease outcomes. We examined complication profiles in Africans with type 2 diabetes who are lean vs overweight/obese. We analysed harmonised, individual-level cross-sectional data from two large, well-characterised African cohorts (Africa America Diabetes Mellitus study, n=2790; Research on Obesity and Diabetes among African Migrants study, n=541; total n=3331) of adults with type 2 diabetes from Ghana, Nigeria and Kenya. Participants were classified as lean (BMI <25 kg/m2) or overweight/obese (BMI ≥25 kg/m2). Robust Poisson regression, adjusted for age, sex, education and treatment, assessed associations with retinopathy, chronic kidney disease, stroke, hypertension and 10-year cardiovascular disease risk. Cohort-specific estimates were pooled using random effects, followed by mediation analysis examining contributions of lifestyle and metabolic markers to observed differences. Type 2 diabetes in Africans who are lean was characterised by lower beta cell function and low insulin levels. Compared with individuals who are overweight/obese, adults who are lean showed a higher prevalence of retinopathy (pooled prevalence ratio [pPR] 1.36 [95% CI 1.13, 1.63]) and stroke (pPR 1.41 [95% CI 1.01, 1.99]), but lower hypertension (pPR 0.77 [95% CI 0.71, 0.85]) and 10-year cardiovascular disease risk (pPR 0.85 [95% CI 0.74, 0.97]). Chronic kidney disease prevalence did not differ between groups. Body fat percentage accounted for most differences (up to 92%). Complication patterns in Africans with type 2 diabetes who are lean vs overweight/obese follow divergent paths. In Africa, where nearly 24 million people have type 2 diabetes, two-fifths of whom are lean, our findings add to growing evidence that lean type 2 diabetes may be a distinct phenotype, underscoring the urgent need for investigation into better-targeted management for this large, potentially mistreated, population.
中文摘要:非洲2型糖尿病成人中近40%为瘦型(BMI<25 kg/m2)。新出现的证据提示,非洲瘦型个体的2型糖尿病可能是由胰岛素分泌受损而非胰岛素抵抗驱动的独特表型,这引发了对治疗不匹配和疾病结局差异的担忧。我们比较了非洲瘦型与超重/肥胖2型糖尿病患者的并发症特征。我们分析了来自两个大型、特征明确的非洲队列(Africa America Diabetes Mellitus研究,n=2790;Research on Obesity and Diabetes among African Migrants研究,n=541;合计n=3331)的协调个体水平横断面数据,对象为来自加纳、尼日利亚和肯尼亚的2型糖尿病成人。参与者按瘦型(BMI<25 kg/m2)或超重/肥胖(BMI≥25 kg/m2)分类。采用稳健Poisson回归,校正年龄、性别、教育和治疗,评估与视网膜病变、慢性肾脏病、卒中、高血压和10年心血管疾病风险的关联。队列特异性估计值通过随机效应合并,随后进行中介分析,考察生活方式和代谢指标对观察到的差异的贡献。非洲瘦型2型糖尿病以β细胞功能较低和胰岛素水平低为特征。与超重/肥胖个体相比,瘦型成人视网膜病变患病率更高(合并患病率比[pPR]1.36[95%CI 1.13,1.63])和卒中更高(pPR 1.41[95%CI 1.01,1.99]),但高血压更低(pPR 0.77[95%CI 0.71,0.85]),10年心血管疾病风险更低(pPR 0.85[95%CI 0.74,0.97])。慢性肾脏病患病率在两组间无差异。体脂百分比解释了大部分差异(高达92%)。非洲瘦型与超重/肥胖2型糖尿病患者的并发症模式沿不同路径发展。在非洲,近2400万人患有2型糖尿病,其中五分之二为瘦型,我们的发现进一步支持瘦型2型糖尿病可能是独特表型,突出迫切需要研究针对这一庞大且可能治疗不当人群的更佳管理策略。
16ANCA血管炎 (1篇)
基础研究 (1篇)
Canagliflozin ameliorated experimental ANCA-associated vasculitis through broad suppression of pathogenic T-cell subsets. The immunomodulatory effect of canagliflozin was mediated in part by inhibition of p38 mitogen-activated protein kinase signaling in T cells. The nephroprotective role of sodium-glucose cotransporter 2 (SGLT2) inhibitors has been well established by several randomized controlled trials involving patients with diabetic and nondiabetic CKD. However, the impact of SGLT2 inhibitors on ANCA-associated vasculitis (AAV) and the underlying mechanisms remain unclear. The therapeutic effects of canagliflozin were evaluated in a rat model of experimental AAV. RNA sequencing was performed on the kidney and lymph nodes. In parallel, mechanistic studies were conducted in mouse models. Myeloperoxidase-deficient ( Mpo-/- ) mice were immunized with mouse myeloperoxidase and treated with canagliflozin. Splenocytes from these donors were then adoptively transferred into recombinase-activating gene-1-deficient ( Rag1-/- ) mice. Comprehensive immune phenotyping by flow cytometry, enzyme-linked immunospot assays, and in vitro differentiation of human T cells were employed to dissect the immunomodulatory effects and underlying mechanisms. Canagliflozin alleviated kidney injury, pulmonary hemorrhage, and T-lymphocyte infiltration in AAV rats. Renal transcriptomic analysis showed a suppression of adaptive immunity pathways. In the adoptive transfer model, canagliflozin treatment of donor mice led to a significant reduction in splenic Th1, Th17, and CD8 + T cells, accompanied by a markedly diminished capacity of splenocytes to secrete IFN- γ and IL-17A upon restimulation. Transfer of these modulated splenocytes conferred significant nephroprotection to recipient mice. In vitro , canagliflozin suppressed the differentiation of primary CD4 + T cells from patients with AAV into both Th1 and Th17 lineages, but did not directly affect B-cell activation or antibody production. Mechanistically, canagliflozin inhibited the phosphorylation of both p38 and extracellular signal-regulated kinase mitogen-activated protein kinases in activated T cells, and the suppressive effect on cytokine production was partially reversed by activation of the p38 mitogen-activated protein kinase pathway. Canagliflozin alleviated experimental AAV by suppressing pathogenic T cell effector responses-an effect mechanistically linked to inhibition of the p38 signaling pathway.
中文摘要:卡格列净通过广泛抑制致病性T细胞亚群改善实验性ANCA相关性血管炎。卡格列净的免疫调节作用部分由抑制T细胞中的p38丝裂原活化蛋白激酶信号介导。钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂的肾脏保护作用已在涉及糖尿病和非糖尿病CKD患者的多项随机对照试验中得到确立。但SGLT2抑制剂对ANCA相关性血管炎(AAV)的影响及潜在机制仍不清楚。研究在实验性AAV大鼠模型中评价卡格列净的治疗效果,并对肾脏和淋巴结进行RNA测序,同时在 mouse models 中开展机制研究。将髓过氧化物酶缺陷(Mpo-/-)小鼠用小鼠髓过氧化物酶免疫并给予卡格列净,随后将其脾细胞过继转移至重组激活基因1缺陷(Rag1-/-)小鼠。采用流式细胞术、酶联免疫斑点试验及人T细胞体外分化进行综合免疫表型分析,以解析免疫调节作用及潜在机制。卡格列净减轻AAV大鼠的肾损伤、肺出血和T淋巴细胞浸润。肾脏转录组分析显示适应性免疫通路受到抑制。在过继转移模型中,供体小鼠接受卡格列净后脾脏Th1、Th17和CD8+ T细胞显著减少,再刺激后脾细胞分泌IFN-γ和IL-17A的能力明显下降。转移这些受调节的脾细胞可给受体小鼠带来显著肾脏保护。体外,卡格列净抑制AAV患者原代CD4+ T细胞向Th1和Th17谱系分化,但不直接影响B细胞活化或抗体产生。机制上,卡格列净抑制活化T细胞中p38和细胞外信号调节激酶丝裂原活化蛋白激酶的磷酸化,激活p38丝裂原活化蛋白激酶通路可部分逆转其对细胞因子产生的抑制作用。卡格列净通过抑制致病性T细胞效应应答减轻实验性AAV,该作用在机制上与抑制p38信号通路相关。
17儿科肾脏病 (1篇)
临床研究 (1篇)
The conduct of randomized clinical trials (RCTs) in kidney disease among children and older youth has historically been challenging, reflecting, in part, the relative rarity of the conditions. This has resulted in a 13-year gap between the granting of approval for novel therapies in adults and their subsequent approval in children and created a significant lag in access to drugs in pediatrics that treat kidney disorders. One contributing factor that has been neglected is the operational barriers created by cultural and institutional structures that (1) divide pediatric from adult clinical nephrology services and (2) ignore the challenge for older pediatric patients who enroll in RCTs and straddle the boundary between pediatrics and internal medicine. In this Perspective, we offer potential approaches to overcome the human, logistical, and administrative impediments to meaningful collaboration between pediatric and adult nephrologists with the objective of promoting the timely initiation and completion of RCTs in pediatric nephrology.
中文摘要:在儿童和较大年龄青年中开展肾脏病随机临床试验(RCT)历来困难,部分反映这些疾病相对少见。这导致新型疗法在成人获批与随后在儿童获批之间相隔13年,并使儿科肾脏病治疗药物可及性明显滞后。一个被忽视的促成因素是文化和制度结构造成的操作障碍:其将儿科与成人临床肾脏病服务分隔,并忽视参加RCT且处于儿科与内科边界的大龄儿科患者所面临的挑战。在本视角文章中,我们提出可能的方法,以克服儿科与成人肾脏科医生之间有意义合作的人力、后勤和行政障碍,目标是促进儿科肾脏病RCT及时启动和完成。
18肝衰竭 (1篇)
临床研究 (1篇)
The acute-on-chronic liver failure (ACLF) multisociety harmonisation initiative represents a global collaborative effort to establish a unified, evidence-based framework for the definition, diagnosis, grading, and management of ACLF. Building on the strengths of existing regional definitions and integrating diverse international perspectives, this consensus provides a pragmatic, globally applicable foundation for clinical practice, research, and education. It also establishes a common framework for patient stratification, organ dysfunction and failure assessment, critical care management, liver transplantation, and the design of future phase II/III trials. Standardised, regulatory-aligned endpoints are expected to improve cross-study comparability, strengthen collaboration, and accelerate development of effective ACLF therapies.
中文摘要:慢加急性肝衰竭(ACLF)多学会协调倡议是一项全球协作,旨在建立统一、循证的ACLF定义、诊断、分级和管理框架。该共识依托现有区域定义的优势,整合国际多元视角,为临床实践、研究和教育提供务实且全球适用的基础。它还建立共同框架,用于患者分层、器官功能障碍与衰竭评估、重症监护管理、肝移植以及未来II/III期试验设计。标准化且与监管要求对齐的终点预计将提高跨研究可比性,加强协作,并加速有效ACLF疗法的开发。